[go: nahoru, domu]

US20100330571A1 - Method of measuring adaptive immunity - Google Patents

Method of measuring adaptive immunity Download PDF

Info

Publication number
US20100330571A1
US20100330571A1 US12/794,507 US79450710A US2010330571A1 US 20100330571 A1 US20100330571 A1 US 20100330571A1 US 79450710 A US79450710 A US 79450710A US 2010330571 A1 US2010330571 A1 US 2010330571A1
Authority
US
United States
Prior art keywords
segment
sequence
primers
composition
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US12/794,507
Inventor
Harlan S. Robins
Edus H. Warren, III
Christopher Scott Carlson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fred Hutchinson Cancer Center
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US12/794,507 priority Critical patent/US20100330571A1/en
Application filed by Individual filed Critical Individual
Publication of US20100330571A1 publication Critical patent/US20100330571A1/en
Assigned to FRED HUTCHINSON CANCER RESEARCH CENTER reassignment FRED HUTCHINSON CANCER RESEARCH CENTER ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ROBINS, HARLAN S, CARLSON, CHRISTOPHER SCOTT, WARREN, EDUS H, III
Priority to US13/217,126 priority patent/US20120058902A1/en
Priority to US14/095,629 priority patent/US20140194295A1/en
Priority to US14/183,177 priority patent/US20140206549A1/en
Priority to US14/183,163 priority patent/US20140206548A1/en
Priority to US14/242,299 priority patent/US20140256567A1/en
Priority to US14/243,875 priority patent/US20140213463A1/en
Priority to US14/252,189 priority patent/US20140221220A1/en
Priority to US14/640,145 priority patent/US20150299785A1/en
Priority to US15/061,827 priority patent/US9809813B2/en
Priority to US15/475,613 priority patent/US20170335386A1/en
Assigned to NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR reassignment NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: FRED HUTCHINSON CANCER RESEARCH CENTER
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: FRED HUTCHINSON CANCER RESEARCH CENTER
Priority to US15/709,719 priority patent/US11214793B2/en
Priority to US16/023,010 priority patent/US11905511B2/en
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1065—Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F17/00—Digital computing or data processing equipment or methods, specially adapted for specific functions
    • G06F17/10—Complex mathematical operations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Definitions

  • What is described is a method to measure the adaptive immunity of a patient by analyzing the diversity of T cell receptor genes or antibody genes using large scale sequencing of nucleic acid extracted from adaptive immune system cells.
  • Immunocompetence is the ability of the body to produce a normal immune response (i.e., antibody production and/or cell-mediated immunity) following exposure to a pathogen, which might be a live organism (such as a bacterium or fungus), a virus, or specific antigenic components isolated from a pathogen and introduced in a vaccine. Immunocompetence is the opposite of immunodeficiency or immuno-incompetent or immunocompromised.
  • immunocompetence means that a B cell or T cell is mature and can recognize antigens and allow a person to mount an immune response.
  • Immunocompetence depends on the ability of the adaptive immune system to mount an immune response specific for any potential foreign antigens, using the highly polymorphic receptors encoded by B cells (immunoglobulins, Igs) and T cells (T cell receptors, TCRs).
  • B cells immunoglobulins, Igs
  • T cells T cell receptors, TCRs
  • Igs expressed by B cells are proteins consisting of four polypeptide chains, two heavy chains (H chains) and two light chains (L chains), forming an H 2 L 2 structure.
  • Each pair of H and L chains contains a hypervariable domain, consisting of a V L and a V H region, and a constant domain.
  • the H chains of Igs are of several types, ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ .
  • the diversity of Igs within an individual is mainly determined by the hypervariable domain.
  • the V domain of H chains is created by the combinatorial joining of three types of germline gene segments, the V H , D H , and J H segments.
  • Hypervariable domain sequence diversity is further increased by independent addition and deletion of nucleotides at the V H -D H , D H -J H , and V H -J H junctions during the process of Ig gene rearrangement. In this respect, immunocompetence is reflected in the diversity of Igs.
  • the sequence diversity of ⁇ T cells is largely determined by the amino acid sequence of the third complementarity-determining region (CDR3) loops of the ⁇ and ⁇ chain variable domains, which diversity is a result of recombination between variable (V ⁇ ), diversity (D ⁇ ), and joining (J ⁇ ) gene segments in the ⁇ chain locus, and between analogous V ⁇ , and J ⁇ , gene segments in the a chain locus, respectively.
  • CDR3 third complementarity-determining region
  • CDR3 sequence diversity is further increased by independent addition and deletion of nucleotides at the V ⁇ -D ⁇ , D ⁇ -J ⁇ , and V ⁇ -J ⁇ , junctions during the process of TCR gene rearrangement. In this respect, immunocompetence is reflected in the diversity of TCRs.
  • composition comprising:
  • V segment primers hybridize with a conserved segment, and have similar annealing strength.
  • V segment primer is anchored at position ⁇ 43 in the V ⁇ segment relative to the recombination signal sequence (RSS).
  • RSS recombination signal sequence
  • multiplicity of V segment primers consist of at least 45 primers specific to 45 different V ⁇ genes.
  • the V segment primers have sequences that are selected from the group consisting of SEQ ID NOS:1-45.
  • the V segment primers have sequences that are selected from the group consisting of SEQ ID NOS:58-102.
  • Another embodiment is wherein there is a V segment primer for each V ⁇ segment.
  • Another embodiment of the invention is the composition, wherein the J segment primers hybridize with a conserved framework region element of the J ⁇ segment, and have similar annealing strength.
  • the composition of claim 2 wherein the multiplicity of J segment primers consist of at least thirteen primers specific to thirteen different J ⁇ genes.
  • Another embodiment is The composition of claim 2 , wherein the J segment primers have sequences that are selected from the group consisting of SEQ ID NOS:46-57.
  • Another embodiment is wherein the J segment primers have sequences that are selected from the group consisting of SEQ ID NOS:102-113.
  • Another embodiment is wherein there is a J segment primer for each J ⁇ segment.
  • Another embodiment is wherein all J segment primers anneal to the same conserved motif.
  • composition wherein the amplified DNA molecule starts from said conserved motif and amplifies adequate sequence to diagnostically identify the J segment and includes the CDR3 junction and extends into the V segment.
  • amplified J ⁇ gene segments each have a unique four base tag at positions +11 through +14 downstream of the RSS site.
  • composition comprising:
  • V segment and J segment primers permit amplification of the TCRG CDR3 region by a multiplex polymerase chain reaction (PCR) to produce a multiplicity of amplified DNA molecules sufficient to quantify the diversity of antibody heavy chain genes.
  • PCR multiplex polymerase chain reaction
  • composition comprising:
  • V segment and J segment primers permit amplification of antibody heavy chain (IGH) CDR3 region by a multiplex polymerase chain reaction (PCR) to produce a multiplicity of amplified DNA molecules sufficient to quantify the diversity of antibody heavy chain genes.
  • IGH antibody heavy chain
  • PCR multiplex polymerase chain reaction
  • composition comprising:
  • V segment and J segment primers permit amplification of antibody light chain (IGL) V L region by a multiplex polymerase chain reaction (PCR) to produce a multiplicity of amplified DNA molecules sufficient to quantify the diversity of antibody light chain genes.
  • PCR multiplex polymerase chain reaction
  • Another aspect of the invention is a method comprising:
  • each V segment primer comprises a sequence that is complementary to a single functional v ⁇ segment
  • each J segment primer comprises a sequence that is complementary to a J ⁇ segment
  • combining the V segment and J segment primers with a sample of genomic DNA permits amplification of a TCR CDR3 region by a multiplex polymerase chain reaction (PCR) and produces a multiplicity of amplified DNA molecules.
  • PCR multiplex polymerase chain reaction
  • each V segment primer comprises a sequence that is complementary to a single functional V ⁇ segment
  • each J segment primer comprises a sequence that is complementary to a J ⁇ segment
  • combining the V segment and J segment primers with a sample of genomic DNA permits amplification of a TCR CDR3 region by a multiplex polymerase chain reaction (PCR) and produces a multiplicity of amplified DNA molecules.
  • PCR multiplex polymerase chain reaction
  • Another embodiment of the invention is the method further comprising a step of sequencing the amplified DNA molecules. Another embodiment is wherein the sequencing step utilizes a set of sequencing oligonucleotides, that hybridize to regions within the amplified DNA molecules. Another embodiment is the method, further comprising a step of calculating the total diversity of TCR ⁇ CDR3 sequences among the amplified DNA molecules. Another embodiment is wherein the method shows that the total diversity of a normal human subject is greater than 1*10 6 sequences, greater than 2*10 6 sequences, or greater than 3*10 6 sequences.
  • Another aspect of the invention is a method of diagnosing immunodeficiency in a human patient, comprising measuring the diversity of TCR CDR3 sequences of the patient, and comparing the diversity of the subject to the diversity obtained from a normal subject.
  • An embodiment of the invention is the method, wherein measuring the diversity of TCR sequences comprises the steps of:
  • An embodiment of the invention is the method, wherein comparing the diversity is determined by calculating using the following equation:
  • G( ⁇ ) is the empirical distribution function of the parameters ⁇ 1 , . . . , ⁇ s , n x is the number of clonotypes sequenced exactly x times, and
  • E ⁇ ( n x ) S ⁇ ⁇ 0 ⁇ ⁇ ( ⁇ - ⁇ ⁇ ⁇ x x ! ) ⁇ ⁇ G ⁇ ( ⁇ ) .
  • Another embodiment of the invention is the method, wherein the diversity of at least two samples of genomic DNA are compared. Another embodiment is wherein one sample of genomic DNA is from a patient and the other sample is from a normal subject. Another embodiment is wherein one sample of genomic DNA is from a patient before a therapeutic treatment and the other sample is from the patient after treatment. Another embodiment is wherein the two samples of genomic DNA are from the same patient at different times during treatment. Another embodiment is wherein a disease is diagnosed based on the comparison of diversity among the samples of genomic DNA. Another embodiment is wherein the immunocompetence of a human patient is assessed by the comparison.
  • the TCR and Ig genes can generate millions of distinct proteins via somatic mutation. Because of this diversity-generating mechanism, the hypervariable complementarity determining regions of these genes can encode sequences that can interact with millions of ligands, and these regions are linked to a constant region that can transmit a signal to the cell indicating binding of the protein's cognate ligand.
  • the adaptive immune system employs several strategies to generate a repertoire of T- and B-cell antigen receptors with sufficient diversity to recognize the universe of potential pathogens.
  • ⁇ and ⁇ T cells which primarily recognize peptide antigens presented by MHC molecules, most of this receptor diversity is contained within the third complementarity-determining region (CDR3) of the T cell receptor (TCR) ⁇ and ⁇ chains (or ⁇ and ⁇ chains).
  • CDR3 complementarity-determining region
  • TCRs T cell receptors
  • ⁇ T cells which primarily recognize peptide antigens presented by major histocompatibility complex (MHC) class I and II molecules, are heterodimeric proteins consisting of two transmembrane polypeptide chains ( ⁇ and ⁇ ), each containing one variable and one constant domain.
  • MHC major histocompatibility complex
  • the peptide specificity of ⁇ T cells is in large part determined by the amino acid sequence encoded in the third complementarity-determining region (CDR3) loops of the ⁇ and ⁇ chain variable domains.
  • CDR3 regions of the ⁇ and ⁇ chains are formed by recombination between noncontiguous variable (V ⁇ ), diversity (D ⁇ ), and joining (J ⁇ ) gene segments in the ⁇ chain locus, and between analogous V ⁇ and J ⁇ gene segments in the ⁇ chain locus, respectively.
  • V ⁇ noncontiguous variable
  • D ⁇ diversity
  • J ⁇ joining
  • CDR3 sequence diversity is further increased by template-independent addition and deletion of nucleotides at the V ⁇ -D ⁇ , D ⁇ -J ⁇ , and V ⁇ -J ⁇ junctions during the process of TCR gene rearrangement.
  • a complex library of template molecules carrying universal PCR adapter sequences at each end is hybridized to a lawn of complementary oligonucleotides immobilized on a solid surface.
  • Solid phase PCR is utilized to amplify the hybridized library, resulting in millions of template clusters on the surface, each comprising multiple ( ⁇ 1,000) identical copies of a single DNA molecule from the original library.
  • a 30-54 bp interval in the molecules in each cluster is sequenced using reversible dye-termination chemistry, to permit simultaneous sequencing from genomic DNA of the rearranged TCR ⁇ chain CDR3 regions carried in millions of T cells. This approach enables direct sequencing of a significant fraction of the uniquely rearranged TCR ⁇ CDR3 regions in populations of ⁇ T cells, which thereby permits estimation of the relative frequency of each CDR3 sequence in the population.
  • TCR ⁇ chain CDR3 diversity in the entire ⁇ T cell repertoire were estimated using direct measurements of the number of unique TCR ⁇ CDR3 sequences observed in blood samples containing millions of ⁇ T cells. The results herein identify a lower bound for TCR ⁇ CDR3 diversity in the CD4 + and CD8 + T cell compartments that is several fold higher than previous estimates.
  • results herein demonstrate that there are at least 1.5 ⁇ 10 6 unique TCR ⁇ CDR3 sequences in the CD45RO + compartment of antigen-experienced T-cells, a large proportion of which are present at low relative frequency.
  • the existence of such a diverse population of TCR ⁇ CDR3 sequences in antigen-experienced cells has not been previously demonstrated.
  • the diverse pool of TCR ⁇ chains in each healthy individual is a sample from an estimated theoretical space of greater than 10 11 possible sequences.
  • the realized set of rearranged of TCRs is not evenly sampled from this theoretical space.
  • Different V ⁇ 's and J ⁇ 's are found with over a thousand-fold frequency difference.
  • the insertion rates of nucleotides are strongly biased.
  • This reduced space of realized TCR ⁇ sequences leads to the possibility of shared ⁇ chains between people.
  • the in vivo J usage, V usage, mono- and di-nucleotide biases, and position dependent amino acid usage can be computed. These biases significantly narrow the size of the sequence space from which TCR ⁇ are selected, suggesting that different individuals share TCR ⁇ chains with identical amino acid sequences. Results herein show that many thousands of such identical sequences are shared pairwise between individual human genomes.
  • the assay technology uses two pools of primers to provide for a highly multiplexed PCR reaction.
  • the “forward” pool has a primer specific to each V segment in the gene (several primers targeting a highly conserved region are used, to simultaneously capture many V segments).
  • the “reverse” pool primers anneal to a conserved sequence in the joining (“J”) segment.
  • the amplified segment pool includes adequate sequence to identify each J segment and also to allow for a J-segment-specific primer to anneal for resequencing. This enables direct observation of a large fraction of the somatic rearrangements present in an individual. This in turn enables rapid comparison of the TCR repertoire in individuals with an autoimmune disorder (or other target disease indication) against the TCR repertoire of controls.
  • the adaptive immune system can in theory generate an enormous diversity of T cell receptor CDR3 sequences—far more than are likely to be expressed in any one individual at any one time. Previous attempts to measure what fraction of this theoretical diversity is actually utilized in the adult ⁇ T cell repertoire, however, have not permitted accurate assessment of the diversity. What is described herein is the development of a novel approach to this question that is based on single molecule DNA sequencing and an analytic computational approach to estimation of repertoire diversity using diversity measurements in finite samples. The analysis demonstrated that the number of unique TCR ⁇ CDR3 sequences in the adult repertoire significantly exceeds previous estimates based on exhaustive capillary sequencing of small segments of the repertoire.
  • the TCR ⁇ chain diversity in the CD45RO ⁇ population (enriched for na ⁇ ve T cells) observed using the methods described herein is five-fold larger than previously reported.
  • a major discovery is the number of unique TCR ⁇ CDR3 sequences expressed in antigen-experienced CD45RO + T cells—the results herein show that this number is between 10 and 20 times larger than expected based on previous results of others.
  • the frequency distribution of CDR3 sequences in CD45RO + cells suggests that the T cell repertoire contains a large number of clones with a small clone size.
  • TCR sequences closer to germ line appear to be created at a relatively high frequency.
  • TCR sequences close to germ line are shared between different people because the germ line sequence for the V's, D's, and J's are shared, modulo a small number of polymorphisms, among the human population.
  • the T cell receptors expressed by mature ⁇ T cells are heterodimers whose two constituent chains are generated by independent rearrangement events of the TCR ⁇ and ⁇ chain variable loci.
  • the ⁇ chain has less diversity than the ⁇ chain, so a higher fraction of ⁇ 's are shared between individuals, and hundreds of exact TCR ⁇ receptors are shared between any pair of individuals.
  • B cells and T cells can be obtained from a variety of tissue samples including marrow, thymus, lymph glands, peripheral tissues and blood, but peripheral blood is most easily accessed.
  • Peripheral blood samples are obtained by phlebotomy from subjects.
  • Peripheral blood mononuclear cells (PBMC) are isolated by techniques known to those of skill in the art, e.g., by Ficoll-Hypaque® density gradient separation.
  • PBMC Peripheral blood mononuclear cells
  • the B and/or T lymphocytes instead, may be flow sorted into multiple compartments for each subject: e.g.
  • CD8 + CD45RO +/ ⁇ and CD4 + CD45RO +/ ⁇ using fluorescently labeled anti-human antibodies e.g, CD4 FITC (clone M-T466, Miltenyi Biotec), CD8 PE (clone RPA-T8, BD Biosciences), CD45RO ECD (clone UCHL-1, Beckman Coulter), and CD45RO APC (clone UCHL-1, BD Biosciences). Staining of total PBMCs may be done with the appropriate combination of antibodies, followed by washing cells before analysis.
  • Lymphocyte subsets can be isolated by FACS sorting, e.g., by a BD FACSAriaTM cell-sorting system (BD Biosciences) and by analyzing results with FlowJo software (Treestar Inc.), and also by conceptually similar methods involving specific antibodies immobilized to surfaces or beads.
  • FACS sorting e.g., by a BD FACSAriaTM cell-sorting system (BD Biosciences) and by analyzing results with FlowJo software (Treestar Inc.), and also by conceptually similar methods involving specific antibodies immobilized to surfaces or beads.
  • Total genomic DNA is extracted from cells, e.g., by using the QIAamp® DNA blood Mini Kit (QIAGEN®).
  • the approximate mass of a single haploid genome is 3 pg.
  • at least 100,000 to 200,000 cells are used for analysis of diversity, i.e., about 0.6 to 1.2 ⁇ g DNA from diploid T cells.
  • the number of T cells can be estimated to be about 30% of total cells.
  • total nucleic acid can be isolated from cells, including both genomic DNA and mRNA. If diversity is to be measured from mRNA in the nucleic acid extract, the mRNA must be converted to cDNA prior to measurement. This can readily be done by methods of one of ordinary skill.
  • a multiplex PCR system is used to amplify rearranged TCR loci from genomic DNA, preferably from a CDR3 region, more preferably from a TCR ⁇ , TCR ⁇ or TCR ⁇ CDR3 region, most preferably from a TCR ⁇ CDR3 region.
  • a multiplex PCR system may use at least 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25, preferably 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, or 39, most preferably 40, 41, 42, 43, 44, or 45 forward primers, in which each forward primer is specific to a sequence corresponding to one or more TRB V region segments shown in SEQ ID NOS:114-248; and at least 3, 4, 5, 6, or 7, preferably 8, 9, 10, 11, 12 or 13 reverse primers, in which each reverse primer is specific to a sequence corresponding to one or more TRB J region segments shown in SEQ ID NOS:249-261. Most preferably, there is a J segment primer for every J segment.
  • the primers are designed not to cross an intron/exon boundary.
  • the forward primers must preferably anneal to the V segments in a region of relatively strong sequence conservation between V segments so as to maximize the conservation of sequence among these primers. Accordingly, this minimizes the potential for differential annealing properties of each primer, and so that the amplified region between V and J primers contains sufficient TCR V sequence information to identify the specific V gene segment used.
  • the J segment primers hybridize with a conserved element of the J segment, and have similar annealing strength. Most preferably, all J segment primers anneal to the same conserved framework region motif.
  • the forward and reverse primers are both preferably modified at the 5′ end with the universal forward primer sequence compatible with a DNA sequencer.
  • a multiplex PCR system may use 45 forward primers (Table 1), each specific to a functional TCR v ⁇ segment, and thirteen reverse primers (Table 2), each specific to a TCR J ⁇ segment.
  • Table 1 forward primers
  • Table 2 reverse primers
  • Xn and Yn correspond to polynucleotides of lengths n and m, respectively, which would be specific to the single molecule sequencing technology being used to read out the assay.
  • the 45 forward PCR primers of Table 1 are complementary to each of the 48 functional Variable segments, and the thirteen reverse PCR primers of Table 2 are complementary to each of the functional joining (J) gene segments from the TRB locus (TRBJ).
  • TRB V region segments are identified in the Sequence Listing at SEQ ID NOS:114-248 and the TRB J region segments are at SEQ ID NOS:249-261.
  • the primers have been designed such that adequate information is present within the amplified sequence to identify both the V and J genes uniquely (>40 base pairs of sequence upstream of the V gene recombination signal sequence (RSS), and >30 base pairs downstream of the J gene RSS).
  • Alternative primers may be selected by one of ordinary skill from the V and J regions of the genes of each TCR subunit.
  • the forward primers are modified at the 5′ end with the universal forward primer sequence compatible with the DNA sequencer (Xn of Table 1). Similarly, all of the reverse primers are modified with a universal reverse primer sequence (Ym of Table 2).
  • Ym of Table 2 One example of such universal primers is shown in Tables 3 and 4, for the Illumina GAII single-end read sequencing system.
  • the 45 TCR V ⁇ forward primers anneal to the V ⁇ segments in a region of relatively strong sequence conservation between V ⁇ segments so as to maximize the conservation of sequence among these primers.
  • TRBJ SEQ ID gene segment NO: Primer sequence* TRBJ1-1 103 AATGATACGGCGACCACCGAGATCT TTACCTACAACTGTGAGTCTGGTGCCTTGTCCAAA TRBJ1-2 468 AATGATACGGCGACCACCGAGATCT ACCTACAACGGTTAACCTGGTCCCCGAACCGAA TRBJ1-3 104 AATGATACGGCGACCACCGAGATCT ACCTACAACAGTGAGCCAACTTCCCTCCAAA TRBJ1-4 105 AATGATACGGCGACCACCGAGATCT CCAAGACAGAGAGCTGGGTTCCACTGCCAAA TRBJ1-5 484 AATGATACGGCGACCACCGAGATCT ACCTAGGATGGAGAGTCGAGTCCCATCACCAAA TRBJ1-6 106 AATGATACGGCGACCACCGAGATCT CTGTCACAGTGAGCCTGGTCCCGTTCCCAAA TRBJ2-1 107 AATGATACGGCG
  • Genomic templates are PCR amplified using a pool of the 45 TCR V ⁇ F primers (the “VF pool”) and a pool of the twelve TCR J ⁇ R primers (the “JR pool”).
  • VF pool a pool of the 45 TCR V ⁇ F primers
  • JR pool a pool of the twelve TCR J ⁇ R primers
  • 50 ⁇ l PCR reactions may be used with 1.0 ⁇ M VF pool (22 nM for each unique TCR V ⁇ F primer), 1.0 ⁇ M JR pool (77 nM for each unique TCRBJR primer), 1 ⁇ QIAGEN Multiple PCR master mix (QIAGEN part number 206145), 10% Q-solution (QIAGEN), and 16 ng/ul gDNA.
  • the IGH primer set was designed to try to accommodate the potential for somatic hypermutation within the rearranged IGH genes, as is observed after initial stimulation of na ⁇ ve B cells. Consequently all primers were designed to be slightly longer than normal, and to anchor the 3′ ends of each primer into highly conserved sequences of three or more nucleotides that should be resistant to both functional and non-functional somatic mutations.
  • the IGHJ reverse primers were designed to anchor the 3′ end of each PCR primer on a highly conserved GGGG sequence motif within the IGHJ segments. These sequences are shown in Table 5. Underlined sequence are ten base pairs in from RSS that may be deleted. These were excluded from barcode design.
  • Bold sequence is the reverse complement of the IGH J reverse PCR primers. Italicized sequence is the barcode for J identity (eight barcodes reveal six genes, and two alleles within genes). Further sequence within underlined segment may reveal additional allelic identities.
  • V primers were designed in a conserved in region of FR2 between the two conserved tryptophan (W) codons.
  • the primer sequences are anchored at the 3′ end on a tryptophan codon for all IGHV families that conserve this codon. This allows for the last three nucleotides (tryptophan's TGG) to anchor on sequence that is expected to be resistant to somatic hypermutation, providing a 3′ anchor of five out of six nucleotides for each primer.
  • the upstream sequence is extended further than normal, and includes degenerate nucleotides to allow for mismatches induced by hypermutation (or between closely relate IGH V families) without dramatically changing the annealing characteristics of the primer, as shown in Table 7.
  • the sequences of the V gene segments are SEQ ID NOS:262-420.
  • Thermal cycling conditions may follow methods of those skilled in the art. For example, using a PCR Express thermal cycler (Hybaid, Ashford, UK), the following cycling conditions may be used: 1 cycle at 95° C. for 15 minutes, 25 to 40 cycles at 94° C. for 30 seconds, 59° C. for 30 seconds and 72° C. for 1 minute, followed by one cycle at 72° C. for 10 minutes.
  • Sequencing is achieved using a set of sequencing oligonucleotides that hybridize to a defined region within the amplified DNA molecules.
  • the amplified J gene segments each have a unique four base tag at positions +11 through +14 downstream from the RSS site. Accordingly, the sequencing oligonucleotides hybridize adjacent to a four base tag within the amplified J ⁇ gene segments at positions +11 through +14 downstream of the RSS site.
  • sequencing oligonucleotides for TCRB may be designed to anneal to a consensus nucleotide motif observed just downstream of this “tag”, so that the first four bases of a sequence read will uniquely identify the J segment (Table 8).
  • the information used to assign the J and V segment of a sequence read is entirely contained within the amplified sequence, and does not rely upon the identity of the PCR primers.
  • These sequencing oligonucleotides were selected such that promiscuous priming of a sequencing reaction for one J segment by an oligonucleotide specific to another J segment would generate sequence data starting at exactly the same nucleotide as sequence data from the correct sequencing oligonucleotide. In this way, promiscuous annealing of the sequencing oligonucleotides did not impact the quality of the sequence data generated.
  • the average length of the CDR3 region defined as the nucleotides between the second conserved cysteine of the V segment and the conserved phenylalanine of the J segment, is 35+/ ⁇ 3, so sequences starting from the J ⁇ segment tag will nearly always capture the complete V-D-J junction in a 50 base pair read.
  • TCR ⁇ J gene segments are roughly 50 base pair in length. PCR primers that anneal and extend to mismatched sequences are referred to as promiscuous primers.
  • the TCR J ⁇ Reverse PCR primers were designed to minimize overlap with the sequencing oligonucleotides to minimize promiscuous priming in the context of multiplex PCR.
  • the 13 TCR J ⁇ reverse primers are anchored at the 3′ end on the consensus splice site motif, with minimal overlap of the sequencing primers.
  • the TCR J ⁇ primers provide consistent annealing temperature using the sequencer program under default parameters.
  • the IGHJ sequencing primers extend three nucleotides across the conserved CAG sequences as shown in Table 9.
  • PCR step to amplify the TCR ⁇ CDR3 regions prior to sequencing could potentially introduce a systematic bias in the inferred relative abundance of the sequences, due to differences in the efficiency of PCR amplification of CDR3 regions utilizing different V ⁇ and J ⁇ gene segments.
  • Sequenced reads were filtered for those including CDR3 sequences.
  • Sequencer data processing involves a series of steps to remove errors in the primary sequence of each read, and to compress the data.
  • a complexity filter removes approximately 20% of the sequences that are misreads from the sequencer.
  • sequences were required to have a minimum of a six base match to both one of the thirteen TCRB J-regions and one of 54 V-regions. Applying the filter to the control lane containing phage sequence, on average only one sequence in 7-8 million passed these steps.
  • a nearest neighbor algorithm was used to collapse the data into unique sequences by merging closely related sequences, in order to remove both PCR error and sequencing error.
  • the ratio of sequences in the PCR product must be derived working backward from the sequence data before estimating the true distribution of clonotypes in the blood. For each sequence observed a given number of times in the data herein, the probability that that sequence was sampled from a particular size PCR pool is estimated. Because the CDR3 regions sequenced are sampled randomly from a massive pool of PCR products, the number of observations for each sequence are drawn from Poisson distributions. The Poisson parameters are quantized according to the number of T cell genomes that provided the template for PCR. A simple Poisson mixture model both estimates these parameters and places a pairwise probability for each sequence being drawn from each distribution. This is an expectation maximization method which reconstructs the abundances of each sequence that was drawn from the blood.
  • G( ⁇ ) is the empirical distribution function of the parameters ⁇ 1 , . . . , ⁇ s , and n x is the number of clonotypes sequenced exactly x times, then the total number of clonotypes, i.e., the measurement of diversity E, is given by the following formula:
  • E ⁇ ( n x ) S ⁇ ⁇ 0 ⁇ ⁇ ( ⁇ - ⁇ ⁇ ⁇ x x ! ) ⁇ ⁇ G ⁇ ( ⁇ ) .
  • the formula is used to estimate the total diversity of species in the entire source.
  • the idea is that the sampled number of clonotypes at each size contains sufficient information to estimate the underlying distribution of clonotypes in the whole source.
  • the number of new species expected if the exact measurement was repeated was estimated.
  • the limit of the formula as if repeating the measurements an infinite number of times. The result is the expect number of species in the total underlying source population.
  • the value for ⁇ (t), the number of new clonotypes observed in a second measurement should be determined, preferably using the following equation:
  • T cell and/or B cell receptor repertoires can be measured at various time points, e.g., after hematopoietic stem cell transplant (HSCT) treatment for leukemia. Both the change in diversity and the overall diversity of TCRB repertoire can be utilized to measure immunocompetence.
  • a standard for the expected rate of immune reconstitution after transplant can be utilized. The rate of change in diversity between any two time points may be used to actively modify treatment.
  • the overall diversity at a fixed time point is also an important measure, as this standard can be used to compare between different patients. In particular, the overall diversity is the measure that should correlate with the clinical definition of immune reconstitution. This information may be used to modify prophylactic drug regiments of antibiotics, antivirals, and antifungals, e.g., after HSCT.
  • the assessment of immune reconstitution after allogeneic hematopoietic cell transplantation can be determined by measuring changes in diversity. These techniques will also enhance the analysis of how lymphocyte diversity declines with age, as measured by analysis of T cell responses to vaccination. Further, the methods of the invention provide a means to evaluate investigational therapeutic agents (e.g., Interleukin-7 (IL-7)) that have a direct effect on the generation, growth, and development of ⁇ T cells. Moreover, application of these techniques to the study of thymic T cell populations will provide insight into the processes of both T cell receptor gene rearrangement as well as positive and negative selection of thymocytes.
  • investigational therapeutic agents e.g., Interleukin-7 (IL-7)
  • a newborn that does not yet have a fully functioning immune system but may have maternally transmitted antibody is immunodeficient.
  • a newborn is susceptible to a number of diseases until its immune system autonomously develops, and our measurement of the adaptive immune system may will likely prove useful with newborn patients.
  • Lymphocyte diversity can be assessed in other states of congenital or acquired immunodeficiency.
  • An AIDS patient with a failed or failing immune system can be monitored to determine the stage of disease, and to measure a patient's response to therapies aimed to reconstitute immunocompetence.
  • Another application of the methods of the invention is to provide diagnostic measures for solid organ transplant recipients taking medication so their body will not reject the donated organ. Generally, these patients are under immunosuppressive therapies. Monitoring the immunocompetence of the host will assist before and after transplantation.
  • the methods of the invention provide a means for qualitatively and quantitatively assessing the bone marrow graft, or reconstitution of lymphocytes in the course of these treatments.
  • One manner of determining diversity is by comparing at least two samples of genomic DNA, preferably in which one sample of genomic DNA is from a patient and the other sample is from a normal subject, or alternatively, in which one sample of genomic DNA is from a patient before a therapeutic treatment and the other sample is from the patient after treatment, or in which the two samples of genomic DNA are from the same patient at different times during treatment.
  • Another manner of diagnosis may be based on the comparison of diversity among the samples of genomic DNA, e.g., in which the immunocompetence of a human patient is assessed by the comparison.
  • TCR sequences between individuals represent a new class of potential biomarkers for a variety of diseases, including cancers, autoimmune diseases, and infectious diseases. These are the public T cells that have been reported for multiple human diseases. TCRs are useful as biomarkers because T cells are a result of clonal expansion, by which the immune system amplifies these biomarkers through rapid cell division. Following amplification, the TCRs are readily detected even if the target is small (e.g. an early stage tumor). TCRs are also useful as biomarkers because in many cases the T cells might additionally contribute to the disease causally and, therefore could constitute a drug target. T cells self interactions are thought to play a major role in several diseases associated with autoimmunity, e.g., multiple sclerosis, Type I diabetes, and rheumatoid arthritis.
  • Peripheral blood samples from two healthy male donors aged 35 and 37 were obtained with written informed consent using forms approved by the Institutional Review Board of the Fred Hutchinson Cancer Research Center (FHCRC).
  • Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-Hypaque® density gradient separation. The T-lymphocytes were flow sorted into four compartments for each subject: CD8 + CD45RO +/ ⁇ and CD4 + CD45RO +/ ⁇ .
  • lymphocytes For the characterization of lymphocytes the following conjugated anti-human antibodies were used: CD4 FITC (clone M-T466, Miltenyi Biotec), CD8 PE (clone RPA-T8, BD Biosciences), CD45RO ECD (clone UCHL-1, Beckman Coulter), and CD45RO APC (clone UCHL-1, BD Biosciences). Staining of total PBMCs was done with the appropriate combination of antibodies for 20 minutes at 4° C., and stained cells were washed once before analysis. Lymphocyte subsets were isolated by FACS sorting in the BD FACSAriaTM cell-sorting system (BD Biosciences). Data were analyzed with FlowJo software (Treestar Inc.).
  • Total genomic DNA was extracted from sorted cells using the QIAamp® DNA blood Mini Kit (QIAGEN®). The approximate mass of a single haploid genome is 3 pg. In order to sample millions of rearranged TCRB in each T cell compartment, 6 to 27 micrograms of template DNA were obtained from each compartment (see Table 10).
  • CD8+/CD45RO ⁇ CD8+/CD45RO+ CD4+/CD45RO ⁇ CD4+/CD45RO+ Donor cells ( ⁇ 10 6 ) 9.9 6.3 6.3 10 2 DNA ( ⁇ g) 27 13 19 25 PCR cycles 25 25 30 30 clusters (K/tile) 29.3 27 102.3* 118.3* VJ sequences 3.0 2.0 4.4 4.2 ( ⁇ 10 6 ) Cells 4.9 4.8 3.3 9 1 DNA 12 13 6.6 19 PCR cycles 30 30 30 30 30 30 Clusters 116.3 121 119.5 124.6 VJ sequences 3.2 3.7 4.0 3.8 Cells NA NA NA NA 0.03 PCR Bias DNA NA NA NA NA 0.015 assessment PCR cycles NA NA NA NA 25 + 15 clusters NA NA NA 1.4/23.8 VJ sequences NA NA NA 1.6
  • Virtual TCR ⁇ chain spectratyping was performed as follows. Complementary DNA was synthesized from RNA extracted from sorted T cell populations and used as template for multiplex PCR amplification of the rearranged TCR ⁇ chain CDR3 region. Each multiplex reaction contained a 6-FAM-labeled antisense primer specific for the TCR ⁇ chain constant region, and two to five TCR ⁇ chain variable (TRBV) gene-specific sense primers. All 23 functional V ⁇ families were studied. PCR reactions were carried out on a Hybaid PCR Express thermal cycler (Hybaid, Ashford, UK) under the following cycling conditions: 1 cycle at 95° C. for 6 minutes, 40 cycles at 94° C. for 30 seconds, 58° C. for 30 seconds, and 72° C.
  • Each reaction contained cDNA template, 500 ⁇ M dNTPs, 2 mM MgCl 2 and 1 unit of AmpliTaq Gold DNA polymerase (Perkin Elmer) in AmpliTaq Gold buffer, in a final volume of 20 ⁇ l.
  • AmpliTaq Gold DNA polymerase Perkin Elmer
  • AmpliTaq Gold buffer a final volume of 20 ⁇ l.
  • an aliquot of the PCR product was diluted 1:50 and analyzed using a DNA analyzer. The output of the DNA analyzer was converted to a distribution of fluorescence intensity vs. length by comparison with the fluorescence intensity trace of a reference sample containing known size standards.
  • the CDR3 junction region was defined operationally, as follows. The junction begins with the second conserved cysteine of the V-region and ends with the conserved phenylalanine of the J-region. Taking the reverse complements of the observed sequences and translating the flanking regions, the amino acids defining the junction boundaries were identified. The number of nucleotides between these boundaries determines the length and therefore the frame of the CDR3 region.
  • a multiplex PCR system was selected to amplify rearranged TCR ⁇ loci from genomic DNA. The multiplex PCR system uses 45 forward primers (Table 3), each specific to a functional TCR V ⁇ segment, and thirteen reverse primers (Table 4), each specific to a TCR J ⁇ segment. The primers were selected to provide that adequate information is present within the amplified sequence to identify both the V and J genes uniquely (>40 base pairs of sequence upstream of the V gene recombination signal sequence (RSS), and >30 base pairs downstream of the J gene RSS).
  • RSS V gene recombination signal sequence
  • the forward primers are modified at the 5′ end with the universal forward primer sequence compatible with the Illumina GA2 cluster station solid-phase PCR.
  • all of the reverse primers are modified with the GA2 universal reverse primer sequence.
  • the 3′ end of each forward primer is anchored at position ⁇ 43 in the V ⁇ segment, relative to the recombination signal sequence (RSS), thereby providing a unique V ⁇ tag sequence within the amplified region.
  • the thirteen reverse primers specific to each J ⁇ segment are anchored in the 3′ intron, with the 3′ end of each primer crossing the intron/exon junction. Thirteen sequencing primers complementary to the J ⁇ segments were designed that are complementary to the amplified portion of the J ⁇ segment, such that the first few bases of sequence generated will capture the unique J ⁇ tag sequence.
  • J deletions were 4 bp+/ ⁇ 2.5 bp, which implies that J deletions greater than 10 nucleotides occur in less than 1% of sequences.
  • the thirteen different TCR J ⁇ gene segments each had a unique four base tag at positions +11 through +14 downstream of the RSS site.
  • sequencing oligonucleotides were designed to anneal to a consensus nucleotide motif observed just downstream of this “tag”, so that the first four bases of a sequence read will uniquely identify the J segment (Table 5).
  • the information used to assign the J and V segment of a sequence read is entirely contained within the amplified sequence, and does not rely upon the identity of the PCR primers.
  • These sequencing oligonucleotides were selected such that promiscuous priming of a sequencing reaction for one J segment by an oligonucleotide specific to another J segment would generate sequence data starting at exactly the same nucleotide as sequence data from the correct sequencing oligonucleotide. In this way, promiscuous annealing of the sequencing oligonucleotides did not impact the quality of the sequence data generated.
  • the average length of the CDR3 region defined following convention as the nucleotides between the second conserved cysteine of the V segment and the conserved phenylalanine of the J segment, is 35+/ ⁇ 3, so sequences starting from the J ⁇ segment tag will nearly always capture the complete VNDNJ junction in a 50 bp read.
  • TCR ⁇ J gene segments are roughly 50 bp in length.
  • PCR primers that anneal and extend to mismatched sequences are referred to as promiscuous primers.
  • the TCR J ⁇ Reverse PCR primers were designed to minimize overlap with the sequencing oligonucleotides.
  • the 13 TCR J ⁇ reverse primers are anchored at the 3′ end on the consensus splice site motif, with minimal overlap of the sequencing primers.
  • the TCR J ⁇ primers were designed for a consistent annealing temperature (58 degrees in 50 mM salt) using the OligoCalc program under default parameters (http://www.basic.northwestern.edu/biotools/oligocalc.html).
  • the 45 TCR V ⁇ forward primers were designed to anneal to the V ⁇ segments in a region of relatively strong sequence conservation between V ⁇ segments, for two express purposes. First, maximizing the conservation of sequence among these primers minimizes the potential for differential annealing properties of each primer. Second, the primers were chosen such that the amplified region between V and J primers will contain sufficient TCR V ⁇ sequence information to identify the specific V ⁇ gene segment used. This obviates the risk of erroneous TCR V ⁇ gene segment assignment, in the event of promiscuous priming by the TCR V ⁇ primers. TCR V ⁇ forward primers were designed for all known non-pseudogenes in the TCR ⁇ locus.
  • the total PCR product for a successfully rearranged TCR ⁇ CDR3 region using this system is expected to be approximately 200 bp long.
  • Genomic templates were PCR amplified using an equimolar pool of the 45 TCR V ⁇ F primers (the “VF pool”) and an equimolar pool of the thirteen TCR J ⁇ R primers (the “JR pool”).
  • 50 ⁇ l PCR reactions were set up at 1.0 ⁇ M VF pool (22 nM for each unique TCR V ⁇ F primer), 1.0 ⁇ M JR pool (77 nM for each unique TCRBJR primer), 1 ⁇ QIAGEN Multiple PCR master mix (QIAGEN part number 206145), 10% Q-solution (QIAGEN), and 16 ng/ul gDNA.
  • thermal cycling conditions were used in a PCR Express thermal cycler (Hybaid, Ashford, UK) under the following cycling conditions: 1 cycle at 95° C. for 15 minutes, 25 to 40 cycles at 94° C. for 30 seconds, 59° C. for 30 seconds and 72° C. for 1 minute, followed by one cycle at 72° C. for 10 minutes. 12-20 wells of PCR were performed for each library, in order to sample hundreds of thousands to millions of rearranged TCR ⁇ CDR3 loci.
  • Sequencer data processing involves a series of steps to remove errors in the primary sequence of each read, and to compress the data.
  • a complexity filter removes approximately 20% of the sequences which are misreads from the sequencer.
  • sequences were required to have a minimum of a six base match to both one of the thirteen J-regions and one of 54 V-regions.
  • a nearest neighbor algorithm was used to collapse the data into unique sequences by merging closely related sequences, in order to remove both PCR error and sequencing error (see Table 10).
  • the underlying distribution of T-cell sequences in the blood reconstructing were derived from the sequence data.
  • the procedure used three steps; 1) flow sorting T-cells drawn from peripheral blood, 2) PCR amplification, and 3) sequencing. Analyzing the data, the ratio of sequences in the PCR product must be derived working backward from the sequence data before estimating the true distribution of clonotypes in the blood.
  • the probability that that sequence was sampled from a particular size PCR pool is estimated. Because the CDR3 regions sequenced are sampled randomly from a massive pool of PCR products, the number of observations for each sequence are drawn from Poisson distributions. The Poisson parameters are quantized according to the number of T cell genomes that provided the template for PCR. A simple Poisson mixture model both estimates these parameters and places a pairwise probability for each sequence being drawn from each distribution. This is an expectation maximization method which reconstructs the abundances of each sequence that was drawn from the blood.
  • a mixture model can reconstruct the frequency of each TCR ⁇ CDR3 species drawn from the blood, but the larger question is how many unique CDR3 species were present in the donor? This is a fundamental question that needs to be answered as the available sample is limited in each donor, and will be more important in the future as these techniques are extrapolated to the smaller volumes of blood that can reasonably be drawn from patients undergoing treatment.
  • the mathematical solution provides that for a total number of TCR ⁇ “species” or clonotypes, S, a sequencing experiment observes x s copies of sequence s. For all of the unobserved clonotypes, x s equals 0, and each TCR clonotype is “captured” in a blood draw according to a Poisson process with parameter ⁇ s . The number of T cell genomes sequenced in the first measurement 1, and in the second measurement. Since there are a large number of unique sequences, an integral will represent the sum. If G( ⁇ ) is the empirical distribution function of the parameters ⁇ 1 , . . . , ⁇ s , and n x is the number of clonotypes sequenced exactly x times, then
  • E ⁇ ( n x ) S ⁇ ⁇ 0 ⁇ ⁇ ( ⁇ - ⁇ ⁇ ⁇ x x ! ) ⁇ ⁇ G ⁇ ( ⁇ ) .
  • ⁇ (t) is the number of new clonotypes observed in the second sequencing experiment.
  • Sequence error in the primary sequence data derives primarily from two sources: (1) nucleotide misincorporation that occurs during the amplification by PCR of TCR ⁇ CDR3 template sequences, and (2) errors in base calls introduced during sequencing of the PCR-amplified library of CDR3 sequences.
  • the large quantity of data allows us to implement a straightforward error correcting code to correct most of the errors in the primary sequence data that are attributable to these two sources. After error correction, the number of unique, in-frame CDR3 sequences and the number of observations of each unique sequence were tabulated for each of the four flow-sorted T cell populations from the two donors.
  • TCR ⁇ CDR3 regions from a sample of approximately 30,000 unique CD4 + CD45RO + T lymphocyte genomes were amplified through 25 cycles of PCR, at which point the PCR product was split in half. Half was set aside, and the other half of the PCR product was amplified for an additional 15 cycles of PCR, for a total of 40 cycles of amplification. The PCR products amplified through 25 and 40 cycles were then sequenced and compared.
  • the CDR3 region in each TCR ⁇ chain includes sequence derived from one of the thirteen J ⁇ gene segments. Analysis of the CDR3 sequences in the four different T cell populations from the two donors demonstrated that the fraction of total sequences which incorporated sequences derived from the thirteen different J ⁇ gene segments varied more than 20-fold. J ⁇ utilization among four different T flow cytometrically-defined T cells from a single donor is was relatively constant within a given donor. Moreover, the J ⁇ usage patterns observed in two donors, which were inferred from analysis of genomic DNA from T cells sequenced using the GA, are qualitatively similar to those observed in T cells from umbilical cord blood and from healthy adult donors, both of which were inferred from analysis of cDNA from T cells sequenced using exhaustive capillary-based techniques.
  • TdT Terminal Deoxynucloetidyl Transferase
  • the N regions from the out of frame TCR sequences were used to measure the di-nucleotide bias.
  • the di-nucleotide frequencies was divided by the mononucleotide frequencies of each of the two bases. The measure is
  • m f ⁇ ( n 1 ⁇ n 2 ) f ⁇ ( n 1 ) ⁇ f ⁇ ( n 2 ) .
  • the distribution of amino acids in the CDR3 regions of TCR ⁇ chains are shaped by the germline sequences for V, D, and J regions, the insertion bias of TdT, and selection.
  • the distribution of amino acids in this region for the four different T cell sub-compartments is very similar between different cell subtypes. Separating the sequences into ⁇ chains of fixed length, a position dependent distribution among amino acids, which are grouped by the six chemical properties: small, special, and large hydrophobic, neutral polar, acidic and basic.
  • the distributions are virtually identical except for the CD8+ antigen experienced T cells, which have a higher proportion of acidic bases, particularly at position 5.
  • CD8 + and CD4 + TCR sequences As they bind to peptides presented by class I and class II HLA molecules, respectively.
  • the CD8 + antigen experienced T cells have a few positions with a higher proportion of acidic amino acids. This could be do binding with a basic residue found on HLA Class I molecules, but not on Class II.
  • the TCR ⁇ chain sequences were translated to amino acids and then compared pairwise between the two donors. Many thousands of exact sequence matches were observed. For example, comparing the CD4 + CD45RO ⁇ sub-compartments, approximately 8,000 of the 250,000 unique amino acid sequences from donor 1 were exact matches to donor 2. Many of these matching sequences at the amino acid level have multiple nucleotide differences at third codon positions. Following the example mentioned above, 1,500/8,000 identical amino acid matches had >5 nucleotide mismatches. Between any two T cell sub-types, 4-5% of the unique TCR ⁇ sequences were found to have identical amino acid matches.
  • Sequences with less insertions and deletions have receptor sequences closer to germ line.
  • One possibility for the increased number of sequences closer to germ line is that they are the created multiple times during T cell development. Since germ line sequences are shared between people, shared TCR ⁇ chains are likely created by TCRs with a small number of insertions and deletions.
  • TCR diversity has commonly been assessed using the technique of TCR spectratyping, an RT-PCR-based technique that does not assess TCR CDR3 diversity at the sequence level, but rather evaluates the diversity of TCR ⁇ or TCR ⁇ CDR3 lengths expressed as mRNA in subsets of ⁇ T cells that use the same V ⁇ or V ⁇ gene segment.
  • the spectratypes of polyclonal T cell populations with diverse repertoires of TCR CDR3 sequences, such as are seen in umbilical cord blood or in peripheral blood of healthy young adults typically contain CDR3 sequences of 8-10 different lengths that are multiples of three nucleotides, reflecting the selection for in-frame transcripts.
  • Spectratyping also provides roughly quantitative information about the relative frequency of CDR3 sequences with each specific length.
  • “virtual” TCR ⁇ spectratypes were generated from the sequence data and compared with TCR ⁇ spectratypes generated using conventional PCR techniques.
  • the virtual spectratypes contained all of the CDR3 length and relative frequency information present in the conventional spectratypes.
  • Direct TCR ⁇ CDR3 sequencing captures all of the TCR diversity information present in a conventional spectratype.
  • the number of unique CDR3 sequences observed in each lane of the sequencer flow cell routinely exceeded 1 ⁇ 10 5 .
  • the total number of unique TCR ⁇ CDR3 sequences in the entire T cell repertoire of each individual is likely to be far higher. Estimating the number of unique sequences in the entire repertoire, therefore, requires an estimate of the number of additional unique CDR3 sequences that exist in the blood but were not observed in the sample.
  • the estimation of total species diversity in a large, complex population using measurements of the species diversity present in a finite sample has historically been called the “unseen species problem” (see Examples above).
  • the solution starts with determining the number of new species, or TCR ⁇ CDR3 sequences, that are observed if the experiment is repeated, i.e., if the sequencing is repeated on an identical sample of peripheral blood T cells, e.g., an identically prepared library of TCR ⁇ CDR3 PCR products in a different lane of the sequencer flow cell and counting the number of new CDR3 sequences.
  • TCR ⁇ CDR3 sequences For CD8 + CD45RO ⁇ cells from donor 2, the predicted and observed number of new CDR3 sequences in a second lane are within 5% (see Examples above), suggesting that this analytic solution can, in fact, be used to estimate the total number of unique TCR ⁇ CDR3 sequences in the entire repertoire.
  • the total TCR ⁇ diversity in these populations is between 3-4 million unique sequences in the peripheral blood.
  • the CD45RO + , or antigen-experienced, compartment constitutes approximately 1.5 million of these sequences. This is at least an order of magnitude larger than expected. This discrepancy is likely attributable to the large number of these sequences observed at low relative frequency, which could only be detected through deep sequencing.
  • the estimated TCR ⁇ CDR3 repertoire sizes of each compartment in the two donors are within 20% of each other.
  • TCR ⁇ receptor diversity is at least five-fold higher than previous estimates ( ⁇ 4*10 6 distinct CDR3 sequences), and, in particular, suggest far greater TCR ⁇ diversity among CD45RO + antigen-experienced ⁇ T cells than has previously been reported ( ⁇ 1.5*10 6 distinct CDR3 sequences).
  • bioinformatic analysis of the TCR sequence data shows strong biases in the mono- and di-nucleotide content, implying that the utilized TCR sequences are sampled from a distribution much smaller than the theoretical size. With the large diversity of TCR ⁇ chains in each person sampled from a severely constrict space of sequences, overlap of the TCR sequence pools can be expected between each person.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Data Mining & Analysis (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Software Systems (AREA)
  • Databases & Information Systems (AREA)
  • Evolutionary Biology (AREA)
  • Evolutionary Computation (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Artificial Intelligence (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioethics (AREA)
  • Mathematical Physics (AREA)

Abstract

A method of measuring immunocompetence is described. This method provides a means for assessing the effects of diseases or conditions that compromise the immune system and of therapies aimed to reconstitute it. This method is based on quantifying T-cell diversity by calculating the number of diverse T-cell receptor (TCR) beta chain variable regions from blood cells.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application claims the benefit of U.S. Provisional Application No. 61/220,344, filed on Jun. 25, 2009 and is hereby incorporated by reference in its entirety.
    • TECHNICAL FIELD
  • What is described is a method to measure the adaptive immunity of a patient by analyzing the diversity of T cell receptor genes or antibody genes using large scale sequencing of nucleic acid extracted from adaptive immune system cells.
    • BACKGROUND
  • Immunocompetence is the ability of the body to produce a normal immune response (i.e., antibody production and/or cell-mediated immunity) following exposure to a pathogen, which might be a live organism (such as a bacterium or fungus), a virus, or specific antigenic components isolated from a pathogen and introduced in a vaccine. Immunocompetence is the opposite of immunodeficiency or immuno-incompetent or immunocompromised. Several examples would be a newborn that does not yet have a fully functioning immune system but may have maternally transmitted antibody (immunodeficient); a late stage AIDS patient with a failed or failing immune system (immuno-incompetent); a transplant recipient taking medication so their body will not reject the donated organ (immunocompromised); age-related attenuation of T cell function in the elderly; or individuals exposed to radiation or chemotherapeutic drugs. There may be cases of overlap but these terms are all indicators of a dysfunctional immune system. In reference to lymphocytes, immunocompetence means that a B cell or T cell is mature and can recognize antigens and allow a person to mount an immune response.
  • Immunocompetence depends on the ability of the adaptive immune system to mount an immune response specific for any potential foreign antigens, using the highly polymorphic receptors encoded by B cells (immunoglobulins, Igs) and T cells (T cell receptors, TCRs).
  • Igs expressed by B cells are proteins consisting of four polypeptide chains, two heavy chains (H chains) and two light chains (L chains), forming an H2L2 structure. Each pair of H and L chains contains a hypervariable domain, consisting of a VL and a VH region, and a constant domain. The H chains of Igs are of several types, μ, δ, γ, α, and β. The diversity of Igs within an individual is mainly determined by the hypervariable domain. The V domain of H chains is created by the combinatorial joining of three types of germline gene segments, the VH, DH, and JH segments. Hypervariable domain sequence diversity is further increased by independent addition and deletion of nucleotides at the VH-DH, DH-JH, and VH-JH junctions during the process of Ig gene rearrangement. In this respect, immunocompetence is reflected in the diversity of Igs.
  • TCRs expressed by αβ T cells are proteins consisting of two transmembrane polypeptide chains (α and β), expressed from the TCRA and TCRB genes, respectively. Similar TCR proteins are expressed in gamma-delta T cells, from the TCRD and TCRG loci. Each TCR peptide contains variable complementarity determining regions (CDRs), as well as framework regions (FRs) and a constant region. The sequence diversity of αβ T cells is largely determined by the amino acid sequence of the third complementarity-determining region (CDR3) loops of the α and β chain variable domains, which diversity is a result of recombination between variable (Vβ), diversity (Dβ), and joining (Jβ) gene segments in the β chain locus, and between analogous Vα, and Jα, gene segments in the a chain locus, respectively. The existence of multiple such gene segments in the TCR α and β chain loci allows for a large number of distinct CDR3 sequences to be encoded. CDR3 sequence diversity is further increased by independent addition and deletion of nucleotides at the Vβ-Dβ, Dβ-Jβ, and Vα-Jα, junctions during the process of TCR gene rearrangement. In this respect, immunocompetence is reflected in the diversity of TCRs.
  • There exists a long-felt need for methods of assessing or measuring the adaptive immune system of patients in a variety of settings, whether immunocompetence in the immunocompromised, or dysregulated adaptive immunity in autoimmune disease. A demand exists for methods of diagnosing a disease state or the effects of aging by assessing the immunocompetence of a patient. In the same way results of therapies that modify the immune system need to be monitored by assessing the immunocompetence of the patient while undergoing the treatment. Conversely, a demand exists for methods to monitor the adaptive immune system in the context of autoimmune disease flares and remissions, in order to monitor response to therapy, or the need to initiate prophylactic therapy pre-symptomatically.
    • SUMMARY
  • One aspect of the invention is composition comprising:
      • a multiplicity of V-segment primers, wherein each primer comprises a sequence that is complementary to a single functional V segment or a small family of V segments; and
      • a multiplicity of J-segment primers, wherein each primer comprises a sequence that is complementary to a J segment;
        wherein the V segment and J-segment primers permit amplification of a TCR CDR3 region by a multiplex polymerase chain reaction (PCR) to produce a multiplicity of amplified DNA molecules sufficient to quantify the diversity of the TCR genes. One embodiment of the invention is the composition, wherein each V-segment primer comprises a sequence that is complementary to a single Vβ segment, and each J segment primer comprises a sequence that is complementary to a Jβ segment, and wherein V segment and J-segment primers permit amplification of a TCRβ CDR3 region. Another embodiment is the composition, wherein each V-segment primer comprises a sequence that is complementary to a single functional Vα segment, and each J segment primer comprises a sequence that is complementary to a Jα segment, and wherein V segment and J-segment primers permit amplification of a TCRα CDR3 region.
  • Another embodiment of the invention is the composition, wherein the V segment primers hybridize with a conserved segment, and have similar annealing strength. Another embodiment is wherein the V segment primer is anchored at position −43 in the Vβ segment relative to the recombination signal sequence (RSS). Another embodiment is wherein the multiplicity of V segment primers consist of at least 45 primers specific to 45 different Vβ genes. Another embodiment is wherein the V segment primers have sequences that are selected from the group consisting of SEQ ID NOS:1-45. Another embodiment is wherein the V segment primers have sequences that are selected from the group consisting of SEQ ID NOS:58-102. Another embodiment is wherein there is a V segment primer for each Vβ segment.
  • Another embodiment of the invention is the composition, wherein the J segment primers hybridize with a conserved framework region element of the Jβ segment, and have similar annealing strength. The composition of claim 2, wherein the multiplicity of J segment primers consist of at least thirteen primers specific to thirteen different Jβ genes. Another embodiment is The composition of claim 2, wherein the J segment primers have sequences that are selected from the group consisting of SEQ ID NOS:46-57. Another embodiment is wherein the J segment primers have sequences that are selected from the group consisting of SEQ ID NOS:102-113. Another embodiment is wherein there is a J segment primer for each Jβ segment. Another embodiment is wherein all J segment primers anneal to the same conserved motif.
  • Another embodiment of the invention is the composition, wherein the amplified DNA molecule starts from said conserved motif and amplifies adequate sequence to diagnostically identify the J segment and includes the CDR3 junction and extends into the V segment. Another embodiment is wherein the amplified Jβ gene segments each have a unique four base tag at positions +11 through +14 downstream of the RSS site.
  • Another aspect of the invention is the composition further comprising a set of sequencing oligonucleotides, wherein the sequencing oligonucleotides hybridize to a regions within the amplified DNA molecules. An embodiment is wherein the sequencing oligonucleotides hybridize adjacent to a four base tag within the amplified Jβ gene segments at positions +11 through +14 downstream of the RSS site. Another embodiment is wherein the sequencing oligonucleotides are selected from the group consisting of SEG ID NOS:58-70. Another embodiment is wherein the V-segment or J-segment are selected to contain a sequence error-correction by merger of closely related sequences. Another embodiment is the composition, further comprising a universal C segment primer for generating cDNA from mRNA.
  • Another aspect of the invention is a composition comprising:
      • a multiplicity of V segment primers, wherein each V segment primer comprises a sequence that is complementary to a single functional V segment or a small family of V segments; and
      • a multiplicity of J segment primers, wherein each J segment primer comprises a sequence that is complementary to a J segment;
  • wherein the V segment and J segment primers permit amplification of the TCRG CDR3 region by a multiplex polymerase chain reaction (PCR) to produce a multiplicity of amplified DNA molecules sufficient to quantify the diversity of antibody heavy chain genes.
  • Another aspect of the invention is a composition comprising:
      • a multiplicity of V segment primers, wherein each V segment primer comprises a sequence that is complementary to a single functional V segment or a small family of V segments; and
      • a multiplicity of J segment primers, wherein each J segment primer comprises a sequence that is complementary to a J segment;
  • wherein the V segment and J segment primers permit amplification of antibody heavy chain (IGH) CDR3 region by a multiplex polymerase chain reaction (PCR) to produce a multiplicity of amplified DNA molecules sufficient to quantify the diversity of antibody heavy chain genes.
  • Another aspect of the invention is a composition comprising:
      • a multiplicity of V segment primers, wherein each V segment primer comprises a sequence that is complementary to a single functional V segment or a small family of V segments; and
      • multiplicity of J segment primers, wherein each J segment primer comprises a sequence that is complementary to a J segment;
  • wherein the V segment and J segment primers permit amplification of antibody light chain (IGL) VL region by a multiplex polymerase chain reaction (PCR) to produce a multiplicity of amplified DNA molecules sufficient to quantify the diversity of antibody light chain genes.
  • Another aspect of the invention is a method comprising:
      • selecting a multiplicity of V segment primers, wherein each V segment primer comprises a sequence that is complementary to a single functional V segment or a small family of V segments; and
      • selecting a multiplicity of J segment primers, wherein each J segment primer comprises a sequence that is complementary to a J segment;
      • combining the V segment and J segment primers with a sample of genomic DNA to permit amplification of a CDR3 region by a multiplex polymerase chain reaction (PCR) to produce a multiplicity of amplified DNA molecules sufficient to quantify the diversity of the TCR genes.
  • One embodiment of the invention is the method wherein each V segment primer comprises a sequence that is complementary to a single functional vβ segment, and each J segment primer comprises a sequence that is complementary to a Jβ segment; and wherein combining the V segment and J segment primers with a sample of genomic DNA permits amplification of a TCR CDR3 region by a multiplex polymerase chain reaction (PCR) and produces a multiplicity of amplified DNA molecules. Another embodiment is wherein each V segment primer comprises a sequence that is complementary to a single functional Vα segment, and each J segment primer comprises a sequence that is complementary to a Jα segment; and wherein combining the V segment and J segment primers with a sample of genomic DNA permits amplification of a TCR CDR3 region by a multiplex polymerase chain reaction (PCR) and produces a multiplicity of amplified DNA molecules.
  • Another embodiment of the invention is the method further comprising a step of sequencing the amplified DNA molecules. Another embodiment is wherein the sequencing step utilizes a set of sequencing oligonucleotides, that hybridize to regions within the amplified DNA molecules. Another embodiment is the method, further comprising a step of calculating the total diversity of TCRβ CDR3 sequences among the amplified DNA molecules. Another embodiment is wherein the method shows that the total diversity of a normal human subject is greater than 1*106 sequences, greater than 2*106 sequences, or greater than 3*106 sequences.
  • Another aspect of the invention is a method of diagnosing immunodeficiency in a human patient, comprising measuring the diversity of TCR CDR3 sequences of the patient, and comparing the diversity of the subject to the diversity obtained from a normal subject. An embodiment of the invention is the method, wherein measuring the diversity of TCR sequences comprises the steps of:
      • selecting a multiplicity of V segment primers, wherein each V segment primer comprises a sequence that is complementary to a single functional V segment or a small family of V segments; and
      • selecting a multiplicity of J segment primers, wherein each J segment primer comprises a sequence that is complementary to a J segment;
      • combining the V segment and J segment primers with a sample of genomic DNA to permit amplification of a TCR CDR3 region by a multiplex polymerase chain reaction (PCR) to produce a multiplicity of amplified DNA molecules;
      • sequencing the amplified DNA molecules;
      • calculating the total diversity of TCR CDR3 sequences among the amplified DNA molecules.
  • An embodiment of the invention is the method, wherein comparing the diversity is determined by calculating using the following equation:
  • Δ ( t ) = ∑ x E ( n x ) measurement 1 + 2 - ∑ x E ( n x ) measurement 2 = S ∫ 0 ∞ - λ ( 1 - - λ t ) G ( λ )
  • wherein G(λ) is the empirical distribution function of the parameters λ1, . . . , λs, nx is the number of clonotypes sequenced exactly x times, and
  • E ( n x ) = S ∫ 0 ∞ ( - λ λ x x ! ) G ( λ ) .
  • Another embodiment of the invention is the method, wherein the diversity of at least two samples of genomic DNA are compared. Another embodiment is wherein one sample of genomic DNA is from a patient and the other sample is from a normal subject. Another embodiment is wherein one sample of genomic DNA is from a patient before a therapeutic treatment and the other sample is from the patient after treatment. Another embodiment is wherein the two samples of genomic DNA are from the same patient at different times during treatment. Another embodiment is wherein a disease is diagnosed based on the comparison of diversity among the samples of genomic DNA. Another embodiment is wherein the immunocompetence of a human patient is assessed by the comparison.
    • DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
  • The TCR and Ig genes can generate millions of distinct proteins via somatic mutation. Because of this diversity-generating mechanism, the hypervariable complementarity determining regions of these genes can encode sequences that can interact with millions of ligands, and these regions are linked to a constant region that can transmit a signal to the cell indicating binding of the protein's cognate ligand.
  • The adaptive immune system employs several strategies to generate a repertoire of T- and B-cell antigen receptors with sufficient diversity to recognize the universe of potential pathogens. In αβ and γδ T cells, which primarily recognize peptide antigens presented by MHC molecules, most of this receptor diversity is contained within the third complementarity-determining region (CDR3) of the T cell receptor (TCR) α and β chains (or γ and δ chains). Although it has been estimated that the adaptive immune system can generate up to 1018 distinct TCR αβ pairs, direct experimental assessment of TCR CDR3 diversity has not been possible.
  • What is described herein is a novel method of measuring TCR CDR3 diversity that is based on single molecule DNA sequencing, and use this approach to sequence the CDR3 regions in millions of rearranged TCRβ genes isolated from peripheral blood T cells of two healthy adults.
  • The ability of the adaptive immune system to mount an immune response specific for any of the vast number of potential foreign antigens to which an individual might be exposed relies on the highly polymorphic receptors encoded by B cells (immunoglobulins) and T cells (T cell receptors; TCRs). The TCRs expressed by αβ T cells, which primarily recognize peptide antigens presented by major histocompatibility complex (MHC) class I and II molecules, are heterodimeric proteins consisting of two transmembrane polypeptide chains (α and β), each containing one variable and one constant domain. The peptide specificity of αβ T cells is in large part determined by the amino acid sequence encoded in the third complementarity-determining region (CDR3) loops of the α and β chain variable domains. The CDR3 regions of the β and α chains are formed by recombination between noncontiguous variable (Vβ), diversity (Dβ), and joining (Jβ) gene segments in the β chain locus, and between analogous Vα and Jα gene segments in the α chain locus, respectively. The existence of multiple such gene segments in the TCR α and β chain loci allows for a large number of distinct CDR3 sequences to be encoded. CDR3 sequence diversity is further increased by template-independent addition and deletion of nucleotides at the Vβ-Dβ, Dβ-Jβ, and Vα-Jα junctions during the process of TCR gene rearrangement.
  • Previous attempts to assess the diversity of receptors in the adult human αβ T cell repertoire relied on examining rearranged TCR α and β chain genes expressed in small, well-defined subsets of the repertoire, followed by extrapolation of the diversity present in these subsets to the entire repertoire, to estimate approximately 106 unique TCRβ chain CDR3 sequences per individual, with 10-20% of these unique TCRβ CDR3 sequences expressed by cells in the antigen-experienced CD45RO+ compartment. The accuracy and precision of this estimate is severely limited by the need to extrapolate the diversity observed in hundreds of sequences to the entire repertoire, and it is possible that the actual number of unique TCRβ chain CDR3 sequences in the αβ T cell repertoire is significantly larger than 1×106.
  • Recent advances in high-throughput DNA sequencing technology have made possible significantly deeper sequencing than capillary-based technologies. A complex library of template molecules carrying universal PCR adapter sequences at each end is hybridized to a lawn of complementary oligonucleotides immobilized on a solid surface. Solid phase PCR is utilized to amplify the hybridized library, resulting in millions of template clusters on the surface, each comprising multiple (˜1,000) identical copies of a single DNA molecule from the original library. A 30-54 bp interval in the molecules in each cluster is sequenced using reversible dye-termination chemistry, to permit simultaneous sequencing from genomic DNA of the rearranged TCRβ chain CDR3 regions carried in millions of T cells. This approach enables direct sequencing of a significant fraction of the uniquely rearranged TCRβ CDR3 regions in populations of αβ T cells, which thereby permits estimation of the relative frequency of each CDR3 sequence in the population.
  • Accurate estimation of the diversity of TCRβ CDR3 sequences in the entire αβ T cell repertoire from the diversity measured in a finite sample of T cells requires an estimate of the number of CDR3 sequences present in the repertoire that were not observed in the sample. TCRβ chain CDR3 diversity in the entire αβ T cell repertoire were estimated using direct measurements of the number of unique TCRβ CDR3 sequences observed in blood samples containing millions of αβ T cells. The results herein identify a lower bound for TCRβ CDR3 diversity in the CD4+ and CD8+ T cell compartments that is several fold higher than previous estimates. In addition, the results herein demonstrate that there are at least 1.5×106 unique TCRβ CDR3 sequences in the CD45RO+ compartment of antigen-experienced T-cells, a large proportion of which are present at low relative frequency. The existence of such a diverse population of TCRβ CDR3 sequences in antigen-experienced cells has not been previously demonstrated.
  • The diverse pool of TCRβ chains in each healthy individual is a sample from an estimated theoretical space of greater than 1011 possible sequences. However, the realized set of rearranged of TCRs is not evenly sampled from this theoretical space. Different Vβ's and Jβ's are found with over a thousand-fold frequency difference. Additionally, the insertion rates of nucleotides are strongly biased. This reduced space of realized TCRβ sequences leads to the possibility of shared β chains between people. With the sequence data generated by the methods described herein, the in vivo J usage, V usage, mono- and di-nucleotide biases, and position dependent amino acid usage can be computed. These biases significantly narrow the size of the sequence space from which TCRβ are selected, suggesting that different individuals share TCRβ chains with identical amino acid sequences. Results herein show that many thousands of such identical sequences are shared pairwise between individual human genomes.
  • The assay technology uses two pools of primers to provide for a highly multiplexed PCR reaction. The “forward” pool has a primer specific to each V segment in the gene (several primers targeting a highly conserved region are used, to simultaneously capture many V segments). The “reverse” pool primers anneal to a conserved sequence in the joining (“J”) segment. The amplified segment pool includes adequate sequence to identify each J segment and also to allow for a J-segment-specific primer to anneal for resequencing. This enables direct observation of a large fraction of the somatic rearrangements present in an individual. This in turn enables rapid comparison of the TCR repertoire in individuals with an autoimmune disorder (or other target disease indication) against the TCR repertoire of controls.
  • The adaptive immune system can in theory generate an enormous diversity of T cell receptor CDR3 sequences—far more than are likely to be expressed in any one individual at any one time. Previous attempts to measure what fraction of this theoretical diversity is actually utilized in the adult αβ T cell repertoire, however, have not permitted accurate assessment of the diversity. What is described herein is the development of a novel approach to this question that is based on single molecule DNA sequencing and an analytic computational approach to estimation of repertoire diversity using diversity measurements in finite samples. The analysis demonstrated that the number of unique TCRβ CDR3 sequences in the adult repertoire significantly exceeds previous estimates based on exhaustive capillary sequencing of small segments of the repertoire. The TCRβ chain diversity in the CD45RO− population (enriched for naïve T cells) observed using the methods described herein is five-fold larger than previously reported. A major discovery is the number of unique TCRβ CDR3 sequences expressed in antigen-experienced CD45RO+ T cells—the results herein show that this number is between 10 and 20 times larger than expected based on previous results of others. The frequency distribution of CDR3 sequences in CD45RO+ cells suggests that the T cell repertoire contains a large number of clones with a small clone size.
  • The results herein show that the realized set of TCRβ chains are sampled non-uniformly from the huge potential space of sequences. In particular, the β chains sequences closer to germ line (few insertions and deletions at the V-D and D-J boundaries) appear to be created at a relatively high frequency. TCR sequences close to germ line are shared between different people because the germ line sequence for the V's, D's, and J's are shared, modulo a small number of polymorphisms, among the human population.
  • The T cell receptors expressed by mature αβ T cells are heterodimers whose two constituent chains are generated by independent rearrangement events of the TCR α and β chain variable loci. The α chain has less diversity than the β chain, so a higher fraction of α's are shared between individuals, and hundreds of exact TCR αβ receptors are shared between any pair of individuals.
    • Cells
  • B cells and T cells can be obtained from a variety of tissue samples including marrow, thymus, lymph glands, peripheral tissues and blood, but peripheral blood is most easily accessed. Peripheral blood samples are obtained by phlebotomy from subjects. Peripheral blood mononuclear cells (PBMC) are isolated by techniques known to those of skill in the art, e.g., by Ficoll-Hypaque® density gradient separation. Preferably, whole PBMCs are used for analysis. The B and/or T lymphocytes, instead, may be flow sorted into multiple compartments for each subject: e.g. CD8+CD45RO+/− and CD4+CD45RO+/− using fluorescently labeled anti-human antibodies, e.g, CD4 FITC (clone M-T466, Miltenyi Biotec), CD8 PE (clone RPA-T8, BD Biosciences), CD45RO ECD (clone UCHL-1, Beckman Coulter), and CD45RO APC (clone UCHL-1, BD Biosciences). Staining of total PBMCs may be done with the appropriate combination of antibodies, followed by washing cells before analysis. Lymphocyte subsets can be isolated by FACS sorting, e.g., by a BD FACSAria™ cell-sorting system (BD Biosciences) and by analyzing results with FlowJo software (Treestar Inc.), and also by conceptually similar methods involving specific antibodies immobilized to surfaces or beads.
    • Nucleic Acid Extraction
  • Total genomic DNA is extracted from cells, e.g., by using the QIAamp® DNA blood Mini Kit (QIAGEN®). The approximate mass of a single haploid genome is 3 pg. Preferably, at least 100,000 to 200,000 cells are used for analysis of diversity, i.e., about 0.6 to 1.2 μg DNA from diploid T cells. Using PBMCs as a source, the number of T cells can be estimated to be about 30% of total cells.
  • Alternatively, total nucleic acid can be isolated from cells, including both genomic DNA and mRNA. If diversity is to be measured from mRNA in the nucleic acid extract, the mRNA must be converted to cDNA prior to measurement. This can readily be done by methods of one of ordinary skill.
    • DNA Amplification
  • A multiplex PCR system is used to amplify rearranged TCR loci from genomic DNA, preferably from a CDR3 region, more preferably from a TCRα, TCRγ or TCRδ CDR3 region, most preferably from a TCRβ CDR3 region.
  • In general, a multiplex PCR system may use at least 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25, preferably 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, or 39, most preferably 40, 41, 42, 43, 44, or 45 forward primers, in which each forward primer is specific to a sequence corresponding to one or more TRB V region segments shown in SEQ ID NOS:114-248; and at least 3, 4, 5, 6, or 7, preferably 8, 9, 10, 11, 12 or 13 reverse primers, in which each reverse primer is specific to a sequence corresponding to one or more TRB J region segments shown in SEQ ID NOS:249-261. Most preferably, there is a J segment primer for every J segment.
  • Preferably, the primers are designed not to cross an intron/exon boundary. The forward primers must preferably anneal to the V segments in a region of relatively strong sequence conservation between V segments so as to maximize the conservation of sequence among these primers. Accordingly, this minimizes the potential for differential annealing properties of each primer, and so that the amplified region between V and J primers contains sufficient TCR V sequence information to identify the specific V gene segment used.
  • Preferably, the J segment primers hybridize with a conserved element of the J segment, and have similar annealing strength. Most preferably, all J segment primers anneal to the same conserved framework region motif. The forward and reverse primers are both preferably modified at the 5′ end with the universal forward primer sequence compatible with a DNA sequencer.
  • For example, a multiplex PCR system may use 45 forward primers (Table 1), each specific to a functional TCR vβ segment, and thirteen reverse primers (Table 2), each specific to a TCR Jβ segment. Xn and Yn correspond to polynucleotides of lengths n and m, respectively, which would be specific to the single molecule sequencing technology being used to read out the assay.
  • TABLE 1
    TCR-Vβ Forward primer sequences
    SEQ
    TRBV gene ID
    segment(s) NO: Primer sequence*
    TRBV2 1 XnTCAAATTTCACTCTGAAGATCCGGTCCACAA
    TRBV3-1 2 XnGCTCACTTAAATCTICACATCAATTCCCTGG
    TRBV4-1 3 XnCTTAAACCTTCACCTACACGCCCTGC
    TRBV 4 XnCTTATTCCTTCACCTACACACCCTGC
    (4-2, 4-3)
    TRBV5-1 5 XnGCTCTGAGATGAATGTGAGCACCTTG
    TRBV5-3 6 XnGCTCTGAGATGAATGTGAGTGCCTTG
    TRBV(5-4,   7 XnGCTCTGAGCTGAATGTGAACGCCTTG
    5-5, 5-6, 
    5-7, 5-8)
    TRBV6-1 8 XnTCGCTCAGGCTGGAGTCGGCTG
    TRBV 9 XnGCTGGGGTTGGAGTCGGCTG
    (6-2, 6-3)
    TRBV6-4 10 XnCCCTCACGTTGGCGTCTGCTG
    TRBV6-5 11 XnGCTCAGGCTGCTGTCGGCTG
    TRBV6-6 12 XnCGCTCAGGCTGGAGTTGGCTG
    TRBV6-7 13 XnCCCCTCAAGCTGGAGTCAGCTG
    TRBV6-8 14 XnCACTCAGGCTGGTGTCGGCTG
    TRBV6-9 15 XnCGCTCAGGCTGGAGTCAGCTG
    TRBV7-1 16 XnCCACTCTGAAGTTCCAGCGCACAC
    TRBV7-2 17 XnCACTCTGACGATCCAGCGCACAC
    TRBV7-3 18 XnCTCTACTCTGAAGATCCAGCGCACAG
    TRBV7-4 19 XnCCACTCTGAAGATCCAGCGCACAG
    TRBV7-6 20 XnCACTCTGACGATCCAGCGCACAG
    TRBV7-7 21 XnCCACTCTGACGATTCAGCGCACAG
    TRBV7-8 22 XnCCACTCTGAAGATCCAGCGCACAC
    TRBV7-9 23 XnCACCTTGGAGATCCAGCGCACAG
    TRBV9 24 XnGCACTCTGAACTAAACCTGAGCTCTCTG
    TRBV10-1 25 XnCCCCTCACTCTGGAGTCTGCTG
    TRBV10-2 26 XnCCCCCTCACTCTGGAGTCAGCTA
    TRBV10-3 27 XnCCTCCTCACTCTGGAGTCCGCTA
    TRBV(11-1, 28 XnCCACTCTCAAGATCCAGCCTGCAG
    11-3)
    TRBV11-2 29 XnCTCCACTCTCAAGATCCAGCCTGCAA
    TRBV(12-3,  30 XnCCACTCTGAAGATCCAGCCCTCAG
    12-4, 12-5)
    TRBV13 31 XnCATTCTGAACTGAACATGAGCTCCTTGG
    TRBV14 32 XnCTACTCTGAAGGTGCAGCCTGCAG
    TRBV15 33 XnGATAACTTCCAATCCAGGAGGCCGAACA
    TRBV16 34 XnCTGTAGCCTTGAGATCCAGGCTACGA
    TRBV17 35 XnCTTCCACGCTGAAGATCCATCCCG
    TRBV18 36 XnGCATCCTGAGGATCCAGCAGGTAG
    TRBV19 37 XnCCTCTCACTGTGACATCGGCCC
    TRBV20-1 38 XnCTTGTCCACTCTGACAGTGACCAGTG
    TRBV23-1 39 XnCAGCCTGGCAATCCTGTCCTCAG
    TRBV24-1 40 XnCTCCCTGTCCCTAGAGTCTGCCAT
    TRBV25-1 41 XnCCCTGACCCTGGAGTCTGCCA
    TRBV27 42 XnCCCTGATCCTGGAGTCGCCCA
    TRBV28 43 XnCTCCCTGATTCTGGAGTCCGCCA
    TRBV29-1 44 XnCTAACATTCTCAACTCTGACTGTGAGCAACA
    TRBV30 45 XnCGGCAGTTCATCCTGAGTTCTAAGAAGC
  • TABLE 2
    TCR-Jβ Reverse Primer Sequences
    SEQ
    TRBJ gene ID
    segment NO: Primer sequence*
    TRBJ1-1  46 YmTTACCTACAACTGTGAGTCTGGTGCCTTGTCCAAA
    TRBJ1-2  47 YmACCTACAACGGTTAACCTGGTCCCCGAACCGAA
    TRBJ1-3  48 YmACCTACAACAGTGAGCCAACTTCCCTCTCCAAA
    TRBJ1-4  49 YmCCAAGACAGAGAGCTGGGTTCCACTGCCAAA
    TRBJ1-5 483 YmACCTAGGATGGAGAGTCGAGTCCCATCACCAAA
    TRBJ1-6  50 YmCTGTCACAGTGAGCCTGGTCCCGTTCCCAAA
    TRBJ2-1  51 YmCGGTGAGCCGTGTCCCTGGCCCGAA
    TRBJ2-2  52 YmCCAGTACGGTCAGCCTAGAGCCTTCTCCAAA
    TRBJ2-3  53 YmACTGTCAGCCGGGTGCCTGGGCCAAA
    TRBJ2-4  54 YmAGAGCCGGGTCCCGGCGCCGAA
    TRBJ2-5  55 YmGGAGCCGCGTGCCTGGCCCGAA
    TRBJ2-6  56 YmGTCAGCCTGCTGCCGGCCCCGAA
    TRBJ2-7  57 YmGTGAGCCTGGTGCCCGGCCCGAA
  • The 45 forward PCR primers of Table 1 are complementary to each of the 48 functional Variable segments, and the thirteen reverse PCR primers of Table 2 are complementary to each of the functional joining (J) gene segments from the TRB locus (TRBJ). The TRB V region segments are identified in the Sequence Listing at SEQ ID NOS:114-248 and the TRB J region segments are at SEQ ID NOS:249-261. The primers have been designed such that adequate information is present within the amplified sequence to identify both the V and J genes uniquely (>40 base pairs of sequence upstream of the V gene recombination signal sequence (RSS), and >30 base pairs downstream of the J gene RSS). Alternative primers may be selected by one of ordinary skill from the V and J regions of the genes of each TCR subunit.
  • The forward primers are modified at the 5′ end with the universal forward primer sequence compatible with the DNA sequencer (Xn of Table 1). Similarly, all of the reverse primers are modified with a universal reverse primer sequence (Ym of Table 2). One example of such universal primers is shown in Tables 3 and 4, for the Illumina GAII single-end read sequencing system. The 45 TCR Vβ forward primers anneal to the Vβ segments in a region of relatively strong sequence conservation between Vβ segments so as to maximize the conservation of sequence among these primers.
  • TABLE 3
    TCR-Vβ Forward primer sequences
    SEQ
    TRBV gene ID
    segment(s) NO: Primer sequence*
    TRBV2 58 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTTCAAATTTCACTCTGAAGATCCGGTCCACAA
    TRBV3-1 59 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTGCTCACTTAAATCTTCACATCAATTCCCTGG
    TRBV4-1 60 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCTTAAACCTTCACCTACACGCCCTGC
    TRBV(4-2, 4-3) 61 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCTTATTCCTTCACCTACACACCCTGC
    TRBV5-1 62 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTGCTCTGAGATGAATGTGAGCACCTTG
    TRBV5-3 63 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTGCTCTGAGATGAATGTGAGTGCCTTG
    TRBV(5-4, 5-5, 64 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTGCTCTGAGCTGAATGTGAACGCCTTG
    5-6, 5-7, 5-8)
    TRBV6-1 65 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTTCGCTCAGGCTGGAGTCGGCTG
    TRBV(6-2, 6-3) 66 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTGCTGGGGTTGGAGTCGGCTG
    TRBV6-4 67 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCCCTCACGTTGGCGTCTGCTG
    TRBV6-5 68 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTGCTCAGGCTGCTGTCGGCTG
    TRBV6-6 69 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCGCTCAGGCTGGAGTTGGCTG
    TRBV6-7 70 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCCCCTCAAGCTGGAGTCAGCTG
    TRBV6-8 71 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCACTCAGGCTGGTGTCGGCTG
    TRBV6-9 72 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCGCTCAGGCTGGAGTCAGCTG
    TRBV7-1 73 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCCACTCTGAAGTTCCAGCGCACAC
    TRBV7-2 74 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCACTCTGACGATCCAGCGCACAC
    TRBV7-3 75 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCTCTACTCTGAAGATCCAGCGCACAG
    TRBV7-4 76 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCCACTCTGAAGATCCAGCGCACAG
    TRBV7-6 77 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCACTCTGACGATCCAGCGCACAG
    TRBV7-7 78 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCCACTCTGACGATTCAGCGCACAG
    TRBV7-8 79 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCCACTCTGAAGATCCAGCGCACAC
    TRBV7-9 80 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCACCTTGGAGATCCAGCGCACAG
    TRBV9 81 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTGCACTCTGAACTAAACCTGAGCTCTCTG
    TRBV10-1 82 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCCCCTCACTCTGGAGTCTGCTG
    TRBV10-2 83 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCCCCCTCACTCTGGAGTCAGCTA
    TRBV10-3 84 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCCTCCTCACTCTGGAGTCCGCTA
    TRBV(11-1, 11-3) 85 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCCACTCTCAAGATCCAGCCTGCAG
    TRBV11-2 86 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCTCCACTCTCAAGATCCAGCCTGCAA
    TRBV(12-3, 12-4, 87 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCCACTCTGAAGATCCAGCCCTCAG
    12-5)
    TRBV13 88 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCATTCTGAACTGAACATGAGCTCCTTGG
    TRBV14 89 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCTACTCTGAAGGTGCAGCCTGCAG
    TRBV15 90 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTGATAACTTCCAATCCAGGAGGCCGAACA
    TRBV16 91 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCTGTAGCCTTGAGATCCAGGCTACGA
    TRBV17 92 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCTTCCACGCTGAAGATCCATCCCG
    TRBV18 93 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTGCATCCTGAGGATCCAGCAGGTAG
    TRBV19 94 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCCTCTCACTGTGACATCGGCCC
    TRBV20-1 95 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCTTGTCCACTCTGACAGTGACCAGTG
    TRBV23-1 96 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCAGCCTGGCAATCCTGTCCTCAG
    TRBV24-1 97 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCTCCCTGTCCCTAGAGTCTGCCAT
    TRBV25-1 98 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCCCTGACCCTGGAGTCTGCCA
    TRBV27 99 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCCCTGATCCTGGAGTCGCCCA
    TRBV28 100 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCTCCCTGATTCTGGAGTCCGCCA
    TRBV29-1 101 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCTAACATTCTCAACTCTGACTGTGAGCAACA
    TRBV30 102 CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCGGCAGTTCATCCTGAGTTCTAAGAAGC
  • TABLE 4
    TCR-Jβ Reverse Primer Sequences
    TRBJ SEQ ID
    gene segment NO: Primer sequence*
    TRBJ1-1 103 AATGATACGGCGACCACCGAGATCTTTACCTACAACTGTGAGTCTGGTGCCTTGTCCAAA
    TRBJ1-2 468 AATGATACGGCGACCACCGAGATCTACCTACAACGGTTAACCTGGTCCCCGAACCGAA
    TRBJ1-3 104 AATGATACGGCGACCACCGAGATCTACCTACAACAGTGAGCCAACTTCCCTCTCCAAA
    TRBJ1-4 105 AATGATACGGCGACCACCGAGATCTCCAAGACAGAGAGCTGGGTTCCACTGCCAAA
    TRBJ1-5 484 AATGATACGGCGACCACCGAGATCTACCTAGGATGGAGAGTCGAGTCCCATCACCAAA
    TRBJ1-6 106 AATGATACGGCGACCACCGAGATCTCTGTCACAGTGAGCCTGGTCCCGTTCCCAAA
    TRBJ2-1 107 AATGATACGGCGACCACCGAGATCTCGGTGAGCCGTGTCCCTGGCCCGAA
    TRBJ2-2 108 AATGATACGGCGACCACCGAGATCTCCAGTACGGTCAGCCTAGAGCCTTCTCCAAA
    TRBJ2-3 109 AATGATACGGCGACCACCGAGATCTACTGTCAGCCGGGTGCCTGGGCCAAA
    TRBJ2-4 110 AATGATACGGCGACCACCGAGATCTAGAGCCGGGTCCCGGCGCCGAA
    TRBJ2-5 111 AATGATACGGCGACCACCGAGATCTGGAGCCGCGTGCCTGGCCCGAA
    TRBJ2-6 112 AATGATACGGCGACCACCGAGATCTGTCAGCCTGCTGCCGGCCCCGAA
    TRBJ2-7 113 AATGATACGGCGACCACCGAGATCTGTGAGCCTGGTGCCCGGCCCGAA
    *bold sequence indicates universal R oligonucleotide for the sequence analysis
  • The total PCR product for a rearranged TCRβ CDR3 region using this system is expected to be approximately 200 bp long. Genomic templates are PCR amplified using a pool of the 45 TCR Vβ F primers (the “VF pool”) and a pool of the twelve TCR Jβ R primers (the “JR pool”). For example, 50 μl PCR reactions may be used with 1.0 μM VF pool (22 nM for each unique TCR Vβ F primer), 1.0 μM JR pool (77 nM for each unique TCRBJR primer), 1× QIAGEN Multiple PCR master mix (QIAGEN part number 206145), 10% Q-solution (QIAGEN), and 16 ng/ul gDNA.
  • The IGH primer set was designed to try to accommodate the potential for somatic hypermutation within the rearranged IGH genes, as is observed after initial stimulation of naïve B cells. Consequently all primers were designed to be slightly longer than normal, and to anchor the 3′ ends of each primer into highly conserved sequences of three or more nucleotides that should be resistant to both functional and non-functional somatic mutations.
  • The IGHJ reverse primers were designed to anchor the 3′ end of each PCR primer on a highly conserved GGGG sequence motif within the IGHJ segments. These sequences are shown in Table 5. Underlined sequence are ten base pairs in from RSS that may be deleted. These were excluded from barcode design. Bold sequence is the reverse complement of the IGH J reverse PCR primers. Italicized sequence is the barcode for J identity (eight barcodes reveal six genes, and two alleles within genes). Further sequence within underlined segment may reveal additional allelic identities.
  • TABLE 5
    SEQ ID
    IgH J segment NO: Sequence
    >IGHJ4*01/1-48 452                ACTACTTTGA CTACTGGGGCCAAGGAACCCTGGTCACCGTCTCCTCAG
    >IGHJ4*03/1-48 453                GCTACTTTGA CTACTGGGGCCAAGGGACCCTGGTCACCGTCTCCTCAG
    >IGHJ4*02/1-48 454                ACTACTTTGA CTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG
    >IGHJ3*01/1-50 455              TGATGCTTTTGATGTCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAG
    >IGHJ3*02/1-50 456              TGATGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAG
    >IGHJ6*01/1-63 457 ATTACTACTACTACTACGGTATGGACGTCTGGGGGCAAGGGACCACGGTCACCGTCTCCTCAG
    >IGHJ6*02/1-62 458 ATTACTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAG
    >IGHJ6*04/1-63 459 ATTACTACTACTACTACGGTATGGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCAG
    >IGHJ6*03/1-62 460 ATTACTACTACTACTACTACATGGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCAG
    >IGHJ2*01/1-53 461           CTACTGGTACTTCGATCTCTGGGGCCGTGGCACCCTGGTCACTGTCTCCTCAG
    >IGHJ5*01/1-51 462             ACAACTGGTTCGACTCCTGGGGCCAAGGAACCCTGGTCACCGTCTCCTCAG
    >IGHJ5*02/1-51 463             ACAACTGGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG
    >IGHJ1*01/1-52 464            GCTGAATACTTCCAGCACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAG
    >IGHJ2P*01/1-61 465   CTACAAGTGCTTGGAGCACTGGGGCAGGGCAGCCCGGACACCGTCTCCCTGGGAACGTCAG
    >IGHJ1P*01/1-54 466          AAAGGTGCTGGGGGTCCCCTGAACCCGACCCGCCCTGAGACCGCAGCCACATCA
    >IGHJ3P*01/1-52 467            CTTGCGGTTGGACTTCCCAGCCGACAGTGGTGGTCTGGCTTCTGAGGGGTCA
  • Sequences of the IGHJ reverse PCR primers are shown in Table 6.
  • TABLE 6
    SEQ
    IgH J ID
    segment NO: sequence
    >IGHJ4_1 421 TGAGGAGACGGTGACCAGGGTTCCTTGGCCC
    >IGHJ4_3 422 TGAGGAGACGGTGACCAGGGTCCCTTGGCCC
    >IGHJ4_2 423 TGAGGAGACGGTGACCAGGGTTCCCTGGCCC
    >IGHJ3_12 424 CTGAAGAGACGGTGACCATTGTCCCTTGGCCC
    >IGHJ6_1 425 CTGAGGAGACGGTGACCGTGGTCCCTTGCCCC
    >IGHJ6_2 426 TGAGGAGACGGTGACCGTGGTCCCTTGGCCC
    >IGHJ6_34 427 CTGAGGAGACGGTGACCGTGGTCCCTTTGCCC
    >IGHJ2_1 428 CTGAGGAGACAGTGACCAGGGTGCCACGGCCC
    >IGHJ5_1 429 CTGAGGAGACGGTGACCAGGGTTCCTTGGCCC
    >IGHJ5_2 430 CTGAGGAGACGGTGACCAGGGTTCCCTGGCCC
    >IGHJ1_1 431 CTGAGGAGACGGTGACCAGGGTGCCCTGGCCC
  • V primers were designed in a conserved in region of FR2 between the two conserved tryptophan (W) codons.
  • The primer sequences are anchored at the 3′ end on a tryptophan codon for all IGHV families that conserve this codon. This allows for the last three nucleotides (tryptophan's TGG) to anchor on sequence that is expected to be resistant to somatic hypermutation, providing a 3′ anchor of five out of six nucleotides for each primer. The upstream sequence is extended further than normal, and includes degenerate nucleotides to allow for mismatches induced by hypermutation (or between closely relate IGH V families) without dramatically changing the annealing characteristics of the primer, as shown in Table 7. The sequences of the V gene segments are SEQ ID NOS:262-420.
  • TABLE 7
    IgH V
    segment SEQ ID NO: sequence
    >IGHV1 443 TGGGTGCACCAGGTCCANGNACAAGGGCTTGAGTGG
    >IGHV2 444 TGGGTGCGACAGGCTCGNGNACAACGCCTTGAGTGG
    >IGHV3 445 TGGGTGCGCCAGATGCCNGNGAAAGGCCTGGAGTGG
    >IGHV4 446 TGGGTCCGCCAGSCYCCNGNGAAGGGGCTGGAGTGG
    >IGHV5 447 TGGGTCCGCCAGGCTCCNGNAAAGGGGCTGGAGTGG
    >IGHV6 448 TGGGTCTGCCAGGCTCCNGNGAAGGGGCAGGAGTGG
    >IGH7_3.25p 449 TGTGTCCGCCAGGCTCCAGGGAATGGGCTGGAGTTGG
    >IGH8_3.54p 450 TCAGATTCCCAAGCTCCAGGGAAGGGGCTGGAGTGAG
    >GH9_3.63p 451 TGGGTCAATGAGACTCTAGGGAAGGGGCTGGAGGGAG
  • Thermal cycling conditions may follow methods of those skilled in the art. For example, using a PCR Express thermal cycler (Hybaid, Ashford, UK), the following cycling conditions may be used: 1 cycle at 95° C. for 15 minutes, 25 to 40 cycles at 94° C. for 30 seconds, 59° C. for 30 seconds and 72° C. for 1 minute, followed by one cycle at 72° C. for 10 minutes.
    • Sequencing
  • Sequencing is achieved using a set of sequencing oligonucleotides that hybridize to a defined region within the amplified DNA molecules.
  • Preferably, the amplified J gene segments each have a unique four base tag at positions +11 through +14 downstream from the RSS site. Accordingly, the sequencing oligonucleotides hybridize adjacent to a four base tag within the amplified Jβ gene segments at positions +11 through +14 downstream of the RSS site.
  • For example, sequencing oligonucleotides for TCRB may be designed to anneal to a consensus nucleotide motif observed just downstream of this “tag”, so that the first four bases of a sequence read will uniquely identify the J segment (Table 8).
  • TABLE 8
    Sequencing oligonucleotides
    Sequencing
    oligonucleotide SEQ ID NO: Oligonucleotide sequence
    Jseq 1-1 470 ACAACTGTGAGTCTGGTGCCTTGTCCAAAGAAA
    Jseq 1-2 471 ACAACGGTTAACCTGGTCCCCGAACCGAAGGTG
    Jseq 1-3 472 ACAACAGTGAGCCAACTTCCCTCTCCAAAATAT
    Jseq 1-4 473 AAGACAGAGAGCTGGGTTCCACTGCCAAAAAAC
    Jseq 1-5 474 AGGATGGAGAGTCGAGTCCCATCACCAAAATGC
    Jseq 1-6 475 GTCACAGTGAGCCTGGTCCCGTTCCCAAAGTGG
    Jseq 2-1 476 AGCACGGTGAGCCGTGTCCCTGGCCCGAAGAAC
    Jseq 2-2 477 AGTACGGTCAGCCTAGAGCCTTCTCCAAAAAAC
    Jseq 2-3 478 AGCACTGTCAGCCGGGTGCCTGGGCCAAAATAC
    Jseq 2-4 479 AGCACTGAGAGCCGGGTCCCGGCGCCGAAGTAC
    Jseq 2-5 480 AGCACCAGGAGCCGCGTGCCTGGCCCGAAGTAC
    Jseq 2-6 481 AGCACGGTCAGCCTGCTGCCGGCCCCGAAAGTC
    Jseq 2-7 482 GTGACCGTGAGCCTGGTGCCCGGCCCGAAGTAC
  • The information used to assign the J and V segment of a sequence read is entirely contained within the amplified sequence, and does not rely upon the identity of the PCR primers. These sequencing oligonucleotides were selected such that promiscuous priming of a sequencing reaction for one J segment by an oligonucleotide specific to another J segment would generate sequence data starting at exactly the same nucleotide as sequence data from the correct sequencing oligonucleotide. In this way, promiscuous annealing of the sequencing oligonucleotides did not impact the quality of the sequence data generated.
  • The average length of the CDR3 region, defined as the nucleotides between the second conserved cysteine of the V segment and the conserved phenylalanine of the J segment, is 35+/−3, so sequences starting from the Jβ segment tag will nearly always capture the complete V-D-J junction in a 50 base pair read.
  • TCR βJ gene segments are roughly 50 base pair in length. PCR primers that anneal and extend to mismatched sequences are referred to as promiscuous primers. The TCR Jβ Reverse PCR primers were designed to minimize overlap with the sequencing oligonucleotides to minimize promiscuous priming in the context of multiplex PCR. The 13 TCR Jβ reverse primers are anchored at the 3′ end on the consensus splice site motif, with minimal overlap of the sequencing primers. The TCR Jβ primers provide consistent annealing temperature using the sequencer program under default parameters.
  • For the sequencing reaction, the IGHJ sequencing primers extend three nucleotides across the conserved CAG sequences as shown in Table 9.
  • TABLE 9
    IgH J
    segment SEQ ID NO: sequence
    >IGHJSEQ4_1 432 TGAGGAGACGGTGACCAGGGTTCCTTGGCCCCAG
    >IGHJSEQ4_3 433 TGAGGAGACGGTGACCAGGGTCCCTTGGCCCCAG
    >IGHJSEQ4_2 434 TGAGGAGACGGTGACCAGGGTTCCCTGGCCCCAG
    >IGHJSEQ3_12 435 CTGAAGAGACGGTGACCATTGTCCCTTGGCCCCAG
    >IGHJSEQ6_1 436 CTGAGGAGACGGTGACCGTGGTCCCTTGCCCCCAG
    >IGHJSEQ6_2 437 TGAGGAGACGGTGACCGTGGTCCCTTGGCCCCAG
    >IGHJSEQ6_34 438 CTGAGGAGACGGTGACCGTGGTCCCTTTGCCCCAG
    >IGHJSEQ2_1 439 CTGAGGAGACAGTGACCAGGGTGCCACGGCCCCAG
    >IGHJSEQ5_1 440 CTGAGGAGACGGTGACCAGGGTTCCTTGGCCCCAG
    >IGHJSEQ5_2 441 CTGAGGAGACGGTGACCAGGGTTCCCTGGCCCCAG
    >IGHJSEQ1_1 442 CTGAGGAGACGGTGACCAGGGTGCCCTGGCCCCAG
    • Processing Sequence Data
  • For rapid analysis of sequencing results, an algorithm can be developed by one of ordinary skill. A preferred method is as follows.
  • The use of a PCR step to amplify the TCRβ CDR3 regions prior to sequencing could potentially introduce a systematic bias in the inferred relative abundance of the sequences, due to differences in the efficiency of PCR amplification of CDR3 regions utilizing different Vβ and Jβ gene segments. Each cycle of PCR amplification potentially introduces a bias of average magnitude 1.51/15=1.027. Thus, the 25 cycles of PCR introduces a total bias of average magnitude 1.02725=1.95 in the inferred relative abundance of distinct CDR3 region sequences.
  • Sequenced reads were filtered for those including CDR3 sequences. Sequencer data processing involves a series of steps to remove errors in the primary sequence of each read, and to compress the data. A complexity filter removes approximately 20% of the sequences that are misreads from the sequencer. Then, sequences were required to have a minimum of a six base match to both one of the thirteen TCRB J-regions and one of 54 V-regions. Applying the filter to the control lane containing phage sequence, on average only one sequence in 7-8 million passed these steps. Finally, a nearest neighbor algorithm was used to collapse the data into unique sequences by merging closely related sequences, in order to remove both PCR error and sequencing error.
  • Analyzing the data, the ratio of sequences in the PCR product must be derived working backward from the sequence data before estimating the true distribution of clonotypes in the blood. For each sequence observed a given number of times in the data herein, the probability that that sequence was sampled from a particular size PCR pool is estimated. Because the CDR3 regions sequenced are sampled randomly from a massive pool of PCR products, the number of observations for each sequence are drawn from Poisson distributions. The Poisson parameters are quantized according to the number of T cell genomes that provided the template for PCR. A simple Poisson mixture model both estimates these parameters and places a pairwise probability for each sequence being drawn from each distribution. This is an expectation maximization method which reconstructs the abundances of each sequence that was drawn from the blood.
  • To estimate diversity, the “unseen species” formula is employed. To apply this formula, unique adaptive immune receptors (e.g. TCRB) clonotypes takes the place of species. The mathematical solution provides that for a total number of TCRβ “species” or clonotypes, S, a sequencing experiment observes xs copies of sequence s. For all of the unobserved clonotypes, xs equals 0, and each TCR clonotype is “captured” in a blood draw according to a Poisson process with parameter λs. The number of T cell genomes sequenced in the first measurement 1, and in the second measurement. Since there are a large number of unique sequences, an integral will represent the sum. If G(λ) is the empirical distribution function of the parameters λ1, . . . , λs, and nx is the number of clonotypes sequenced exactly x times, then the total number of clonotypes, i.e., the measurement of diversity E, is given by the following formula:
  • E ( n x ) = S ∫ 0 ∞ ( - λ λ x x ! ) G ( λ ) .
  • For a given experiment, where T cells are sampled from some arbitrary source (e.g. a blood draw), the formula is used to estimate the total diversity of species in the entire source. The idea is that the sampled number of clonotypes at each size contains sufficient information to estimate the underlying distribution of clonotypes in the whole source. To derive the formula, the number of new species expected if the exact measurement was repeated was estimated. The limit of the formula as if repeating the measurements an infinite number of times. The result is the expect number of species in the total underlying source population. The value for Δ(t), the number of new clonotypes observed in a second measurement, should be determined, preferably using the following equation:
  • Δ ( t ) = ∑ x E ( n x ) msmt 1 + msmt 2 - ∑ x E ( n x ) msmt 1 = S ∫ 0 ∞ - λ ( 1 - - λ t ) G ( λ )
  • in which msmt1 and msmt2 are the number of clonotypes from measurement 1 and 2, respectively. Taylor expansion of 1−e−λt gives Δ(t)=E(x1)t−E(x2)t2+E(x3)t3− . . . , which can be approximated by replacing the expectations E(nx) with the observed numbers in the first measurement. Using in the numbers observed in the first measurement, this formula predicts that 1.6*105 new unique sequences should be observed in the second measurement. The actual value of the second measurement was 1.8*105 new TCRβ sequences, which implies that the prediction provided a valid lower bound on total diversity. An Euler's transformation was used to regularize Δ(t) to produce a lower bound for Δ(∞).
    • Using a Measurement of Diversity to Diagnose Disease
  • The measurement of diversity can be used to diagnose disease or the effects of a treatment, as follows. T cell and/or B cell receptor repertoires can be measured at various time points, e.g., after hematopoietic stem cell transplant (HSCT) treatment for leukemia. Both the change in diversity and the overall diversity of TCRB repertoire can be utilized to measure immunocompetence. A standard for the expected rate of immune reconstitution after transplant can be utilized. The rate of change in diversity between any two time points may be used to actively modify treatment. The overall diversity at a fixed time point is also an important measure, as this standard can be used to compare between different patients. In particular, the overall diversity is the measure that should correlate with the clinical definition of immune reconstitution. This information may be used to modify prophylactic drug regiments of antibiotics, antivirals, and antifungals, e.g., after HSCT.
  • The assessment of immune reconstitution after allogeneic hematopoietic cell transplantation can be determined by measuring changes in diversity. These techniques will also enhance the analysis of how lymphocyte diversity declines with age, as measured by analysis of T cell responses to vaccination. Further, the methods of the invention provide a means to evaluate investigational therapeutic agents (e.g., Interleukin-7 (IL-7)) that have a direct effect on the generation, growth, and development of αβ T cells. Moreover, application of these techniques to the study of thymic T cell populations will provide insight into the processes of both T cell receptor gene rearrangement as well as positive and negative selection of thymocytes.
  • A newborn that does not yet have a fully functioning immune system but may have maternally transmitted antibody is immunodeficient. A newborn is susceptible to a number of diseases until its immune system autonomously develops, and our measurement of the adaptive immune system may will likely prove useful with newborn patients.
  • Lymphocyte diversity can be assessed in other states of congenital or acquired immunodeficiency. An AIDS patient with a failed or failing immune system can be monitored to determine the stage of disease, and to measure a patient's response to therapies aimed to reconstitute immunocompetence.
  • Another application of the methods of the invention is to provide diagnostic measures for solid organ transplant recipients taking medication so their body will not reject the donated organ. Generally, these patients are under immunosuppressive therapies. Monitoring the immunocompetence of the host will assist before and after transplantation.
  • Individuals exposed to radiation or chemotherapeutic drugs are subject to bone marrow transplantations or otherwise require replenishment of T cell populations, along with associated immunocompetence. The methods of the invention provide a means for qualitatively and quantitatively assessing the bone marrow graft, or reconstitution of lymphocytes in the course of these treatments.
  • One manner of determining diversity is by comparing at least two samples of genomic DNA, preferably in which one sample of genomic DNA is from a patient and the other sample is from a normal subject, or alternatively, in which one sample of genomic DNA is from a patient before a therapeutic treatment and the other sample is from the patient after treatment, or in which the two samples of genomic DNA are from the same patient at different times during treatment. Another manner of diagnosis may be based on the comparison of diversity among the samples of genomic DNA, e.g., in which the immunocompetence of a human patient is assessed by the comparison.
    • Biomarkers
  • Shared TCR sequences between individuals represent a new class of potential biomarkers for a variety of diseases, including cancers, autoimmune diseases, and infectious diseases. These are the public T cells that have been reported for multiple human diseases. TCRs are useful as biomarkers because T cells are a result of clonal expansion, by which the immune system amplifies these biomarkers through rapid cell division. Following amplification, the TCRs are readily detected even if the target is small (e.g. an early stage tumor). TCRs are also useful as biomarkers because in many cases the T cells might additionally contribute to the disease causally and, therefore could constitute a drug target. T cells self interactions are thought to play a major role in several diseases associated with autoimmunity, e.g., multiple sclerosis, Type I diabetes, and rheumatoid arthritis.
    • EXAMPLES Example 1 Sample Acquisition, PBMC Isolation, FACS Sorting and Genomic DNA Extraction
  • Peripheral blood samples from two healthy male donors aged 35 and 37 were obtained with written informed consent using forms approved by the Institutional Review Board of the Fred Hutchinson Cancer Research Center (FHCRC). Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-Hypaque® density gradient separation. The T-lymphocytes were flow sorted into four compartments for each subject: CD8+CD45RO+/− and CD4+CD45RO+/−. For the characterization of lymphocytes the following conjugated anti-human antibodies were used: CD4 FITC (clone M-T466, Miltenyi Biotec), CD8 PE (clone RPA-T8, BD Biosciences), CD45RO ECD (clone UCHL-1, Beckman Coulter), and CD45RO APC (clone UCHL-1, BD Biosciences). Staining of total PBMCs was done with the appropriate combination of antibodies for 20 minutes at 4° C., and stained cells were washed once before analysis. Lymphocyte subsets were isolated by FACS sorting in the BD FACSAria™ cell-sorting system (BD Biosciences). Data were analyzed with FlowJo software (Treestar Inc.).
  • Total genomic DNA was extracted from sorted cells using the QIAamp® DNA blood Mini Kit (QIAGEN®). The approximate mass of a single haploid genome is 3 pg. In order to sample millions of rearranged TCRB in each T cell compartment, 6 to 27 micrograms of template DNA were obtained from each compartment (see Table 10).
  • TABLE 10
    CD8+/CD45RO− CD8+/CD45RO+ CD4+/CD45RO− CD4+/CD45RO+ Donor
    cells (×106) 9.9 6.3 6.3 10 2
    DNA (μg) 27 13 19 25
    PCR cycles 25 25 30 30
    clusters (K/tile) 29.3 27 102.3* 118.3*
    VJ sequences 3.0 2.0 4.4 4.2
    (×106)
    Cells 4.9 4.8 3.3 9 1
    DNA 12 13 6.6 19
    PCR cycles 30 30 30 30
    Clusters 116.3 121 119.5 124.6
    VJ sequences 3.2 3.7 4.0 3.8
    Cells NA NA NA 0.03 PCR Bias
    DNA NA NA NA 0.015 assessment
    PCR cycles NA NA NA 25 + 15
    clusters NA NA NA 1.4/23.8
    VJ sequences NA NA NA 1.6
    • Example 2 Virtual T Cell Receptor β Chain Spectratyping
  • Virtual TCR β chain spectratyping was performed as follows. Complementary DNA was synthesized from RNA extracted from sorted T cell populations and used as template for multiplex PCR amplification of the rearranged TCR β chain CDR3 region. Each multiplex reaction contained a 6-FAM-labeled antisense primer specific for the TCR β chain constant region, and two to five TCR β chain variable (TRBV) gene-specific sense primers. All 23 functional Vβ families were studied. PCR reactions were carried out on a Hybaid PCR Express thermal cycler (Hybaid, Ashford, UK) under the following cycling conditions: 1 cycle at 95° C. for 6 minutes, 40 cycles at 94° C. for 30 seconds, 58° C. for 30 seconds, and 72° C. for 40 seconds, followed by 1 cycle at 72° C. for 10 minutes. Each reaction contained cDNA template, 500 μM dNTPs, 2 mM MgCl2 and 1 unit of AmpliTaq Gold DNA polymerase (Perkin Elmer) in AmpliTaq Gold buffer, in a final volume of 20 μl. After completion, an aliquot of the PCR product was diluted 1:50 and analyzed using a DNA analyzer. The output of the DNA analyzer was converted to a distribution of fluorescence intensity vs. length by comparison with the fluorescence intensity trace of a reference sample containing known size standards.
    • Example 3 Multiplex PCR Amplification of TCRβ CDR3 Regions
  • The CDR3 junction region was defined operationally, as follows. The junction begins with the second conserved cysteine of the V-region and ends with the conserved phenylalanine of the J-region. Taking the reverse complements of the observed sequences and translating the flanking regions, the amino acids defining the junction boundaries were identified. The number of nucleotides between these boundaries determines the length and therefore the frame of the CDR3 region. In order to generate the template library for sequencing, a multiplex PCR system was selected to amplify rearranged TCRβ loci from genomic DNA. The multiplex PCR system uses 45 forward primers (Table 3), each specific to a functional TCR Vβ segment, and thirteen reverse primers (Table 4), each specific to a TCR Jβ segment. The primers were selected to provide that adequate information is present within the amplified sequence to identify both the V and J genes uniquely (>40 base pairs of sequence upstream of the V gene recombination signal sequence (RSS), and >30 base pairs downstream of the J gene RSS).
  • The forward primers are modified at the 5′ end with the universal forward primer sequence compatible with the Illumina GA2 cluster station solid-phase PCR. Similarly, all of the reverse primers are modified with the GA2 universal reverse primer sequence. The 3′ end of each forward primer is anchored at position −43 in the Vβ segment, relative to the recombination signal sequence (RSS), thereby providing a unique Vβ tag sequence within the amplified region. The thirteen reverse primers specific to each Jβ segment are anchored in the 3′ intron, with the 3′ end of each primer crossing the intron/exon junction. Thirteen sequencing primers complementary to the Jβ segments were designed that are complementary to the amplified portion of the Jβ segment, such that the first few bases of sequence generated will capture the unique Jβ tag sequence.
  • On average J deletions were 4 bp+/−2.5 bp, which implies that J deletions greater than 10 nucleotides occur in less than 1% of sequences. The thirteen different TCR Jβ gene segments each had a unique four base tag at positions +11 through +14 downstream of the RSS site. Thus, sequencing oligonucleotides were designed to anneal to a consensus nucleotide motif observed just downstream of this “tag”, so that the first four bases of a sequence read will uniquely identify the J segment (Table 5).
  • The information used to assign the J and V segment of a sequence read is entirely contained within the amplified sequence, and does not rely upon the identity of the PCR primers. These sequencing oligonucleotides were selected such that promiscuous priming of a sequencing reaction for one J segment by an oligonucleotide specific to another J segment would generate sequence data starting at exactly the same nucleotide as sequence data from the correct sequencing oligonucleotide. In this way, promiscuous annealing of the sequencing oligonucleotides did not impact the quality of the sequence data generated.
  • The average length of the CDR3 region, defined following convention as the nucleotides between the second conserved cysteine of the V segment and the conserved phenylalanine of the J segment, is 35+/−3, so sequences starting from the Jβ segment tag will nearly always capture the complete VNDNJ junction in a 50 bp read.
  • TCR βJ gene segments are roughly 50 bp in length. PCR primers that anneal and extend to mismatched sequences are referred to as promiscuous primers. Because of the risk of promiscuous priming in the context of multiplex PCR, especially in the context of a gene family, the TCR Jβ Reverse PCR primers were designed to minimize overlap with the sequencing oligonucleotides. Thus, the 13 TCR Jβ reverse primers are anchored at the 3′ end on the consensus splice site motif, with minimal overlap of the sequencing primers. The TCR Jβ primers were designed for a consistent annealing temperature (58 degrees in 50 mM salt) using the OligoCalc program under default parameters (http://www.basic.northwestern.edu/biotools/oligocalc.html).
  • The 45 TCR Vβ forward primers were designed to anneal to the Vβ segments in a region of relatively strong sequence conservation between Vβ segments, for two express purposes. First, maximizing the conservation of sequence among these primers minimizes the potential for differential annealing properties of each primer. Second, the primers were chosen such that the amplified region between V and J primers will contain sufficient TCR Vβ sequence information to identify the specific Vβ gene segment used. This obviates the risk of erroneous TCR Vβ gene segment assignment, in the event of promiscuous priming by the TCR Vβ primers. TCR Vβ forward primers were designed for all known non-pseudogenes in the TCRβ locus.
  • The total PCR product for a successfully rearranged TCRβ CDR3 region using this system is expected to be approximately 200 bp long. Genomic templates were PCR amplified using an equimolar pool of the 45 TCR Vβ F primers (the “VF pool”) and an equimolar pool of the thirteen TCR Jβ R primers (the “JR pool”). 50 μl PCR reactions were set up at 1.0 μM VF pool (22 nM for each unique TCR Vβ F primer), 1.0 μM JR pool (77 nM for each unique TCRBJR primer), 1× QIAGEN Multiple PCR master mix (QIAGEN part number 206145), 10% Q-solution (QIAGEN), and 16 ng/ul gDNA. The following thermal cycling conditions were used in a PCR Express thermal cycler (Hybaid, Ashford, UK) under the following cycling conditions: 1 cycle at 95° C. for 15 minutes, 25 to 40 cycles at 94° C. for 30 seconds, 59° C. for 30 seconds and 72° C. for 1 minute, followed by one cycle at 72° C. for 10 minutes. 12-20 wells of PCR were performed for each library, in order to sample hundreds of thousands to millions of rearranged TCRβ CDR3 loci.
    • Example 4 Pre-Processing of Sequence Data
  • Sequencer data processing involves a series of steps to remove errors in the primary sequence of each read, and to compress the data. First, a complexity filter removes approximately 20% of the sequences which are misreads from the sequencer. Then, sequences were required to have a minimum of a six base match to both one of the thirteen J-regions and one of 54 V-regions. Applying the filter to the control lane containing phage sequence, on average only one sequence in 7-8 million passed these steps without false positives. Finally, a nearest neighbor algorithm was used to collapse the data into unique sequences by merging closely related sequences, in order to remove both PCR error and sequencing error (see Table 10).
    • Example 5 Estimating Relative CDR3 Sequence Abundance in PCR Pools and Blood Samples
  • After collapsing the data, the underlying distribution of T-cell sequences in the blood reconstructing were derived from the sequence data. The procedure used three steps; 1) flow sorting T-cells drawn from peripheral blood, 2) PCR amplification, and 3) sequencing. Analyzing the data, the ratio of sequences in the PCR product must be derived working backward from the sequence data before estimating the true distribution of clonotypes in the blood.
  • For each sequence observed a given number of times in the data herein, the probability that that sequence was sampled from a particular size PCR pool is estimated. Because the CDR3 regions sequenced are sampled randomly from a massive pool of PCR products, the number of observations for each sequence are drawn from Poisson distributions. The Poisson parameters are quantized according to the number of T cell genomes that provided the template for PCR. A simple Poisson mixture model both estimates these parameters and places a pairwise probability for each sequence being drawn from each distribution. This is an expectation maximization method which reconstructs the abundances of each sequence that was drawn from the blood.
    • Example 6 Unseen Species Model for Estimation of True Diversity
  • A mixture model can reconstruct the frequency of each TCRβ CDR3 species drawn from the blood, but the larger question is how many unique CDR3 species were present in the donor? This is a fundamental question that needs to be answered as the available sample is limited in each donor, and will be more important in the future as these techniques are extrapolated to the smaller volumes of blood that can reasonably be drawn from patients undergoing treatment.
  • The mathematical solution provides that for a total number of TCRβ “species” or clonotypes, S, a sequencing experiment observes xs copies of sequence s. For all of the unobserved clonotypes, xs equals 0, and each TCR clonotype is “captured” in a blood draw according to a Poisson process with parameter λs. The number of T cell genomes sequenced in the first measurement 1, and in the second measurement. Since there are a large number of unique sequences, an integral will represent the sum. If G(λ) is the empirical distribution function of the parameters λ1, . . . , λs, and nx is the number of clonotypes sequenced exactly x times, then
  • E ( n x ) = S ∫ 0 ∞ ( - λ λ x x ! ) G ( λ ) .
  • The value Δ(t) is the number of new clonotypes observed in the second sequencing experiment.
  • Δ ( t ) = ∑ x E ( n x ) exp 1 + exp 2 - ∑ x E ( n x ) exp 1 = S ∫ 0 ∞ - λ ( 1 - - λ t ) G ( λ )
  • Taylor expansion of 1−e−λt gives Δ(t)=E(x1)t−E(x2)t2+E(x3)t3− . . . , which can be approximated by replacing the expectations (E(nx)) with the observed numbers in the first measurement. Using in the numbers observed in the first measurement, this formula predicts that 1.6*105 new unique sequences should be observed in the second measurement. The actual value of the second measurement was 1.8*105 new TCRβ sequences, which implies that the prediction provided a valid lower bound on total diversity. An Euler's transformation was used to regularize Δ(t) to produce a lower bound for Δ(∞).
    • Example 7 Error Correction and Bias Assessment
  • Sequence error in the primary sequence data derives primarily from two sources: (1) nucleotide misincorporation that occurs during the amplification by PCR of TCRβ CDR3 template sequences, and (2) errors in base calls introduced during sequencing of the PCR-amplified library of CDR3 sequences. The large quantity of data allows us to implement a straightforward error correcting code to correct most of the errors in the primary sequence data that are attributable to these two sources. After error correction, the number of unique, in-frame CDR3 sequences and the number of observations of each unique sequence were tabulated for each of the four flow-sorted T cell populations from the two donors. The relative frequency distribution of CDR3 sequences in the four flow cytometrically-defined populations demonstrated that antigen-experienced CD45RO+ populations contained significantly more unique CDR3 sequences with high relative frequency than the CD45RO− populations. Frequency histograms of TCRβ CDR3 sequences observed in four different T cell subsets distinguished by expression of CD4, CD8, and CD45RO and present in blood showed that ten unique sequences were each observed 200 times in the CD4+CD45RO+ (antigen-experienced) T cell sample, which was more than twice as frequent as that observed in the CD4+CD45RO− populations.
  • The use of a PCR step to amplify the TCRβ CDR3 regions prior to sequencing could potentially introduce a systematic bias in the inferred relative abundance of the sequences, due to differences in the efficiency of PCR amplification of CDR3 regions utilizing different Vβ and Jβ gene segments. To estimate the magnitude of any such bias, the TCRβ CDR3 regions from a sample of approximately 30,000 unique CD4+CD45RO+ T lymphocyte genomes were amplified through 25 cycles of PCR, at which point the PCR product was split in half. Half was set aside, and the other half of the PCR product was amplified for an additional 15 cycles of PCR, for a total of 40 cycles of amplification. The PCR products amplified through 25 and 40 cycles were then sequenced and compared. Over 95% of the 25 cycle sequences were also found in the 40-cycle sample: a linear correlation is observed when comparing the frequency of sequences between these samples. For sequences observed a given number of times in the 25 cycle lane, a combination of PCR bias and sampling variance accounts for the variance around the mean of the number of observations at 40 cycles. Conservatively attributing the mean variation about the line (1.5-fold) entirely to PCR bias, each cycle of PCR amplification potentially introduces a bias of average magnitude 1.51/15=1.027. Thus, the 25 cycles of PCR introduces a total bias of average magnitude 1.02725=1.95 in the inferred relative abundance of distinct CDR3 region sequences.
    • Example 8 Jβ Gene Segment Usage
  • The CDR3 region in each TCR β chain includes sequence derived from one of the thirteen Jβ gene segments. Analysis of the CDR3 sequences in the four different T cell populations from the two donors demonstrated that the fraction of total sequences which incorporated sequences derived from the thirteen different Jβ gene segments varied more than 20-fold. Jβ utilization among four different T flow cytometrically-defined T cells from a single donor is was relatively constant within a given donor. Moreover, the Jβ usage patterns observed in two donors, which were inferred from analysis of genomic DNA from T cells sequenced using the GA, are qualitatively similar to those observed in T cells from umbilical cord blood and from healthy adult donors, both of which were inferred from analysis of cDNA from T cells sequenced using exhaustive capillary-based techniques.
    • Example 9 Nucleotide Insertion Bias
  • Much of the diversity at the CDR3 junctions in TCR α and β chains is created by non-templated nucleotide insertions by the enzyme Terminal Deoxynucloetidyl Transferase (TdT). However, in vivo, selection plays a significant role in shaping the TCR repertoire giving rise to unpredictability. The TdT nucleotide insertion frequencies, independent of selection, were calculated using out of frame TCR sequences. These sequences are non-functional rearrangements that are carried on one allele in T cells where the second allele has a functional rearrangement. The mono-nucleotide insertion bias of TdT favors C and G (Table 11).
  • TABLE 11
    Mono-nucleotide bias in out of frame data
    A C G T
    Lane 1 0.24 0.294 0.247 0.216
    Lane 2 0.247 0.284 0.256 0.211
    Lane 3 0.25 0.27 0.268 0.209
    Lane 4 0.255 0.293 0.24 0.21
  • Similar nucleotide frequencies are observed in the in frame sequences (Table 12).
  • TABLE 12
    Mono-nucleotide bias in in-frame data
    A C G T
    Lane 1 0.21 0.285 0.275 0.228
    Lane 2 0.216 0.281 0.266 0.235
    Lane 3 0.222 0.266 0.288 0.221
    Lane 4 0.206 0.294 0.228 0.27
  • The N regions from the out of frame TCR sequences were used to measure the di-nucleotide bias. To isolate the marginal contribution of a di-nucleotide bias, the di-nucleotide frequencies was divided by the mononucleotide frequencies of each of the two bases. The measure is
  • m = f ( n 1 n 2 ) f ( n 1 ) f ( n 2 ) .
  • The matrix for m is found in Table 13.
  • TABLE 13
    Di-nucleotide odd ratios for out of frame data
    A C G T
    A 1.198 0.938 0.945 0.919
    C 0.988 1.172 0.88 0.931
    G 0.993 0.701 1.352 0.964
    T 0.784 1.232 0.767 1.23
  • Many of the dinucleotides are under or over represented. As an example, the odds of finding a GG pair are very high. Since the codons GGN translate to glycine, many glycines are expected in the CDR3 regions.
    • Example 10 Amino Acid Distributions in the CDR3 Regions
  • The distribution of amino acids in the CDR3 regions of TCRβ chains are shaped by the germline sequences for V, D, and J regions, the insertion bias of TdT, and selection. The distribution of amino acids in this region for the four different T cell sub-compartments is very similar between different cell subtypes. Separating the sequences into β chains of fixed length, a position dependent distribution among amino acids, which are grouped by the six chemical properties: small, special, and large hydrophobic, neutral polar, acidic and basic. The distributions are virtually identical except for the CD8+ antigen experienced T cells, which have a higher proportion of acidic bases, particularly at position 5.
  • Of particular interest is the comparison between CD8+ and CD4+ TCR sequences as they bind to peptides presented by class I and class II HLA molecules, respectively. The CD8+ antigen experienced T cells have a few positions with a higher proportion of acidic amino acids. This could be do binding with a basic residue found on HLA Class I molecules, but not on Class II.
    • Example 11 TCR β Chains with Identical Amino Acid Sequences Found in Different People
  • The TCR β chain sequences were translated to amino acids and then compared pairwise between the two donors. Many thousands of exact sequence matches were observed. For example, comparing the CD4+ CD45RO− sub-compartments, approximately 8,000 of the 250,000 unique amino acid sequences from donor 1 were exact matches to donor 2. Many of these matching sequences at the amino acid level have multiple nucleotide differences at third codon positions. Following the example mentioned above, 1,500/8,000 identical amino acid matches had >5 nucleotide mismatches. Between any two T cell sub-types, 4-5% of the unique TCRβ sequences were found to have identical amino acid matches.
  • Two possibilities were examined: that 1) selection during TCR development is producing these common sequences and 2) the large bias in nucleotide insertion frequency by TdT creates similar nucleotide sequences. The in-frame pairwise matches were compared to the out-of-frame pairwise matches (see Examples 1-4, above). Changing frames preserved all of the features of the genetic code and so the same number of matches should be found if the sequence bias was responsible for the entire observation. However, almost twice as many in-frame matches as out-of-frame matches were found, suggesting that selection at the protein level is playing a significant role.
  • To confirm this finding of thousands of identical TCR β chain amino acid sequences, two donors were compared with respect to the CD8+ CD62L+ CD45RA+ (naïve-like) TCRs from a third donor, a 44 year old CMV+ Caucasian female. Identical pairwise matches of many thousands of sequences at the amino acid level between the third donor and each of the original two donors were found. In contrast, 460 sequences were shared between all three donors. The large variation in total number of unique sequences between the donors is a product of the starting material and variations in loading onto the sequencer, and is not representative of a variation in true diversity in the blood of the donors.
    • Example 12 Higher Frequency Clonotypes are Closer to Germline
  • The variation in copy number between different sequences within every T cell sub-compartment ranged by a factor of over 10.000-fold. The only property that correlated with copy number was (the number of insertions plus the number of deletions), which inversely correlated. Results of the analysis showed that deletions play a smaller role than insertions in the inverse correlation with copy number.
  • Sequences with less insertions and deletions have receptor sequences closer to germ line. One possibility for the increased number of sequences closer to germ line is that they are the created multiple times during T cell development. Since germ line sequences are shared between people, shared TCRβ chains are likely created by TCRs with a small number of insertions and deletions.
    • Example 13 “Spectratype” Analysis of TCRβ CDR3 Sequences by V Gene Segment Utilization and CDR3 Length
  • TCR diversity has commonly been assessed using the technique of TCR spectratyping, an RT-PCR-based technique that does not assess TCR CDR3 diversity at the sequence level, but rather evaluates the diversity of TCRα or TCRβ CDR3 lengths expressed as mRNA in subsets of αβ T cells that use the same Vα or Vβ gene segment. The spectratypes of polyclonal T cell populations with diverse repertoires of TCR CDR3 sequences, such as are seen in umbilical cord blood or in peripheral blood of healthy young adults typically contain CDR3 sequences of 8-10 different lengths that are multiples of three nucleotides, reflecting the selection for in-frame transcripts. Spectratyping also provides roughly quantitative information about the relative frequency of CDR3 sequences with each specific length. To assess whether direct sequencing of TCRβ CDR3 regions from T cell genomic DNA using the sequencer could faithfully capture all of the CDR3 length diversity that is identified by spectratyping, “virtual” TCRβ spectratypes (see Examples above) were generated from the sequence data and compared with TCRβ spectratypes generated using conventional PCR techniques. The virtual spectratypes contained all of the CDR3 length and relative frequency information present in the conventional spectratypes. Direct TCRβ CDR3 sequencing captures all of the TCR diversity information present in a conventional spectratype. A comparison of standard TCRβ spectratype data and calculated TCRβ CDR3 length distributions for sequences utilizing representative TCR Vβ gene segments and present in CD4+CD45RO+ cells from donor 1. Reducing the information contained in the sequence data to a frequency histogram of the unique CDR3 sequences with different lengths within each Vβ family readily reproduces all of the information contained in the spectratype data. In addition, the virtual spectratypes revealed the presence within each Vβ family of rare CDR3 sequences with both very short and very long CDR3 lengths that were not detected by conventional PCR-based spectratyping.
    • Example 14 Estimation of Total CDR3 Sequence Diversity
  • After error correction, the number of unique CDR3 sequences observed in each lane of the sequencer flow cell routinely exceeded 1×105. Given that the PCR products sequenced in each lane were necessarily derived from a small fraction of the T cell genomes present in each of the two donors, the total number of unique TCRβ CDR3 sequences in the entire T cell repertoire of each individual is likely to be far higher. Estimating the number of unique sequences in the entire repertoire, therefore, requires an estimate of the number of additional unique CDR3 sequences that exist in the blood but were not observed in the sample. The estimation of total species diversity in a large, complex population using measurements of the species diversity present in a finite sample has historically been called the “unseen species problem” (see Examples above). The solution starts with determining the number of new species, or TCRβ CDR3 sequences, that are observed if the experiment is repeated, i.e., if the sequencing is repeated on an identical sample of peripheral blood T cells, e.g., an identically prepared library of TCRβ CDR3 PCR products in a different lane of the sequencer flow cell and counting the number of new CDR3 sequences. For CD8+CD45RO− cells from donor 2, the predicted and observed number of new CDR3 sequences in a second lane are within 5% (see Examples above), suggesting that this analytic solution can, in fact, be used to estimate the total number of unique TCRβ CDR3 sequences in the entire repertoire.
  • The resulting estimates of the total number of unique TCRβ CDR3 sequences in the four flow cytometrically-defined T cell compartments are shown in Table 14.
  • TABLE 14
    TCR repertoire diversity
    Donor CD8 CD4 CD45RO Diversity
    1 + − + 6.3 * 105
    + − − 1.24 * 106 
    − + + 8.2 * 105
    − + − 1.28 * 106 
    Total T cell diversity 3.97 * 106 
    2 + − + 4.4 * 105
    + − − 9.7 * 105
    − + + 8.7 * 105
    − + − 1.03 * 106 
    Total T cell diversity 3.31 * 106 
  • Of note, the total TCRβ diversity in these populations is between 3-4 million unique sequences in the peripheral blood. Surprisingly, the CD45RO+, or antigen-experienced, compartment constitutes approximately 1.5 million of these sequences. This is at least an order of magnitude larger than expected. This discrepancy is likely attributable to the large number of these sequences observed at low relative frequency, which could only be detected through deep sequencing. The estimated TCRβ CDR3 repertoire sizes of each compartment in the two donors are within 20% of each other.
  • The results herein demonstrate that the realized TCRβ receptor diversity is at least five-fold higher than previous estimates (˜4*106 distinct CDR3 sequences), and, in particular, suggest far greater TCRβ diversity among CD45RO+ antigen-experienced αβ T cells than has previously been reported (˜1.5*106 distinct CDR3 sequences). However, bioinformatic analysis of the TCR sequence data shows strong biases in the mono- and di-nucleotide content, implying that the utilized TCR sequences are sampled from a distribution much smaller than the theoretical size. With the large diversity of TCRβ chains in each person sampled from a severely constrict space of sequences, overlap of the TCR sequence pools can be expected between each person. In fact, the results showed about 5% of CD8+ naïve TCRβ chains with exact amino acid matches are shared between each pair of three different individuals. As the TCRα pool has been previously measured to be substantially smaller than the theoretical TCRβ diversity, these results show that hundreds to thousands of truly public αβ TCRs can be found.

Claims (45)

1. A composition comprising:
(a) a multiplicity of V-segment primers, wherein each primer comprises a sequence that is complementary to a single functional V segment or a small family of V segments; and
(b) a multiplicity of J-segment primers, wherein each primer comprises a sequence that is complementary to a J segment;
wherein the V segment and J-segment primers permit amplification of a TCR or IG CDR3 region by a multiplex polymerase chain reaction (PCR) to produce a multiplicity of amplified DNA molecules sufficient to quantify the diversity of the TCR or IG genes.
2. The composition of claim 1, wherein each V-segment primer comprises a sequence that is complementary to a single Vγ segment or a family of similar Vγ segments, and each J segment primer comprises a sequence that is complementary to a Jγ segment, and wherein V segment and J-segment primers permit amplification of a TCRγ CDR3 region.
3. The composition of claim 1, wherein each V-segment primer comprises a sequence that is complementary to a single Vδ segment or a family of similar Vδ segments, and each J segment primer comprises a sequence that is complementary to a Jδ segment, and wherein V segment and J-segment primers permit amplification of a TCRα CDR3 region.
4. The composition of claim 1, wherein each V-segment primer comprises a sequence that is complementary to a single Vα segment or a family of similar Vα segments, and each J segment primer comprises a sequence that is complementary to a Jα segment, and wherein V segment and J-segment primers permit amplification of a TCRα CDR3 region.
5. The composition of claim 1, wherein each V-segment primer comprises a sequence that is complementary to a single Vβ segment or a family of similar Vβ segments, and each J segment primer comprises a sequence that is complementary to a Jβ segment, and wherein V segment and J-segment primers permit amplification of a TCRβ CDR3 region.
6. The composition of claim 1, wherein the V segment have similar annealing strength.
7. The composition of claim 1, wherein all J segment primers anneal to the same conserved framework region motif.
8. The composition of claim 1, wherein the amplified DNA molecule starts from said conserved motif and diagnostically identifies the J segment and includes the junction and into the V segment.
9. The composition of claim 1, further comprising a set of sequencing oligonucleotides, wherein the sequencing oligonucleotides hybridize to a regions within the amplified DNA molecules.
10. The composition of claim 1, wherein the amplified DNA spans a V-D-J junction.
11. The composition of claim 1, wherein the V-segment or J-segment are selected to contain a sequence error-correction by merger of closely related sequences.
12. The composition of claim 1, further comprising a universal C segment primer for generating cDNA from mRNA.
13. The composition of claim 5, wherein the V segment primer is anchored at position −43 in the Vβ segment relative to the recombination signal sequence (RSS).
14. The composition of claim 5, wherein the multiplicity of V segment primers consist of at least 14 primers specific to 14 different Vβ genes.
15. The composition of claim 5, wherein the V segment primers have sequences that are selected from the group consisting of SEQ ID NOS:1-45.
16. The composition of claim 5, wherein the V segment primers have sequences that are selected from the group consisting of SEQ ID NOS:58-102.
17. The composition of claim 5, wherein there is a V segment primer for each Vβ segment or family of Vβ segments.
18. The composition of claim 5, wherein the primers do not cross an intron/exon boundary.
19. The composition of claim 5, wherein the J segment primers hybridize with a conserved element of the Jβ segment, and have similar annealing strength.
20. The composition of claim 5, wherein the multiplicity of J segment primers consist of at least five primers specific to five different Jβ genes.
21. The composition of claim 5, wherein the J segment primers have sequences that are selected from the group consisting of SEQ ID NOS:46-57 and 483.
22. The composition of claim 5, wherein the J segment primers have sequences that are selected from the group consisting of SEQ ID NOS:103-113, 468 and 484.
23. The composition of claim 5, wherein there is a J segment primer for each Jβ segment.
24. The composition of claim 5, wherein the amplified Jβ gene segments each have a unique four base tag at positions +11 through +14 downstream of the RSS site.
25. The composition of claim 24, wherein the sequencing oligonucleotides hybridize adjacent to a four base tag within the amplified Jβ gene segments at positions +11 through +14 downstream of the RSS site.
26. The composition of claim 24, wherein the sequencing oligonucleotides are selected from the group consisting of SEG ID NOS:470-482.
27. A composition comprising:
(a) a multiplicity of V segment primers, wherein each V segment primer comprises a sequence that is complementary to a single functional V segment or a small family of V segments; and
(b) a multiplicity of J segment primers, wherein each J segment primer comprises a sequence that is complementary to a J segment;
wherein the V segment and J segment primers permit amplification of antibody heavy chain (IGH) VH region by a multiplex polymerase chain reaction (PCR) to produce a multiplicity of amplified DNA molecules sufficient to quantify the diversity of antibody heavy chain genes.
28. A composition comprising:
(a) a multiplicity of V segment primers, wherein each V segment primer comprises a sequence that is complementary to a single functional V segment or a small family of V segments; and
(b) a multiplicity of J segment primers, wherein each J segment primer comprises a sequence that is complementary to a J segment;
wherein the V segment and J segment primers permit amplification of antibody light chain (IGL) VL region by a multiplex polymerase chain reaction (PCR) to produce a multiplicity of amplified DNA molecules sufficient to quantify the diversity of antibody light chain genes.
29. A method comprising:
(a) selecting a multiplicity of V segment primers, wherein each V segment primer comprises a sequence that is complementary to a single functional V segment or a small family of V segments; and
(b) selecting a multiplicity of J segment primers, wherein each J segment primer comprises a sequence that is complementary to a J segment;
(c) combining the V segment and J segment primers with a sample of genomic DNA to permit amplification of a TCR CDR3 region by a multiplex polymerase chain reaction (PCR) to produce a multiplicity of amplified DNA molecules sufficient to quantify the diversity of the TCR genes.
30. The method of claim 29, wherein each V segment primer comprises a sequence that is complementary to a single Vβ segment or a family of Vβ segments, and each J segment primer comprises a sequence that is complementary to a Jβ segment; and wherein combining the V segment and J segment primers with a sample of genomic DNA permits amplification of a TCRB CDR3 region by a multiplex polymerase chain reaction (PCR) and produces a multiplicity of amplified DNA molecules.
31. The method of claim 30, further comprising a step of sequencing the amplified DNA molecules.
32. The method of claim 31, wherein the sequencing step utilizes a set of sequencing oligonucleotides, that hybridize to a defined region within the amplified DNA molecules.
33. The method of claim 32, further comprising a step of calculating the total diversity of TCRβ CDR3 sequences among the amplified DNA molecules.
34. The method of claim 33, wherein the method shows that the total diversity of a normal human subject is greater than 1*106 sequences.
35. The method of claim 33, wherein the method shows that the total diversity of a normal human subject is greater than 2*106 sequences.
36. The method of claim 33, wherein the method shows that the total diversity of a normal human subject is greater than 3*106 sequences.
37. A method of diagnosing immunodeficiency in a human patient, comprising measuring the diversity of TCR CDR3 sequences of the patient, and comparing the diversity of the subject to the diversity obtained from a normal subject.
38. The method of claim 37, wherein measuring the diversity of TCR sequences comprises the steps of:
(a) selecting a multiplicity of V segment primers, wherein each V segment primer comprises a sequence that is complementary to a single functional V segment or a small family of V segments; and
(b) selecting a multiplicity of J segment primers, wherein each J segment primer comprises a sequence that is complementary to a J segment;
(c) combining the V segment and J segment primers with a sample of genomic DNA to permit amplification of a TCR CDR3 region by a multiplex polymerase chain reaction (PCR) to produce a multiplicity of amplified DNA molecules;
(d) sequencing the amplified DNA molecules;
(e) calculating the total diversity of TCR CDR3 sequences among the amplified DNA molecules.
39. The method of claim 38, wherein comparing the diversity is determined by calculating using the following equation:
Δ ( t ) = ∑ x E ( n x ) measurement 1 + 2 - ∑ x E ( n x ) measurement 2 = S ∫ 0 ∞ - λ ( 1 - - λ t ) G ( λ )
wherein G(λ) is the empirical distribution function of the parameters λ1, . . . , λs, nx is the number of clonotypes sequenced exactly x times, and
E ( n x ) = S ∫ 0 ∞ ( - λ λ x x ! ) G ( λ ) .
40. The method of claim 38, wherein the diversity of at least two samples of genomic DNA are compared.
41. The method of claim 40, wherein one sample of genomic DNA is from a patient and the other sample is from a normal subject.
42. The method of claim 40, wherein one sample of genomic DNA is from a patient before a therapeutic treatment and the other sample is from the patient after treatment.
43. The method of claim 40, wherein the two samples of genomic DNA are from the same patient at different times during treatment.
44. The method of claim 40, in which a disease is diagnosed based on the comparison of diversity among the samples of genomic DNA.
45. The method of claim 40, wherein the immunocompetence of a human patient is assessed by the comparison.
US12/794,507 2009-06-25 2010-06-04 Method of measuring adaptive immunity Granted US20100330571A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
US12/794,507 US20100330571A1 (en) 2009-06-25 2010-06-04 Method of measuring adaptive immunity
US13/217,126 US20120058902A1 (en) 2009-06-25 2011-08-24 Method of measuring adaptive immunity
US14/095,629 US20140194295A1 (en) 2009-06-25 2013-12-03 Method of Measuring Adaptive Immunity
US14/183,177 US20140206549A1 (en) 2009-06-25 2014-02-18 Method of measuring adaptive immunity
US14/183,163 US20140206548A1 (en) 2009-06-25 2014-02-18 Method of measuring adaptive immunity
US14/242,299 US20140256567A1 (en) 2009-06-25 2014-04-01 Method of Measuring Adaptive Immunity
US14/243,875 US20140213463A1 (en) 2009-06-25 2014-04-02 Method of Measuring Adaptive Immunity
US14/252,189 US20140221220A1 (en) 2009-06-25 2014-04-14 Method of measuring adaptive immunity
US14/640,145 US20150299785A1 (en) 2009-06-25 2015-03-06 Method of measuring adaptive immunity
US15/061,827 US9809813B2 (en) 2009-06-25 2016-03-04 Method of measuring adaptive immunity
US15/475,613 US20170335386A1 (en) 2009-06-25 2017-03-31 Method of measuring adaptive immunity
US15/709,719 US11214793B2 (en) 2009-06-25 2017-09-20 Method of measuring adaptive immunity
US16/023,010 US11905511B2 (en) 2009-06-25 2018-06-29 Method of measuring adaptive immunity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22034409P 2009-06-25 2009-06-25
US12/794,507 US20100330571A1 (en) 2009-06-25 2010-06-04 Method of measuring adaptive immunity

Related Child Applications (7)

Application Number Title Priority Date Filing Date
US13/217,126 Continuation-In-Part US20120058902A1 (en) 2009-06-25 2011-08-24 Method of measuring adaptive immunity
US201313960761A Continuation 2009-06-25 2013-08-06
US14/095,629 Continuation US20140194295A1 (en) 2009-06-25 2013-12-03 Method of Measuring Adaptive Immunity
US14/183,177 Continuation US20140206549A1 (en) 2009-06-25 2014-02-18 Method of measuring adaptive immunity
US14/183,163 Continuation US20140206548A1 (en) 2009-06-25 2014-02-18 Method of measuring adaptive immunity
US14/243,875 Continuation US20140213463A1 (en) 2009-06-25 2014-04-02 Method of Measuring Adaptive Immunity
US14/252,189 Division US20140221220A1 (en) 2009-06-25 2014-04-14 Method of measuring adaptive immunity

Publications (1)

Publication Number Publication Date
US20100330571A1 true US20100330571A1 (en) 2010-12-30

Family

ID=42543134

Family Applications (10)

Application Number Title Priority Date Filing Date
US12/794,507 Granted US20100330571A1 (en) 2009-06-25 2010-06-04 Method of measuring adaptive immunity
US14/095,629 Abandoned US20140194295A1 (en) 2009-06-25 2013-12-03 Method of Measuring Adaptive Immunity
US14/183,163 Abandoned US20140206548A1 (en) 2009-06-25 2014-02-18 Method of measuring adaptive immunity
US14/183,177 Abandoned US20140206549A1 (en) 2009-06-25 2014-02-18 Method of measuring adaptive immunity
US14/242,299 Abandoned US20140256567A1 (en) 2009-06-25 2014-04-01 Method of Measuring Adaptive Immunity
US14/243,875 Abandoned US20140213463A1 (en) 2009-06-25 2014-04-02 Method of Measuring Adaptive Immunity
US14/252,189 Abandoned US20140221220A1 (en) 2009-06-25 2014-04-14 Method of measuring adaptive immunity
US15/061,827 Active 2030-07-05 US9809813B2 (en) 2009-06-25 2016-03-04 Method of measuring adaptive immunity
US15/709,719 Active 2032-07-05 US11214793B2 (en) 2009-06-25 2017-09-20 Method of measuring adaptive immunity
US16/023,010 Active 2033-12-26 US11905511B2 (en) 2009-06-25 2018-06-29 Method of measuring adaptive immunity

Family Applications After (9)

Application Number Title Priority Date Filing Date
US14/095,629 Abandoned US20140194295A1 (en) 2009-06-25 2013-12-03 Method of Measuring Adaptive Immunity
US14/183,163 Abandoned US20140206548A1 (en) 2009-06-25 2014-02-18 Method of measuring adaptive immunity
US14/183,177 Abandoned US20140206549A1 (en) 2009-06-25 2014-02-18 Method of measuring adaptive immunity
US14/242,299 Abandoned US20140256567A1 (en) 2009-06-25 2014-04-01 Method of Measuring Adaptive Immunity
US14/243,875 Abandoned US20140213463A1 (en) 2009-06-25 2014-04-02 Method of Measuring Adaptive Immunity
US14/252,189 Abandoned US20140221220A1 (en) 2009-06-25 2014-04-14 Method of measuring adaptive immunity
US15/061,827 Active 2030-07-05 US9809813B2 (en) 2009-06-25 2016-03-04 Method of measuring adaptive immunity
US15/709,719 Active 2032-07-05 US11214793B2 (en) 2009-06-25 2017-09-20 Method of measuring adaptive immunity
US16/023,010 Active 2033-12-26 US11905511B2 (en) 2009-06-25 2018-06-29 Method of measuring adaptive immunity

Country Status (11)

Country Link
US (10) US20100330571A1 (en)
EP (2) EP2446052B1 (en)
JP (2) JP2012531202A (en)
KR (2) KR20120044941A (en)
CN (1) CN102459643B (en)
AU (1) AU2010263172B2 (en)
CA (1) CA2765949C (en)
IL (1) IL217200A (en)
RU (2) RU2014144463A (en)
SG (2) SG10201403451QA (en)
WO (1) WO2010151416A1 (en)

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100151471A1 (en) * 2008-11-07 2010-06-17 Malek Faham Methods of monitoring conditions by sequence analysis
US20110207135A1 (en) * 2008-11-07 2011-08-25 Sequenta, Inc. Methods of monitoring conditions by sequence analysis
US20110207134A1 (en) * 2008-11-07 2011-08-25 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
WO2012097374A1 (en) 2011-01-14 2012-07-19 Cb Biotechnologies, Inc. Immunodiversity assessment method and its use
WO2013059725A1 (en) * 2011-10-21 2013-04-25 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
WO2013086450A1 (en) 2011-12-09 2013-06-13 Adaptive Biotechnologies Corporation Diagnosis of lymphoid malignancies and minimal residual disease detection
WO2013169957A1 (en) 2012-05-08 2013-11-14 Adaptive Biotechnologies Corporation Compositions and method for measuring and calibrating amplification bias in multiplexed pcr reactions
WO2013188831A1 (en) 2012-06-15 2013-12-19 Adaptive Biotechnologies Corporation Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set
WO2014008448A1 (en) * 2012-07-03 2014-01-09 Sloan Kettering Institute For Cancer Research Quantitative assessment of human t-cell repertoire recovery after allogeneic hematopoietic stem cell transplantation
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
WO2014055561A1 (en) 2012-10-01 2014-04-10 Adaptive Biotechnologies Corporation Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization
WO2014145992A1 (en) 2013-03-15 2014-09-18 Adaptive Biotechnologies Corporation Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set
US9043160B1 (en) 2009-11-09 2015-05-26 Sequenta, Inc. Method of determining clonotypes and clonotype profiles
WO2016069886A1 (en) 2014-10-29 2016-05-06 Adaptive Biotechnologies Corporation Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples
US9365901B2 (en) 2008-11-07 2016-06-14 Adaptive Biotechnologies Corp. Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
US9422547B1 (en) 2015-06-09 2016-08-23 Gigagen, Inc. Recombinant fusion proteins and libraries from immune cell repertoires
WO2016138122A1 (en) 2015-02-24 2016-09-01 Adaptive Biotechnologies Corp. Methods for diagnosing infectious disease and determining hla status using immune repertoire sequencing
WO2016161273A1 (en) 2015-04-01 2016-10-06 Adaptive Biotechnologies Corp. Method of identifying human compatible t cell receptors specific for an antigenic target
US9499865B2 (en) 2011-12-13 2016-11-22 Adaptive Biotechnologies Corp. Detection and measurement of tissue-infiltrating lymphocytes
US9506119B2 (en) 2008-11-07 2016-11-29 Adaptive Biotechnologies Corp. Method of sequence determination using sequence tags
US9528160B2 (en) 2008-11-07 2016-12-27 Adaptive Biotechnolgies Corp. Rare clonotypes and uses thereof
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
US9809813B2 (en) 2009-06-25 2017-11-07 Fred Hutchinson Cancer Research Center Method of measuring adaptive immunity
US9816088B2 (en) 2013-03-15 2017-11-14 Abvitro Llc Single cell bar-coding for antibody discovery
US9834822B2 (en) * 2012-09-04 2017-12-05 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US9902992B2 (en) 2012-09-04 2018-02-27 Guardant Helath, Inc. Systems and methods to detect rare mutations and copy number variation
WO2017210469A3 (en) * 2016-06-01 2018-03-15 F. Hoffman-La Roche Ag Immuno-pete
US9920366B2 (en) 2013-12-28 2018-03-20 Guardant Health, Inc. Methods and systems for detecting genetic variants
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
US10077478B2 (en) 2012-03-05 2018-09-18 Adaptive Biotechnologies Corp. Determining paired immune receptor chains from frequency matched subunits
US10150996B2 (en) 2012-10-19 2018-12-11 Adaptive Biotechnologies Corp. Quantification of adaptive immune cell genomes in a complex mixture of cells
US10168328B2 (en) 2015-07-22 2019-01-01 Roche Sequencing Solutions, Inc. Identification of antigen epitopes and immune sequences recognizing the antigens
US10202640B2 (en) * 2014-05-07 2019-02-12 The Board Of Trustees Of The Leland Stanford Junior University Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
US10323276B2 (en) 2009-01-15 2019-06-18 Adaptive Biotechnologies Corporation Adaptive immunity profiling and methods for generation of monoclonal antibodies
EP3498866A1 (en) 2014-11-25 2019-06-19 Adaptive Biotechnologies Corp. Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing
CN109929924A (en) * 2019-03-27 2019-06-25 上海科医联创医学检验所有限公司 A kind of IGH gene rearrangement detection method based on high-flux sequence
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
CN110246539A (en) * 2019-04-15 2019-09-17 成都益安博生物技术有限公司 A kind of method and device of immunity level assessment
US10428325B1 (en) 2016-09-21 2019-10-01 Adaptive Biotechnologies Corporation Identification of antigen-specific B cell receptors
WO2019238939A1 (en) 2018-06-15 2019-12-19 F. Hoffmann-La Roche Ag A system for identification of antigens recognized by t cell receptors expressed on tumor infiltrating lymphocytes
US10539564B2 (en) 2015-07-22 2020-01-21 Roche Sequencing Solutions, Inc. Identification of antigen epitopes and immune sequences recognizing the antigens
US10590483B2 (en) 2014-09-15 2020-03-17 Abvitro Llc High-throughput nucleotide library sequencing
US10704086B2 (en) 2014-03-05 2020-07-07 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US11242569B2 (en) 2015-12-17 2022-02-08 Guardant Health, Inc. Methods to determine tumor gene copy number by analysis of cell-free DNA
US11248253B2 (en) 2014-03-05 2022-02-15 Adaptive Biotechnologies Corporation Methods using randomer-containing synthetic molecules
US11254980B1 (en) 2017-11-29 2022-02-22 Adaptive Biotechnologies Corporation Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements
US11390921B2 (en) 2014-04-01 2022-07-19 Adaptive Biotechnologies Corporation Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
US11421220B2 (en) 2019-03-21 2022-08-23 Gigamune, Inc. Engineered cells expressing anti-viral T cell receptors and methods of use thereof
US11913065B2 (en) 2012-09-04 2024-02-27 Guardent Health, Inc. Systems and methods to detect rare mutations and copy number variation
US12060610B2 (en) 2008-04-16 2024-08-13 iRepertoire, Inc. Method for evaluating and comparing immunorepertoires
US12129462B2 (en) 2021-08-03 2024-10-29 Abvitro Llc Single cell bar-coding for antibody discovery

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011106738A2 (en) 2010-02-25 2011-09-01 Fred Hutchinson Cancer Research Center Use of tcr clonotypes as biomarkers for disease
CN103289994B (en) * 2012-03-05 2015-08-05 深圳华大基因科技有限公司 Primer composition for amplifying T cell receptor alpha chain CDR3 coding sequence and application thereof
WO2013097744A1 (en) * 2011-12-27 2013-07-04 深圳华大基因科技有限公司 Primer composition for use in amplifying cdr3 coding sequence and use of the primer composition
CN103184216B (en) * 2011-12-27 2015-03-18 深圳华大基因科技有限公司 Primer composition for amplifying coding sequence of immunoglobulin heavy chain CDR3 and use thereof
CN103205420B (en) * 2012-01-13 2015-04-01 深圳华大基因科技有限公司 Primer composition for amplifying T cell receptor beta chain CDR3 coding sequence and application thereof
WO2015075939A1 (en) 2013-11-21 2015-05-28 Ｒｅｐｅｒｔｏｉｒｅ Ｇｅｎｅｓｉｓ株式会社 T cell receptor and b cell receptor repertoire analysis system, and use of same in treatment and diagnosis
DK3080302T3 (en) 2013-12-10 2020-10-26 Conexio Genomics Pty Ltd METHODS AND PROSPECTS FOR IDENTIFYING GENALS
CN105040111B (en) * 2015-05-28 2017-07-14 眭维国 The construction method of systemic loupus erythematosus spectrum model
US20180300453A1 (en) * 2015-08-07 2018-10-18 Beth Israel Deaconess Medical Center, Inc. Estimation of Descriptive Parameters from a Sample
CN105154440B (en) * 2015-08-14 2016-11-30 深圳市瀚海基因生物科技有限公司 A kind of multiple PCR primer and method building Minimal Residual Disease of Leukemia stove TCR library based on high-flux sequence
WO2017086394A1 (en) * 2015-11-18 2017-05-26 国立研究開発法人海洋研究開発機構 Method for quantifying target nucleic acid and kit therefor
CN105447336B (en) * 2015-12-29 2018-06-19 北京百迈客生物科技有限公司 Analysis of Microbial Diversity system based on biological cloud platform
CN106957905B (en) * 2016-12-23 2020-12-04 孙涛 Molecular detection method, primer composition and kit for evaluating tumor immunotherapy effect
GB201718238D0 (en) * 2017-11-03 2017-12-20 Univ Oxford Innovation Ltd Method and system for determining the disease status of a subject
RU2694412C9 (en) * 2017-12-25 2019-09-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Monoclonal antibodies and methods of using them
WO2019232525A1 (en) * 2018-06-01 2019-12-05 Mayo Foundation For Medical Education And Research Methods and materials for assessing and treating cancers
EP3802870A4 (en) * 2018-06-11 2022-03-23 Monoquant PTY LTD Amplification method and primers for use therein
RU2711871C1 (en) * 2018-12-25 2020-01-23 Федеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Monoclonal antibodies which specifically bind to the beta-chain region of the trbv-9 family of the human t-cell receptor, and methods for use thereof
RU2712251C1 (en) * 2018-12-25 2020-01-27 Федеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Humanised anti-beta 9 chain antibodies of human trbv9 tkp family, and methods of using
CN111755075B (en) * 2019-03-28 2023-09-29 深圳华大生命科学研究院 Method for filtering sequence pollution among high-throughput sequencing samples of immune repertoire
US20220372566A1 (en) 2019-09-20 2022-11-24 Roche Sequencing Solutions, Inc. Immune repertoire profiling by primer extension target enrichment
WO2023201265A1 (en) * 2022-04-12 2023-10-19 The Johns Hopkins University Method of measuring level of immune suppression
CN116153407A (en) * 2023-04-03 2023-05-23 广州华银医学检验中心有限公司 System for judging immunity strength of subject against new crown based on gene sequencing

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030120061A1 (en) * 1999-02-23 2003-06-26 Baylor College Of Medicine T cell receptor Vbeta-Dbeta-Jbeta sequence and methods for its detection
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
US20060234234A1 (en) * 2002-10-11 2006-10-19 Van Dongen Jacobus Johannes M Nucleic acid amplification primers for pcr-based clonality studies
WO2006110855A2 (en) * 2005-04-12 2006-10-19 454 Life Sciences Corporation Methods for determining sequence variants using ultra-deep sequencing
US20070117134A1 (en) * 2005-11-18 2007-05-24 Kou Zhong C Method for detection and quantification of T-cell receptor Vbeta repertoire
US20080069770A1 (en) * 1990-02-12 2008-03-20 Aventis Pharma S.A. Nucleotide sequence coding for variable regions of beta chains of human t lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses
US20080166704A1 (en) * 2003-12-05 2008-07-10 Patrice Marche Method for Quantitative Evaluation of a Rearrangement or a Targeted Genetic Recombination of an Individual and Uses Thereof
US20100021896A1 (en) * 2008-04-16 2010-01-28 Jian Han Method for Evaluating and Comparing Immunorepertoires
US20100151471A1 (en) * 2008-11-07 2010-06-17 Malek Faham Methods of monitoring conditions by sequence analysis
US7741463B2 (en) * 2005-11-01 2010-06-22 Illumina Cambridge Limited Method of preparing libraries of template polynucleotides

Family Cites Families (318)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE3211263A1 (en) 1981-03-31 1983-01-27 Otsuka Pharmaceutical Co. Ltd., Tokyo HUMAN INTERFERON RELATED PEPTIDES, ANTIGENS AND ANTIBODIES, AND METHOD FOR THE PRODUCTION THEREOF
DE3238353A1 (en) 1982-10-15 1984-04-19 Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen METHOD FOR SIMULTANEOUSLY QUANTITATIVE DETERMINATION OF BLOOD CELLS AND REAGENT THEREFOR
US5189147A (en) 1984-06-13 1993-02-23 Massachusetts Institute Of Technology Meterodimeric T lymphocyte receptor antibody
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DE3541033A1 (en) 1985-11-19 1987-05-21 Boehringer Mannheim Gmbh METHOD FOR QUANTIFYING CELL POPULATIONS OR SUBPOPULATIONS AND REAGENT SUITABLE FOR THIS
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4942124A (en) 1987-08-11 1990-07-17 President And Fellows Of Harvard College Multiplex sequencing
US5149625A (en) 1987-08-11 1992-09-22 President And Fellows Of Harvard College Multiplex analysis of DNA
US5667967A (en) 1990-05-01 1997-09-16 The Board Of Trustees Of The Leland Stanford Junior University T-cell receptor varible transcripts as disease related markers
US5506126A (en) 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
US5168038A (en) 1988-06-17 1992-12-01 The Board Of Trustees Of The Leland Stanford Junior University In situ transcription in cells and tissues
JP2781438B2 (en) 1988-10-20 1998-07-30 モーリィ，アリグザンダー，アラン Diagnostic method of monoclonality in leukemia and lymphoma
US5075217A (en) 1989-04-21 1991-12-24 Marshfield Clinic Length polymorphisms in (dC-dA)n ·(dG-dT)n sequences
US5231012A (en) 1989-06-28 1993-07-27 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10)
CA2020958C (en) 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
US5336598A (en) 1989-11-15 1994-08-09 National Jewish Center For Immunology And Respiratory Medicine Method for diagnosing a superantigen caused pathologial condition via assay of T-cells
US5298396A (en) 1989-11-15 1994-03-29 National Jewish Center For Immunology And Respiratory Medicine Method for identifying T cells disease involved in autoimmune disease
US6054034A (en) 1990-02-28 2000-04-25 Aclara Biosciences, Inc. Acrylic microchannels and their use in electrophoretic applications
US5126022A (en) 1990-02-28 1992-06-30 Soane Tecnologies, Inc. Method and device for moving molecules by the application of a plurality of electrical fields
US6916605B1 (en) 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
IE76732B1 (en) 1990-08-07 1997-11-05 Becton Dickinson Co One step test for absolute counts
US5699798A (en) 1990-08-10 1997-12-23 University Of Washington Method for optically imaging solid tumor tissue
US5635354A (en) 1991-01-09 1997-06-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for describing the repertoires of antibodies (Ab) and of T-cell receptors (TcR) of an individual's immune system
US5364759B2 (en) 1991-01-31 1999-07-20 Baylor College Medicine Dna typing with short tandem repeat polymorphisms and identification of polymorphic short tandem repeats
JP3080178B2 (en) 1991-02-18 2000-08-21 東洋紡績株式会社 Method for amplifying nucleic acid sequence and reagent kit therefor
US6091000A (en) 1991-03-15 2000-07-18 Duke University SCID mouse engrafted with human synovium tissue
JP3266311B2 (en) 1991-05-02 2002-03-18 生化学工業株式会社 Novel polypeptide and anti-HIV agent using the same
US5674679A (en) 1991-09-27 1997-10-07 Amersham Life Science, Inc. DNA cycle sequencing
US5981179A (en) 1991-11-14 1999-11-09 Digene Diagnostics, Inc. Continuous amplification reaction
US5256542A (en) 1992-03-09 1993-10-26 Tanox Biosystems, Inc. Selecting low frequency antigen-specific single B lymphocytes with correction for background noise
US5213960A (en) 1992-03-09 1993-05-25 Tanox Biosystems, Inc. Methods for selecting low frequency antigen-specific single B lymphocytes
US5837447A (en) 1992-04-15 1998-11-17 Blood Center Research Foundation, Inc., The Monitoring an immune response by analysis of amplified immunoglobulin or T-cell-receptor nucleic acid
US5587128A (en) 1992-05-01 1996-12-24 The Trustees Of The University Of Pennsylvania Mesoscale polynucleotide amplification devices
US5498392A (en) 1992-05-01 1996-03-12 Trustees Of The University Of Pennsylvania Mesoscale polynucleotide amplification device and method
US5981176A (en) 1992-06-17 1999-11-09 City Of Hope Method of detecting and discriminating between nucleic acid sequences
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
EP0753060A4 (en) 1994-04-18 1999-11-24 New York Society Conserved t-cell receptor sequences
US6001229A (en) 1994-08-01 1999-12-14 Lockheed Martin Energy Systems, Inc. Apparatus and method for performing microfluidic manipulations for chemical analysis
US6090592A (en) 1994-08-03 2000-07-18 Mosaic Technologies, Inc. Method for performing amplification of nucleic acid on supports
FR2724182B1 (en) 1994-09-02 1996-12-13 Pasteur Institut OBTAINING A RECOMBINANT MONOCLONAL ANTIBODY FROM A HUMAN ANTI-RHESUS D MONOCLONAL ANTIBODY, ITS PRODUCTION IN INSECT CELLS, AND USES THEREOF
US5846719A (en) 1994-10-13 1998-12-08 Lynx Therapeutics, Inc. Oligonucleotide tags for sorting and identification
US5604097A (en) 1994-10-13 1997-02-18 Spectragen, Inc. Methods for sorting polynucleotides using oligonucleotide tags
US5776737A (en) 1994-12-22 1998-07-07 Visible Genetics Inc. Method and composition for internal identification of samples
US6919434B1 (en) 1995-02-20 2005-07-19 Sankyo Co., Ltd. Monoclonal antibodies that bind OCIF
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
AU7437996A (en) 1995-10-11 1997-04-30 Leonard Adleman Large scale dna sequencing by position sensitive hybridization
WO1997013877A1 (en) 1995-10-12 1997-04-17 Lynx Therapeutics, Inc. Measurement of gene expression profiles in toxicity determination
US6087096A (en) 1995-11-13 2000-07-11 Dau; Peter C. Method of intrafamily fragment analysis of the T cell receptor α and β chain CDR3 regions
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
KR19990087749A (en) 1996-03-13 1999-12-27 시오노 요시히코 Human T Cell Clones Specific to Rheumatoid Arthritis
US6458530B1 (en) 1996-04-04 2002-10-01 Affymetrix Inc. Selecting tag nucleic acids
EP0910668A4 (en) 1996-06-03 2003-02-19 Univ Alberta Methods for detection of rearranged dna
AU726501B2 (en) 1996-06-04 2000-11-09 University Of Utah Research Foundation Monitoring hybridization during PCR
AU3878697A (en) 1996-06-20 1998-02-02 Cornell Research Foundation Inc. Identification of abnormalities in the expression of t and cell antigen receptors as indicators of disease diagnosis, prognosis and therapeutic predictors
US6074827A (en) 1996-07-30 2000-06-13 Aclara Biosciences, Inc. Microfluidic method for nucleic acid purification and processing
JP4117031B2 (en) 1996-09-06 2008-07-09 オーソ―マクニール・フアーマシユーチカル・インコーポレーテツド Purification of antigen-specific T cells
WO1998015644A2 (en) 1996-09-27 1998-04-16 The Chinese University Of Hong Kong Parallel polynucleotide sequencing method
GB9626815D0 (en) 1996-12-23 1997-02-12 Cemu Bioteknik Ab Method of sequencing DNA
GB9704444D0 (en) 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis
AU6846698A (en) 1997-04-01 1998-10-22 Glaxo Group Limited Method of nucleic acid amplification
US6143496A (en) 1997-04-17 2000-11-07 Cytonix Corporation Method of sampling, amplifying and quantifying segment of nucleic acid, polymerase chain reaction assembly having nanoliter-sized sample chambers, and method of filling assembly
DE69838521T2 (en) 1997-07-07 2008-05-21 Medical Research Council Method for increasing the concentration of nucleic acid molecules
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
WO1999019717A1 (en) 1997-10-15 1999-04-22 Aclara Biosciences, Inc. Laminate microstructure device and method for making same
AU753732B2 (en) 1997-10-23 2002-10-24 Genzyme Corporation Methods for detecting contamination in molecular diagnostics using PCR
US7351578B2 (en) 1999-12-10 2008-04-01 Invitrogen Corp. Use of multiple recombination sites with unique specificity in recombinational cloning
US6210910B1 (en) 1998-03-02 2001-04-03 Trustees Of Tufts College Optical fiber biosensor array comprising cell populations confined to microcavities
JP4262799B2 (en) 1998-04-16 2009-05-13 平田機工株式会社 Raw tire supply method
DE19833738A1 (en) 1998-07-27 2000-02-03 Michael Giesing Process for isolating cancer cells from cell-containing body fluids and kits for performing this process
US6787308B2 (en) 1998-07-30 2004-09-07 Solexa Ltd. Arrayed biomolecules and their use in sequencing
DE19844931C1 (en) 1998-09-30 2000-06-15 Stefan Seeger Procedures for DNA or RNA sequencing
AR021833A1 (en) 1998-09-30 2002-08-07 Applied Research Systems METHODS OF AMPLIFICATION AND SEQUENCING OF NUCLEIC ACID
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US6300070B1 (en) 1999-06-04 2001-10-09 Mosaic Technologies, Inc. Solid phase methods for amplifying multiple nucleic acids
US6440706B1 (en) 1999-08-02 2002-08-27 Johns Hopkins University Digital amplification
US20040209314A1 (en) 1999-09-06 2004-10-21 Institut National De La Sante Et De La Recherche Medicale France Means for detection and purification of CD8+ T lymphocyte populations specific to peptides presented in the context of HLA
US6235483B1 (en) 2000-01-31 2001-05-22 Agilent Technologies, Inc. Methods and kits for indirect labeling of nucleic acids
WO2001075172A1 (en) 2000-03-31 2001-10-11 University Of Southern California Epigenetic sequences for esophageal adenocarcinoma
AUPQ687600A0 (en) 2000-04-13 2000-05-11 Flinders Technologies Pty Ltd A method of detection
US20030207300A1 (en) 2000-04-28 2003-11-06 Matray Tracy J. Multiplex analytical platform using molecular tags
GB0016138D0 (en) * 2000-06-30 2000-08-23 Novartis Ag Organic compounds
US6596492B2 (en) 2000-07-11 2003-07-22 Colorado State University Research Foundation PCR materials and methods useful to detect canine and feline lymphoid malignancies
US7567870B1 (en) 2000-07-31 2009-07-28 Institute For Systems Biology Multiparameter analysis for predictive medicine
US6939451B2 (en) 2000-09-19 2005-09-06 Aclara Biosciences, Inc. Microfluidic chip having integrated electrodes
CA2426824A1 (en) 2000-10-24 2002-07-25 The Board Of Trustees Of The Leland Stanford Junior University Direct multiplex characterization of genomic dna
US6778724B2 (en) 2000-11-28 2004-08-17 The Regents Of The University Of California Optical switching and sorting of biological samples and microparticles transported in a micro-fluidic device, including integrated bio-chip devices
DE60238308D1 (en) 2001-02-20 2010-12-30 Univ Georgia QUICK PRODUCTION MONOCLONAL ANTIBODY
US7265208B2 (en) 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
WO2002094009A2 (en) 2001-05-24 2002-11-28 Guard Inc. Methods for selecting and producing animals having a predicted level of immune response
US20050260570A1 (en) 2001-05-29 2005-11-24 Mao Jen-I Sequencing by proxy
US6720144B1 (en) 2001-06-21 2004-04-13 Quest Diagnostics Detection of clonal T-cell receptor-γ gene rearrangement by PCR/temporal temperature gradient gel electrophoresis (TTGE)
WO2003008624A2 (en) 2001-07-15 2003-01-30 Keck Graduate Institute Nucleic acid amplification using nicking agents
WO2003020983A1 (en) 2001-08-30 2003-03-13 Virginia Commonwealth University Allele specific pcr for genotyping
PL208712B1 (en) 2001-08-31 2011-05-31 Avidex Ltd Soluble t cell receptor
AU2002322518A1 (en) 2001-08-31 2003-03-18 Rosetta Inpharmactis Llc Methods for preparing nucleic acid samples
US7306906B2 (en) 2001-09-19 2007-12-11 Alexion Pharmaceuticals, Inc. Engineered templates and their use in single primer amplification
CN1612936A (en) 2001-11-09 2005-05-04 苏尔斯精细医药公司 Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
GB2382137A (en) 2001-11-20 2003-05-21 Mats Gullberg Nucleic acid enrichment
GB0128153D0 (en) 2001-11-23 2002-01-16 Bayer Ag Profiling of the immune gene repertoire
WO2003052101A1 (en) 2001-12-14 2003-06-26 Rosetta Inpharmatics, Inc. Sample tracking using molecular barcodes
GB0130267D0 (en) 2001-12-19 2002-02-06 Neutec Pharma Plc Focussed antibody technology
AU2003207528A1 (en) 2002-01-09 2003-07-30 Maxx Genetech Co. Ltd Method of detecting t-cell proliferation for diagnosis of diseases by gene array
US7157274B2 (en) 2002-06-24 2007-01-02 Cytonome, Inc. Method and apparatus for sorting particles
EP1511690A4 (en) 2002-05-16 2007-10-24 Univ Vanderbilt Method for predicting autoimmune diseases
WO2004003820A2 (en) 2002-07-01 2004-01-08 Institut Pasteur System, method, device, and computer program product for extraction, gathering, manipulation, and analysis of peak data from an automated sequencer
US7691994B2 (en) 2002-07-03 2010-04-06 Brewer Jamie L Compositions and methods for the detection of human T cell receptor variable family gene expression
WO2004006951A1 (en) 2002-07-12 2004-01-22 The Johns Hopkins University Reagents and methods for engaging unique clonotypic lymphocyte receptors
ATE470722T1 (en) 2002-07-19 2010-06-15 Althea Technologies Inc STRATEGIES FOR GENE EXPRESSION ANALYSIS
US7157228B2 (en) 2002-09-09 2007-01-02 Bioarray Solutions Ltd. Genetic analysis and authentication
US7459273B2 (en) 2002-10-04 2008-12-02 Affymetrix, Inc. Methods for genotyping selected polymorphism
US20050009096A1 (en) 2002-10-11 2005-01-13 The Regents Of The University Of California Method for diagnosis and prognosis of multiple sclerosis
US20060147925A1 (en) 2002-11-13 2006-07-06 Morley Alexander A Method of detection
EP2365331B1 (en) 2002-11-14 2015-11-04 Valneva Method to clone a single antigen-specfic lymphocyte.
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
WO2004063706A2 (en) 2003-01-08 2004-07-29 Maxx Genetech Co., Ltd. Method of detecting over-expression of t-cell receptor genes by real-time pcr
DE602004036672C5 (en) 2003-01-29 2012-11-29 454 Life Sciences Corporation Nucleic acid amplification based on bead emulsion
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
WO2004096985A2 (en) 2003-04-24 2004-11-11 Mayo Foundation For Medical Education And Research Methods for assessing biologic diversity
AU2003902299A0 (en) 2003-05-13 2003-05-29 Flinders Medical Centre A method of analysing a marker nucleic acid molecule
WO2005020784A2 (en) 2003-05-23 2005-03-10 Mount Sinai School Of Medicine Of New York University Surrogate cell gene expression signatures for evaluating the physical state of a subject
US20050010030A1 (en) 2003-07-02 2005-01-13 Zang Jingwu Z. T cell receptor CDR3 sequence and methods for detecting and treating rheumatoid arthritis
US8048627B2 (en) 2003-07-05 2011-11-01 The Johns Hopkins University Method and compositions for detection and enumeration of genetic variations
US20050048498A1 (en) 2003-08-29 2005-03-03 Applera Corporation Compositions, methods, and kits for assembling probes
US7365179B2 (en) 2003-09-09 2008-04-29 Compass Genetics, Llc Multiplexed analytical platform
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
WO2005053603A2 (en) 2003-12-08 2005-06-16 Yeda Research And Development Co. Ltd. Antigen receptor variable region typing
US20080166718A1 (en) 2003-12-15 2008-07-10 Institut Pasteur Repertoire determination of a lymphocyte B population
EP1544308B1 (en) 2003-12-15 2009-01-28 Institut Pasteur Repertoire determination of a lymphocyte B population
EP1704251A1 (en) 2003-12-15 2006-09-27 Institut Pasteur Repertoire determination of a lymphocyte b population
US7709262B2 (en) 2004-02-18 2010-05-04 Trustees Of Boston University Method for detecting and quantifying rare mutations/polymorphisms
US20060046258A1 (en) 2004-02-27 2006-03-02 Lapidus Stanley N Applications of single molecule sequencing
WO2005084134A2 (en) 2004-03-04 2005-09-15 Dena Leshkowitz Quantifying and profiling antibody and t cell receptor gene expression
JP4480423B2 (en) 2004-03-08 2010-06-16 独立行政法人科学技術振興機構 Method for determining the presence or absence of expansion of immune cell clones
DE102004016437A1 (en) 2004-04-04 2005-10-20 Oligene Gmbh Method for detecting signatures in complex gene expression profiles
US20050250147A1 (en) 2004-05-10 2005-11-10 Macevicz Stephen C Digital profiling of polynucleotide populations
JP2007536939A (en) 2004-05-14 2007-12-20 アモークス インコーポレーティッド Immune cell biosensor and method of use thereof
EP1598429A1 (en) 2004-05-19 2005-11-23 Amplion Ltd. Detection of amplicon contamination during PCR exhibiting two different annealing temperatures
GB0412973D0 (en) 2004-06-10 2004-07-14 Celltech R&D Ltd Identification of antibody producing cells
US20060020397A1 (en) 2004-07-21 2006-01-26 Kermani Bahram G Methods for nucleic acid and polypeptide similarity search employing content addressable memories
WO2006014869A1 (en) 2004-07-26 2006-02-09 Parallele Bioscience, Inc. Simultaneous analysis of multiple genomes
US7820382B2 (en) 2004-08-03 2010-10-26 Bauer A Robert Method for the early detection of breast cancer, lung cancer, pancreatic cancer and colon polyps, growths and cancers as well as other gastrointestinal disease conditions and the preoperative and postoperative monitoring of transplanted organs from the donor and in the recipient and their associated conditions related and unrelated to the organ transplantation
US20060094018A1 (en) 2004-08-03 2006-05-04 Bauer A R Jr Discovery and a method for the early detection of pancreatic cancer and other disease conditions
RS51326B (en) 2004-08-05 2010-12-31 Genentech Inc. Humanized anti-cmet antagonists
CA2580412A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
US7170050B2 (en) 2004-09-17 2007-01-30 Pacific Biosciences Of California, Inc. Apparatus and methods for optical analysis of molecules
EP1812563B1 (en) 2004-10-29 2013-04-10 Benaroya Research Institute at Virginia Mason Methods of generating antigen-specific cd4+cd25+ regulatory t cells, compositions and methods of use
US7966988B2 (en) 2005-01-11 2011-06-28 Exxonmobil Research And Engineering Company Method for controlling soot induced lubricant viscosity increase
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
FR2881436B1 (en) 2005-02-03 2007-04-27 Commissariat Energie Atomique METHOD FOR DETERMINING THE DIVERSITY OF T LYMPHOCYTES IN A BIOLOGICAL SAMPLE
US7393665B2 (en) 2005-02-10 2008-07-01 Population Genetics Technologies Ltd Methods and compositions for tagging and identifying polynucleotides
KR20070106027A (en) 2005-02-16 2007-10-31 와이어쓰 Methods and systems for diagnosis, prognosis and selection of treatment of leukemia
US7537894B2 (en) 2005-03-02 2009-05-26 The University Of Chicago Methods and kits for monitoring Barrett's metaplasia
WO2006099164A2 (en) 2005-03-10 2006-09-21 Applera Corporation Methods for multiplex amplification
WO2006099604A2 (en) 2005-03-16 2006-09-21 Compass Genetics, Llc Methods and compositions for assay readouts on multiple analytical platforms
WO2006116155A2 (en) 2005-04-21 2006-11-02 The Regents Of The University Of California A method for diagnosis and prognosis of multiple sclerosis subtypes
US20060263789A1 (en) 2005-05-19 2006-11-23 Robert Kincaid Unique identifiers for indicating properties associated with entities to which they are attached, and methods for using
US7208795B2 (en) 2005-05-24 2007-04-24 Atmel Corporation Low-cost, low-voltage single-layer polycrystalline EEPROM memory cell integration into BiCMOS technology
CA2611671C (en) 2005-06-15 2013-10-08 Callida Genomics, Inc. Single molecule arrays for genetic and chemical analysis
WO2007008759A2 (en) 2005-07-07 2007-01-18 Hematologics, Inc. Methods for detecting and confirming minimal disease in a cancer patient
US20070020640A1 (en) 2005-07-21 2007-01-25 Mccloskey Megan L Molecular encoding of nucleic acid templates for PCR and other forms of sequence analysis
GB0521521D0 (en) 2005-10-21 2005-11-30 Medical Res Council Diagnostic methods and kits
US20070105165A1 (en) 2005-11-04 2007-05-10 Charles Goolsby Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers
US8137936B2 (en) 2005-11-29 2012-03-20 Macevicz Stephen C Selected amplification of polynucleotides
WO2007087312A2 (en) 2006-01-23 2007-08-02 Population Genetics Technologies Ltd. Molecular counting
EP1987162A4 (en) 2006-01-23 2009-11-25 Population Genetics Technologi Nucleic acid analysis using sequence tokens
SG170028A1 (en) 2006-02-24 2011-04-29 Callida Genomics Inc High throughput genome sequencing on dna arrays
CN101395182A (en) 2006-03-06 2009-03-25 西福根有限公司 Recombinant antibodies for treatment of respiratory syncytial virus infections
ES2546848T3 (en) 2006-03-10 2015-09-29 Epigenomics Ag A method to identify a biological sample for methylation analysis
ES2645661T3 (en) 2006-04-04 2017-12-07 Keygene N.V. High performance detection of molecular markers based on restriction fragments
WO2007134220A2 (en) 2006-05-11 2007-11-22 University Of Maryland Biotechnology Institute A general method for generating human antibody responses in vitro
WO2007136518A2 (en) 2006-05-17 2007-11-29 Torrey Pines Institute For Molecular Studies Treatment of autoimmune disorders
US20090208955A1 (en) 2006-05-25 2009-08-20 Institute For Advance Study Methods for identifying sequence motifs, and applications thereof
US7833716B2 (en) 2006-06-06 2010-11-16 Gen-Probe Incorporated Tagged oligonucleotides and their use in nucleic acid amplification methods
CN101915957B (en) 2006-06-12 2012-12-12 加利福尼亚太平洋生物科学公司 Substrates for performing analytical reactions
US20100027896A1 (en) * 2006-06-28 2010-02-04 Amir Geva Automated application interaction using a virtual operator
CA2656525A1 (en) 2006-06-30 2008-01-10 Applera Corporation Reversible terminator nucleotides and methods of use
WO2008108803A2 (en) 2006-07-13 2008-09-12 Amaox, Ltd. Immune cell biosensors and methods of using same
US8394590B2 (en) 2006-08-02 2013-03-12 California Institute Of Technology Capture agents and related methods and systems for detecting and/or sorting targets
US20080274904A1 (en) 2006-08-10 2008-11-06 Niall Anthony Gormley Method of target enrichment
WO2008026927A2 (en) 2006-08-30 2008-03-06 Academisch Medisch Centrum Process for displaying t- and b-cell receptor repertoires
US20100035764A1 (en) 2006-09-26 2010-02-11 St. Jude Children's Research Hospital Methods and compositions for monitoring t cell receptor diversity
WO2008039818A2 (en) 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
JP5026047B2 (en) 2006-10-18 2012-09-12 株式会社膠原病研究所 Method for identifying self-responsive T cells or T cell receptors involved in the development of autoimmune diseases and use thereof
US8148067B2 (en) 2006-11-09 2012-04-03 Xdx, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
US8262900B2 (en) 2006-12-14 2012-09-11 Life Technologies Corporation Methods and apparatus for measuring analytes using large scale FET arrays
US7862999B2 (en) 2007-01-17 2011-01-04 Affymetrix, Inc. Multiplex targeted amplification using flap nuclease
ATE521704T1 (en) 2007-03-01 2011-09-15 Symphogen As METHOD FOR CLONING RELATED ANTIBODIES
WO2008147879A1 (en) 2007-05-22 2008-12-04 Ryan Golhar Automated method and device for dna isolation, sequence determination, and identification
EP2164985A4 (en) 2007-06-01 2014-05-14 454 Life Sciences Corp System and meth0d for identification of individual samples from a multiplex mixture
WO2009015296A1 (en) 2007-07-24 2009-01-29 The Regents Of The University Of California Microfabricated dropley generator
EP2183388A4 (en) 2007-07-26 2010-09-08 Pacific Biosciences California Molecular redundant sequencing
ITRM20070429A1 (en) 2007-08-06 2009-02-07 Uni Cattolica Del Sacro Cuor E MEANS FOR DIAGNOSIS PREVENTION AND CARE OF RHEUMATOID ARTHRITIS.
JP5547071B2 (en) 2007-08-09 2014-07-09 セルラ・インコーポレイテッド Method and apparatus for associating multi-parameter single cell measurements and recovery of residual biological material
US8268564B2 (en) 2007-09-26 2012-09-18 President And Fellows Of Harvard College Methods and applications for stitched DNA barcodes
US7960116B2 (en) 2007-09-28 2011-06-14 Pacific Biosciences Of California, Inc. Nucleic acid sequencing methods and systems
US20100285984A1 (en) 2007-09-28 2010-11-11 Wettstein Peter J Assessing t cell repertoires
MX2010005080A (en) 2007-11-07 2010-07-28 Genentech Inc Methods and compositions for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies.
WO2009070767A2 (en) 2007-11-28 2009-06-04 Whitehead Institute For Biomedical Research Systemic instigation systems to study tumor growth or metastasis
EP2062982A1 (en) * 2007-11-26 2009-05-27 ImmunID Method for studying the V(D)J combinatorial diversity.
CN101225441B (en) 2007-12-05 2010-12-01 浙江大学 Method for detecting genetic constitution of clone-specific T lymphocyte TCR BV CDR3
US8621502B2 (en) 2007-12-21 2013-12-31 Microsoft Corporation Obtaining user reactions to video
US7767400B2 (en) 2008-02-03 2010-08-03 Helicos Biosciences Corporation Paired-end reads in sequencing by synthesis
EP2088432A1 (en) 2008-02-11 2009-08-12 MorphoSys AG Methods for identification of an antibody or a target
WO2009108866A2 (en) 2008-02-28 2009-09-03 The Ohio State University Research Foundation Microrna signatures associated with cytogenetics and prognosis in acute myeloid leukemia (aml) and uses thereof
CN104031984A (en) 2008-02-28 2014-09-10 俄亥俄州立大学研究基金会 Microrna-based methods and compositions for the diagnosis, prognosis and treatment of prostate related disorders
US20090226975A1 (en) 2008-03-10 2009-09-10 Illumina, Inc. Constant cluster seeding
TW200938840A (en) 2008-03-12 2009-09-16 Emo Biomedicine Corp A method for in vitro study of immune modulation using pig blood cell
EP2100970B1 (en) 2008-03-13 2017-05-10 National Institute of Immunology Ig genes specific oligonucleotides and uses thereof
AU2009229157B2 (en) 2008-03-28 2015-01-29 Pacific Biosciences Of California, Inc. Compositions and methods for nucleic acid sequencing
EP2107040B1 (en) 2008-03-31 2011-10-26 Sony Deutschland Gmbh A method of fabricating a membrane having a tapered pore
US8911948B2 (en) 2008-04-30 2014-12-16 Integrated Dna Technologies, Inc. RNase H-based assays utilizing modified RNA monomers
WO2009137832A2 (en) 2008-05-09 2009-11-12 Duke University Autoantibodies in the detection and treatment of cancer
US9068181B2 (en) 2008-05-23 2015-06-30 The General Hospital Corporation Microfluidic droplet encapsulation
DE102008025656B4 (en) 2008-05-28 2016-07-28 Genxpro Gmbh Method for the quantitative analysis of nucleic acids, markers therefor and their use
WO2009145925A1 (en) 2008-05-30 2009-12-03 Massachusetts Institute Of Technology Compositions and methods for spatial separation and screening of cells
WO2009151628A2 (en) 2008-06-12 2009-12-17 Gov't Of The Usa, As Represented By The Secretary, Department Of Health Human Services Monitoring tcr-b to determine hiv therapy and disease progression
SG182951A1 (en) 2008-06-25 2012-08-30 Baylor Res Inst Blood transcriptional signature of mycobacterium tuberculosis infection
US8394583B2 (en) 2008-07-24 2013-03-12 The Board Of Regents Of The University Of Texas System VH4 codon signature for multiple sclerosis
ES2752025T3 (en) 2008-07-25 2020-04-02 Wagner Richard W Protein screening methods
CN102405402A (en) 2008-09-23 2012-04-04 阔达生命有限公司 Droplet-based assay system
US9156010B2 (en) 2008-09-23 2015-10-13 Bio-Rad Laboratories, Inc. Droplet-based assay system
US8699361B2 (en) 2008-09-30 2014-04-15 Qualcomm Incorporated Out-of-synchronization handling method and apparatus
US8546128B2 (en) 2008-10-22 2013-10-01 Life Technologies Corporation Fluidics system for sequential delivery of reagents
US20100137143A1 (en) 2008-10-22 2010-06-03 Ion Torrent Systems Incorporated Methods and apparatus for measuring analytes
US8748103B2 (en) 2008-11-07 2014-06-10 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US9394567B2 (en) 2008-11-07 2016-07-19 Adaptive Biotechnologies Corporation Detection and quantification of sample contamination in immune repertoire analysis
US8691510B2 (en) 2008-11-07 2014-04-08 Sequenta, Inc. Sequence analysis of complex amplicons
US9506119B2 (en) 2008-11-07 2016-11-29 Adaptive Biotechnologies Corp. Method of sequence determination using sequence tags
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US20140234835A1 (en) 2008-11-07 2014-08-21 Sequenta, Inc. Rare clonotypes and uses thereof
US9365901B2 (en) 2008-11-07 2016-06-14 Adaptive Biotechnologies Corp. Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
US9528160B2 (en) 2008-11-07 2016-12-27 Adaptive Biotechnolgies Corp. Rare clonotypes and uses thereof
WO2010060051A2 (en) 2008-11-21 2010-05-27 Emory University Systems biology approach predicts the immunogenicity of vaccines
US8367330B2 (en) 2008-12-22 2013-02-05 Quest Diagnostics Investments Incorporated Methods for detecting TCR-gamma gene rearrangement
KR20110110247A (en) 2008-12-30 2011-10-06 센토코 오르토 바이오테크 인코포레이티드 Serum markers predicting clinical response to anti-tnf antibodies in patients with ankylosing spondylitis
DK2387627T3 (en) 2009-01-15 2016-07-04 Adaptive Biotechnologies Corp Adaptive immunity profiling and methods for producing monoclonal antibodies
EP3020830A1 (en) 2009-01-20 2016-05-18 The Board Of Trustees Of The Leland Stanford Junior University Single cell gene expression for diagnosis, prognosis and identification of drug targets
US20100323348A1 (en) 2009-01-31 2010-12-23 The Regents Of The University Of Colorado, A Body Corporate Methods and Compositions for Using Error-Detecting and/or Error-Correcting Barcodes in Nucleic Acid Amplification Process
US8673627B2 (en) 2009-05-29 2014-03-18 Life Technologies Corporation Apparatus and methods for performing electrochemical reactions
US8574835B2 (en) 2009-05-29 2013-11-05 Life Technologies Corporation Scaffolded nucleic acid polymer particles and methods of making and using
US20120058902A1 (en) 2009-06-25 2012-03-08 Livingston Robert J Method of measuring adaptive immunity
KR20120044941A (en) 2009-06-25 2012-05-08 프레드 헛친슨 켄서 리서치 센터 Method of measuring adaptive immunity
US8497071B2 (en) 2009-06-29 2013-07-30 California Institute Of Technology Isolation of unknown rearranged T-cell receptors from single cells
WO2011035870A1 (en) 2009-09-22 2011-03-31 Roche Diagnostics Gmbh Determination of kir haplotypes associated with disease
US9043160B1 (en) 2009-11-09 2015-05-26 Sequenta, Inc. Method of determining clonotypes and clonotype profiles
US9315857B2 (en) 2009-12-15 2016-04-19 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse label-tags
US8835358B2 (en) 2009-12-15 2014-09-16 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
US8545248B2 (en) 2010-01-07 2013-10-01 Life Technologies Corporation System to control fluid flow based on a leak detected by a sensor
KR101323827B1 (en) 2010-01-08 2013-10-31 키스트 유럽 에프게엠베하 Primers for diagnosing ankylosing spondylitis, and method for diagnosing ankylosing spondylitis using the same
GB201000375D0 (en) 2010-01-09 2010-02-24 Univ Cardiff T Cell clonotypes
WO2011106738A2 (en) 2010-02-25 2011-09-01 Fred Hutchinson Cancer Research Center Use of tcr clonotypes as biomarkers for disease
EP2367000A1 (en) 2010-03-04 2011-09-21 Charité Universitätsmedizin Berlin High throughput analysis of T-cell receptor repertoires
EP2567226B1 (en) 2010-05-06 2016-08-10 Adaptive Biotechnologies Corporation Monitoring health and disease status using clonotype profiles
CA2796822C (en) 2010-05-07 2021-10-05 The Board Of Trustees Of The Leland Standford Junior University Measurement and comparison of immune diversity by high-throughput sequencing
US20130123120A1 (en) 2010-05-18 2013-05-16 Natera, Inc. Highly Multiplex PCR Methods and Compositions
AU2011226792A1 (en) 2010-06-11 2012-01-12 Life Technologies Corporation Alternative nucleotide flows in sequencing-by-synthesis methods
ES2523140T3 (en) 2010-09-21 2014-11-21 Population Genetics Technologies Ltd. Increased confidence in allele identifications with molecular count
US9562897B2 (en) 2010-09-30 2017-02-07 Raindance Technologies, Inc. Sandwich assays in droplets
US10392726B2 (en) 2010-10-08 2019-08-27 President And Fellows Of Harvard College High-throughput immune sequencing
DK2625320T3 (en) 2010-10-08 2019-07-01 Harvard College HIGH-THROUGHPUT SINGLE COVERAGE CODING
EP2633069B1 (en) 2010-10-26 2015-07-01 Illumina, Inc. Sequencing methods
EP2635679B1 (en) 2010-11-05 2017-04-19 Illumina, Inc. Linking sequence reads using paired code tags
WO2012083069A2 (en) 2010-12-15 2012-06-21 The Board Of Trustees Of The Leland Stanford Junior University Measurement and monitoring of cell clonality
WO2012083225A2 (en) 2010-12-16 2012-06-21 Gigagen, Inc. System and methods for massively parallel analysis of nycleic acids in single cells
WO2012118555A1 (en) 2010-12-29 2012-09-07 Life Technologies Corporation Time-warped background signal for sequencing-by-synthesis operations
EP2658999B1 (en) 2010-12-30 2019-03-13 Life Technologies Corporation Models for analyzing data from sequencing-by-synthesis operations
US8759036B2 (en) 2011-03-21 2014-06-24 Affymetrix, Inc. Methods for synthesizing pools of probes
US9476095B2 (en) 2011-04-15 2016-10-25 The Johns Hopkins University Safe sequencing system
NZ730355A (en) 2011-05-24 2022-10-28 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Individualized vaccines for cancer
WO2013033721A1 (en) 2011-09-02 2013-03-07 Atreca, Inc. Dna barcodes for multiplexed sequencing
US20140356339A1 (en) 2011-09-09 2014-12-04 Sequenta Inc. Sequence-based measures of immune response
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
US20140256592A1 (en) 2011-10-11 2014-09-11 Sequenta, Inc. Determining responsiveness of autoimmune patients to dmard treatment
EP2768982A4 (en) 2011-10-21 2015-06-03 Adaptive Biotechnologies Corp Quantification of adaptive immune cell genomes in a complex mixture of cells
EP2773773B1 (en) 2011-11-04 2017-01-11 Adaptive Biotechnologies Corporation T-cell receptor clonotypes shared among ankylosing spondylitis patients
WO2013085855A1 (en) 2011-12-05 2013-06-13 Sequenta, Inc. Clonotypes as biometric specimen tags
EP3388535B1 (en) 2011-12-09 2021-03-24 Adaptive Biotechnologies Corporation Diagnosis of lymphoid malignancies and minimal residual disease detection
WO2013086462A1 (en) 2011-12-09 2013-06-13 Sequenta, Inc. Method of measuring immune activation
US9499865B2 (en) 2011-12-13 2016-11-22 Adaptive Biotechnologies Corp. Detection and measurement of tissue-infiltrating lymphocytes
WO2013090390A2 (en) 2011-12-13 2013-06-20 Sequenta, Inc. Method of measuring immune activation
JP2015504661A (en) 2011-12-20 2015-02-16 シーケンタ インコーポレイテッド Monitoring of transformation from follicular lymphoma to diffuse large B-cell lymphoma by immunorepertoire analysis
WO2013112655A1 (en) 2012-01-24 2013-08-01 Gigagen, Inc. Method for correction of bias in multiplexed amplification
ES2776673T3 (en) 2012-02-27 2020-07-31 Univ North Carolina Chapel Hill Methods and uses for molecular tags
WO2013131074A1 (en) 2012-03-02 2013-09-06 Diogenix, Inc. Methods and reagents for evaluating autoimmune disease and determining antibody repertoire
EP2823060B1 (en) 2012-03-05 2018-02-14 Adaptive Biotechnologies Corporation Determining paired immune receptor chains from frequency matched subunits
US20150038346A1 (en) 2012-03-05 2015-02-05 Sequenta, Inc. Monitoring immune responsiveness to cancer vaccination
WO2013134302A1 (en) 2012-03-05 2013-09-12 Sequenta, Inc. Monitoring immune responsiveness to cancer vaccination
AU2013246050B2 (en) 2012-04-13 2017-03-16 Adaptive Biotechnologies Corp. Detection and quantitation of sample contamination in immune repertoire analysis
WO2013158936A1 (en) 2012-04-20 2013-10-24 Sequenta, Inc Monitoring immunoglobulin heavy chain evolution in b-cell acute lymphoblastic leukemia
AU2013259544B9 (en) 2012-05-08 2017-09-28 Adaptive Biotechnologies Corporation Compositions and method for measuring and calibrating amplification bias in multiplexed PCR reactions
US20150247201A1 (en) 2012-05-31 2015-09-03 Malek Faham Predicting relapse of chronic lymphocytic leukemia patients treated by allogeneic stem cell transplantation
US20130324422A1 (en) 2012-06-04 2013-12-05 Sequenta, Inc. Detecting disease-correlated clonotypes from fixed samples
SG11201407888RA (en) 2012-06-11 2014-12-30 Sequenta Inc Method of sequence determination using sequence tags
EP2861761A1 (en) 2012-06-15 2015-04-22 Adaptive Biotechnologies Corporation Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set
US20150247182A1 (en) 2012-07-24 2015-09-03 Adaptive Biotechnologies Corp. Single cell analysis using sequence tags
WO2014026031A1 (en) 2012-08-10 2014-02-13 Sequenta, Inc. High sensitivity mutation detection using sequence tags
CA2884246C (en) 2012-09-24 2023-11-07 Cb Biotechnologies, Inc. Multiplex pyrosequencing using non-interfering noise-canceling polynucleotide identification tags
AU2013331212A1 (en) 2012-10-19 2015-05-07 Adaptive Biotechnologies Corp. Monitoring clonotypes of plasma cell proliferative disorders in peripheral blood
AU2013331135A1 (en) 2012-10-19 2015-05-07 Adaptive Biotechnologies Corp. Monitoring diffuse large B-cell lymphoma from peripheral blood samples
WO2014066184A1 (en) 2012-10-22 2014-05-01 Sequenta, Inc. Monitoring mantle cell lymphoma clonotypes in peripheral blood after immunotransplant
ES2748204T3 (en) 2013-02-22 2020-03-13 Adaptive Biotechnologies Corp Procedure for selecting rare clonotypes
US20140255944A1 (en) 2013-03-08 2014-09-11 Sequenta, Inc. Monitoring treatment-resistant clones in lymphoid and myeloid neoplasms by relative levels of evolved clonotypes
US20140255929A1 (en) 2013-03-11 2014-09-11 Sequenta, Inc. Mosaic tags for labeling templates in large-scale amplifications
WO2014189635A1 (en) * 2013-05-20 2014-11-27 The Trustees Of Columbia University In The City Of New York Tracking donor-reactive tcr as a biomarker in transplantation
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
WO2015013461A2 (en) 2013-07-26 2015-01-29 Sequenta, Inc. Cancer vaccination with antigen evolution
AU2014337063A1 (en) 2013-10-18 2016-05-19 Adaptive Biotechnologies Corp. Predicting patient responsiveness to immune checkpoint inhibitors
US20150218656A1 (en) 2014-02-03 2015-08-06 Adaptive Biotechnologies Corp. Methods for detection and diagnosis of a lymphoid malignancy using high throughput sequencing
ES2777529T3 (en) 2014-04-17 2020-08-05 Adaptive Biotechnologies Corp Quantification of adaptive immune cell genomes in a complex mixture of cells
CA2966201A1 (en) 2014-10-29 2016-05-06 Adaptive Biotechnologies Corp. Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080069770A1 (en) * 1990-02-12 2008-03-20 Aventis Pharma S.A. Nucleotide sequence coding for variable regions of beta chains of human t lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses
US20030120061A1 (en) * 1999-02-23 2003-06-26 Baylor College Of Medicine T cell receptor Vbeta-Dbeta-Jbeta sequence and methods for its detection
US20060234234A1 (en) * 2002-10-11 2006-10-19 Van Dongen Jacobus Johannes M Nucleic acid amplification primers for pcr-based clonality studies
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
US20080166704A1 (en) * 2003-12-05 2008-07-10 Patrice Marche Method for Quantitative Evaluation of a Rearrangement or a Targeted Genetic Recombination of an Individual and Uses Thereof
WO2006110855A2 (en) * 2005-04-12 2006-10-19 454 Life Sciences Corporation Methods for determining sequence variants using ultra-deep sequencing
US7741463B2 (en) * 2005-11-01 2010-06-22 Illumina Cambridge Limited Method of preparing libraries of template polynucleotides
US20070117134A1 (en) * 2005-11-18 2007-05-24 Kou Zhong C Method for detection and quantification of T-cell receptor Vbeta repertoire
US20100021896A1 (en) * 2008-04-16 2010-01-28 Jian Han Method for Evaluating and Comparing Immunorepertoires
US20100151471A1 (en) * 2008-11-07 2010-06-17 Malek Faham Methods of monitoring conditions by sequence analysis

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Arstila et al., Science 286:958-961, October 1999 *
Droese et al. Leukemia 2004, 18:1531-1538 *
Droese et al., Leukemia 2004, 18:1531-1538 *
Duby et al. Human T-cell receptor aberrantly rearranged beta-chain J1.5-Dx-J2.1 gene. Proc. Natl. Acad. Sci. USA (1986) GenBank accession No. M13574.1, bases 1 to 100. *
Miqueu et al., Molecular Immunology 2007, 44:1057-1064 *
Van Dongen et al., Leukemia (2003) 17, 2257-2317 *

Cited By (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12060610B2 (en) 2008-04-16 2024-08-13 iRepertoire, Inc. Method for evaluating and comparing immunorepertoires
US8795970B2 (en) 2008-11-07 2014-08-05 Sequenta, Inc. Methods of monitoring conditions by sequence analysis
US9347099B2 (en) 2008-11-07 2016-05-24 Adaptive Biotechnologies Corp. Single cell analysis by polymerase cycling assembly
US9512487B2 (en) 2008-11-07 2016-12-06 Adaptive Biotechnologies Corp. Monitoring health and disease status using clonotype profiles
US8236503B2 (en) 2008-11-07 2012-08-07 Sequenta, Inc. Methods of monitoring conditions by sequence analysis
US10246752B2 (en) 2008-11-07 2019-04-02 Adaptive Biotechnologies Corp. Methods of monitoring conditions by sequence analysis
US10760133B2 (en) 2008-11-07 2020-09-01 Adaptive Biotechnologies Corporation Monitoring health and disease status using clonotype profiles
US8507205B2 (en) 2008-11-07 2013-08-13 Sequenta, Inc. Single cell analysis by polymerase cycling assembly
US9528160B2 (en) 2008-11-07 2016-12-27 Adaptive Biotechnolgies Corp. Rare clonotypes and uses thereof
US10266901B2 (en) 2008-11-07 2019-04-23 Adaptive Biotechnologies Corp. Methods of monitoring conditions by sequence analysis
US10519511B2 (en) 2008-11-07 2019-12-31 Adaptive Biotechnologies Corporation Monitoring health and disease status using clonotype profiles
US20110207135A1 (en) * 2008-11-07 2011-08-25 Sequenta, Inc. Methods of monitoring conditions by sequence analysis
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US8691510B2 (en) 2008-11-07 2014-04-08 Sequenta, Inc. Sequence analysis of complex amplicons
US20100151471A1 (en) * 2008-11-07 2010-06-17 Malek Faham Methods of monitoring conditions by sequence analysis
US9416420B2 (en) 2008-11-07 2016-08-16 Adaptive Biotechnologies Corp. Monitoring health and disease status using clonotype profiles
US8748103B2 (en) 2008-11-07 2014-06-10 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US9365901B2 (en) 2008-11-07 2016-06-14 Adaptive Biotechnologies Corp. Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
US9523129B2 (en) 2008-11-07 2016-12-20 Adaptive Biotechnologies Corp. Sequence analysis of complex amplicons
US10865453B2 (en) 2008-11-07 2020-12-15 Adaptive Biotechnologies Corporation Monitoring health and disease status using clonotype profiles
US9506119B2 (en) 2008-11-07 2016-11-29 Adaptive Biotechnologies Corp. Method of sequence determination using sequence tags
US9228232B2 (en) 2008-11-07 2016-01-05 Sequenta, LLC. Methods of monitoring conditions by sequence analysis
US20110207134A1 (en) * 2008-11-07 2011-08-25 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US10155992B2 (en) 2008-11-07 2018-12-18 Adaptive Biotechnologies Corp. Monitoring health and disease status using clonotype profiles
US9217176B2 (en) 2008-11-07 2015-12-22 Sequenta, Llc Methods of monitoring conditions by sequence analysis
US10323276B2 (en) 2009-01-15 2019-06-18 Adaptive Biotechnologies Corporation Adaptive immunity profiling and methods for generation of monoclonal antibodies
US11905511B2 (en) 2009-06-25 2024-02-20 Fred Hutchinson Cancer Center Method of measuring adaptive immunity
US9809813B2 (en) 2009-06-25 2017-11-07 Fred Hutchinson Cancer Research Center Method of measuring adaptive immunity
US11214793B2 (en) 2009-06-25 2022-01-04 Fred Hutchinson Cancer Research Center Method of measuring adaptive immunity
US9043160B1 (en) 2009-11-09 2015-05-26 Sequenta, Inc. Method of determining clonotypes and clonotype profiles
CN103797366A (en) * 2011-01-14 2014-05-14 Cb生物技术公司 Immunodiversity assessment method and its use
WO2012097374A1 (en) 2011-01-14 2012-07-19 Cb Biotechnologies, Inc. Immunodiversity assessment method and its use
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
US9181591B2 (en) 2011-10-21 2015-11-10 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
US20140186848A1 (en) * 2011-10-21 2014-07-03 Fred Hutchinson Cancer Research Center Quantification of Adaptive Immune Cell Genomes in a Complex Mixture of Cells
US9181590B2 (en) * 2011-10-21 2015-11-10 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
US9279159B2 (en) * 2011-10-21 2016-03-08 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
US20130288237A1 (en) * 2011-10-21 2013-10-31 Fred Hutchinson Cancer Research Center Quantification of adaptive immune cell genomes in a complex mixture of cells
WO2013059725A1 (en) * 2011-10-21 2013-04-25 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
EP3904536A1 (en) 2011-12-09 2021-11-03 Adaptive Biotechnologies Corporation Diagnosis of lymphoid malignancies and minimal residual disease detection
US9824179B2 (en) 2011-12-09 2017-11-21 Adaptive Biotechnologies Corp. Diagnosis of lymphoid malignancies and minimal residual disease detection
WO2013086450A1 (en) 2011-12-09 2013-06-13 Adaptive Biotechnologies Corporation Diagnosis of lymphoid malignancies and minimal residual disease detection
EP3388535A1 (en) 2011-12-09 2018-10-17 Adaptive Biotechnologies Corporation Diagnosis of lymphoid malignancies and minimal residual disease detection
US9499865B2 (en) 2011-12-13 2016-11-22 Adaptive Biotechnologies Corp. Detection and measurement of tissue-infiltrating lymphocytes
US10077478B2 (en) 2012-03-05 2018-09-18 Adaptive Biotechnologies Corp. Determining paired immune receptor chains from frequency matched subunits
US10214770B2 (en) 2012-05-08 2019-02-26 Adaptive Biotechnologies Corp. Compositions and method for measuring and calibrating amplification bias in multiplexed PCR reactions
US10894977B2 (en) 2012-05-08 2021-01-19 Adaptive Biotechnologies Corporation Compositions and methods for measuring and calibrating amplification bias in multiplexed PCR reactions
US9150905B2 (en) 2012-05-08 2015-10-06 Adaptive Biotechnologies Corporation Compositions and method for measuring and calibrating amplification bias in multiplexed PCR reactions
US9371558B2 (en) 2012-05-08 2016-06-21 Adaptive Biotechnologies Corp. Compositions and method for measuring and calibrating amplification bias in multiplexed PCR reactions
WO2013169957A1 (en) 2012-05-08 2013-11-14 Adaptive Biotechnologies Corporation Compositions and method for measuring and calibrating amplification bias in multiplexed pcr reactions
US20140322716A1 (en) * 2012-06-15 2014-10-30 Adaptive Biotechnologies Corporation Uniquely Tagged Rearranged Adaptive Immune Receptor Genes in a Complex Gene Set
WO2013188831A1 (en) 2012-06-15 2013-12-19 Adaptive Biotechnologies Corporation Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set
WO2014008448A1 (en) * 2012-07-03 2014-01-09 Sloan Kettering Institute For Cancer Research Quantitative assessment of human t-cell repertoire recovery after allogeneic hematopoietic stem cell transplantation
US10501808B2 (en) 2012-09-04 2019-12-10 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US12110560B2 (en) 2012-09-04 2024-10-08 Guardant Health, Inc. Methods for monitoring residual disease
US11773453B2 (en) 2012-09-04 2023-10-03 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10822663B2 (en) 2012-09-04 2020-11-03 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US11434523B2 (en) 2012-09-04 2022-09-06 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US11879158B2 (en) 2012-09-04 2024-01-23 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10738364B2 (en) 2012-09-04 2020-08-11 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10837063B2 (en) 2012-09-04 2020-11-17 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US12116624B2 (en) 2012-09-04 2024-10-15 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US11319597B2 (en) 2012-09-04 2022-05-03 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US11319598B2 (en) 2012-09-04 2022-05-03 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US11913065B2 (en) 2012-09-04 2024-02-27 Guardent Health, Inc. Systems and methods to detect rare mutations and copy number variation
US12049673B2 (en) 2012-09-04 2024-07-30 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US12054783B2 (en) 2012-09-04 2024-08-06 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US9902992B2 (en) 2012-09-04 2018-02-27 Guardant Helath, Inc. Systems and methods to detect rare mutations and copy number variation
US10876152B2 (en) 2012-09-04 2020-12-29 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10683556B2 (en) 2012-09-04 2020-06-16 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10876171B2 (en) 2012-09-04 2020-12-29 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10793916B2 (en) 2012-09-04 2020-10-06 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10876172B2 (en) 2012-09-04 2020-12-29 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US9840743B2 (en) 2012-09-04 2017-12-12 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10894974B2 (en) 2012-09-04 2021-01-19 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US11001899B1 (en) 2012-09-04 2021-05-11 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10995376B1 (en) 2012-09-04 2021-05-04 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10961592B2 (en) 2012-09-04 2021-03-30 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10947600B2 (en) 2012-09-04 2021-03-16 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10457995B2 (en) 2012-09-04 2019-10-29 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10494678B2 (en) 2012-09-04 2019-12-03 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US9834822B2 (en) * 2012-09-04 2017-12-05 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10501810B2 (en) 2012-09-04 2019-12-10 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10041127B2 (en) 2012-09-04 2018-08-07 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US11180813B2 (en) 2012-10-01 2021-11-23 Adaptive Biotechnologies Corporation Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization
EP3330384A1 (en) 2012-10-01 2018-06-06 Adaptive Biotechnologies Corporation Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization
US12104211B2 (en) 2012-10-01 2024-10-01 Adaptive Biotechnologies Corporation Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization
WO2014055561A1 (en) 2012-10-01 2014-04-10 Adaptive Biotechnologies Corporation Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization
US10221461B2 (en) 2012-10-01 2019-03-05 Adaptive Biotechnologies Corp. Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization
EP3640343A1 (en) 2012-10-01 2020-04-22 Adaptive Biotechnologies Corporation Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization
US10150996B2 (en) 2012-10-19 2018-12-11 Adaptive Biotechnologies Corp. Quantification of adaptive immune cell genomes in a complex mixture of cells
WO2014145992A1 (en) 2013-03-15 2014-09-18 Adaptive Biotechnologies Corporation Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set
US10876107B2 (en) 2013-03-15 2020-12-29 Abvitro Llc Single cell bar-coding for antibody discovery
US9816088B2 (en) 2013-03-15 2017-11-14 Abvitro Llc Single cell bar-coding for antibody discovery
US10119134B2 (en) 2013-03-15 2018-11-06 Abvitro Llc Single cell bar-coding for antibody discovery
US11118176B2 (en) 2013-03-15 2021-09-14 Abvitro Llc Single cell bar-coding for antibody discovery
US10392614B2 (en) 2013-03-15 2019-08-27 Abvitro Llc Methods of single-cell barcoding and sequencing
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
US10077473B2 (en) 2013-07-01 2018-09-18 Adaptive Biotechnologies Corp. Method for genotyping clonotype profiles using sequence tags
US10526650B2 (en) 2013-07-01 2020-01-07 Adaptive Biotechnologies Corporation Method for genotyping clonotype profiles using sequence tags
US10889858B2 (en) 2013-12-28 2021-01-12 Guardant Health, Inc. Methods and systems for detecting genetic variants
US11649491B2 (en) 2013-12-28 2023-05-16 Guardant Health, Inc. Methods and systems for detecting genetic variants
US11639525B2 (en) 2013-12-28 2023-05-02 Guardant Health, Inc. Methods and systems for detecting genetic variants
US11434531B2 (en) 2013-12-28 2022-09-06 Guardant Health, Inc. Methods and systems for detecting genetic variants
US11667967B2 (en) 2013-12-28 2023-06-06 Guardant Health, Inc. Methods and systems for detecting genetic variants
US11767556B2 (en) 2013-12-28 2023-09-26 Guardant Health, Inc. Methods and systems for detecting genetic variants
US11767555B2 (en) 2013-12-28 2023-09-26 Guardant Health, Inc. Methods and systems for detecting genetic variants
US10883139B2 (en) 2013-12-28 2021-01-05 Guardant Health, Inc. Methods and systems for detecting genetic variants
US12024745B2 (en) 2013-12-28 2024-07-02 Guardant Health, Inc. Methods and systems for detecting genetic variants
US11639526B2 (en) 2013-12-28 2023-05-02 Guardant Health, Inc. Methods and systems for detecting genetic variants
US12098421B2 (en) 2013-12-28 2024-09-24 Guardant Health, Inc. Methods and systems for detecting genetic variants
US9920366B2 (en) 2013-12-28 2018-03-20 Guardant Health, Inc. Methods and systems for detecting genetic variants
US12098422B2 (en) 2013-12-28 2024-09-24 Guardant Health, Inc. Methods and systems for detecting genetic variants
US11959139B2 (en) 2013-12-28 2024-04-16 Guardant Health, Inc. Methods and systems for detecting genetic variants
US12054774B2 (en) 2013-12-28 2024-08-06 Guardant Health, Inc. Methods and systems for detecting genetic variants
US11149307B2 (en) 2013-12-28 2021-10-19 Guardant Health, Inc. Methods and systems for detecting genetic variants
US10801063B2 (en) 2013-12-28 2020-10-13 Guardant Health, Inc. Methods and systems for detecting genetic variants
US11149306B2 (en) 2013-12-28 2021-10-19 Guardant Health, Inc. Methods and systems for detecting genetic variants
US12024746B2 (en) 2013-12-28 2024-07-02 Guardant Health, Inc. Methods and systems for detecting genetic variants
US11118221B2 (en) 2013-12-28 2021-09-14 Guardant Health, Inc. Methods and systems for detecting genetic variants
US11091797B2 (en) 2014-03-05 2021-08-17 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US11248253B2 (en) 2014-03-05 2022-02-15 Adaptive Biotechnologies Corporation Methods using randomer-containing synthetic molecules
US11091796B2 (en) 2014-03-05 2021-08-17 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10704085B2 (en) 2014-03-05 2020-07-07 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10704086B2 (en) 2014-03-05 2020-07-07 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US11447813B2 (en) 2014-03-05 2022-09-20 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10870880B2 (en) 2014-03-05 2020-12-22 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US11667959B2 (en) 2014-03-05 2023-06-06 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10982265B2 (en) 2014-03-05 2021-04-20 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US11390921B2 (en) 2014-04-01 2022-07-19 Adaptive Biotechnologies Corporation Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
US10435745B2 (en) 2014-04-01 2019-10-08 Adaptive Biotechnologies Corp. Determining antigen-specific T-cells
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
US11261490B2 (en) 2014-04-01 2022-03-01 Adaptive Biotechnologies Corporation Determining antigen-specific T-cells
US10202640B2 (en) * 2014-05-07 2019-02-12 The Board Of Trustees Of The Leland Stanford Junior University Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing
US10590483B2 (en) 2014-09-15 2020-03-17 Abvitro Llc High-throughput nucleotide library sequencing
EP3715455A1 (en) 2014-10-29 2020-09-30 Adaptive Biotechnologies Corp. Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples
US10392663B2 (en) 2014-10-29 2019-08-27 Adaptive Biotechnologies Corp. Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from a large number of samples
WO2016069886A1 (en) 2014-10-29 2016-05-06 Adaptive Biotechnologies Corporation Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
EP3498866A1 (en) 2014-11-25 2019-06-19 Adaptive Biotechnologies Corp. Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing
US11066705B2 (en) 2014-11-25 2021-07-20 Adaptive Biotechnologies Corporation Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing
WO2016138122A1 (en) 2015-02-24 2016-09-01 Adaptive Biotechnologies Corp. Methods for diagnosing infectious disease and determining hla status using immune repertoire sequencing
US11047008B2 (en) 2015-02-24 2021-06-29 Adaptive Biotechnologies Corporation Methods for diagnosing infectious disease and determining HLA status using immune repertoire sequencing
EP3591074A1 (en) 2015-02-24 2020-01-08 Adaptive Biotechnologies Corp. Methods for diagnosing infectious disease and determining hla status using immune repertoire sequencing
US11041202B2 (en) 2015-04-01 2021-06-22 Adaptive Biotechnologies Corporation Method of identifying human compatible T cell receptors specific for an antigenic target
WO2016161273A1 (en) 2015-04-01 2016-10-06 Adaptive Biotechnologies Corp. Method of identifying human compatible t cell receptors specific for an antigenic target
US9738699B2 (en) 2015-06-09 2017-08-22 Gigagen, Inc. Recombinant fusion proteins and libraries from immune cell repertoires
US11702765B2 (en) 2015-06-09 2023-07-18 Gigagen, Inc. Recombinant fusion proteins and libraries from immune cell repertoires
US10689641B2 (en) 2015-06-09 2020-06-23 Gigagen, Inc. Recombinant fusion proteins and libraries from immune cell repertoires
US9422547B1 (en) 2015-06-09 2016-08-23 Gigagen, Inc. Recombinant fusion proteins and libraries from immune cell repertoires
US9926555B2 (en) 2015-06-09 2018-03-27 Gigamune, Inc. Recombinant fusion proteins and libraries from immune cell repertoires
US9926554B2 (en) 2015-06-09 2018-03-27 Gigamune, Inc. Recombinant fusion proteins and libraries from immune cell repertoires
US10214740B2 (en) 2015-06-09 2019-02-26 Gigagen, Inc. Recombinant fusion proteins and libraries from immune cell repertoires
US10168328B2 (en) 2015-07-22 2019-01-01 Roche Sequencing Solutions, Inc. Identification of antigen epitopes and immune sequences recognizing the antigens
US10539564B2 (en) 2015-07-22 2020-01-21 Roche Sequencing Solutions, Inc. Identification of antigen epitopes and immune sequences recognizing the antigens
US11242569B2 (en) 2015-12-17 2022-02-08 Guardant Health, Inc. Methods to determine tumor gene copy number by analysis of cell-free DNA
US11098360B2 (en) 2016-06-01 2021-08-24 Roche Sequencing Solutions, Inc. Immuno-PETE
US12043919B2 (en) 2016-06-01 2024-07-23 Roche Sequencing Solutions, Inc. Immune profiling by primer extension target enrichment
WO2017210469A3 (en) * 2016-06-01 2018-03-15 F. Hoffman-La Roche Ag Immuno-pete
US11773511B2 (en) 2016-06-01 2023-10-03 Roche Sequencing Solutions, Inc. Immune profiling by primer extension target enrichment
US11306356B2 (en) 2016-06-01 2022-04-19 Roche Sequencing Solutions, Inc. Immuno-PETE
US11725307B2 (en) 2016-06-01 2023-08-15 Roche Sequencing Solutions, Inc. Immuno-PETE
US10428325B1 (en) 2016-09-21 2019-10-01 Adaptive Biotechnologies Corporation Identification of antigen-specific B cell receptors
US11254980B1 (en) 2017-11-29 2022-02-22 Adaptive Biotechnologies Corporation Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements
WO2019238939A1 (en) 2018-06-15 2019-12-19 F. Hoffmann-La Roche Ag A system for identification of antigens recognized by t cell receptors expressed on tumor infiltrating lymphocytes
US11421220B2 (en) 2019-03-21 2022-08-23 Gigamune, Inc. Engineered cells expressing anti-viral T cell receptors and methods of use thereof
CN109929924A (en) * 2019-03-27 2019-06-25 上海科医联创医学检验所有限公司 A kind of IGH gene rearrangement detection method based on high-flux sequence
CN110246539A (en) * 2019-04-15 2019-09-17 成都益安博生物技术有限公司 A kind of method and device of immunity level assessment
US12129462B2 (en) 2021-08-03 2024-10-29 Abvitro Llc Single cell bar-coding for antibody discovery

Also Published As

Publication number Publication date
EP3409792C0 (en) 2023-09-20
AU2010263172B2 (en) 2016-03-31
US20140206549A1 (en) 2014-07-24
US11905511B2 (en) 2024-02-20
US9809813B2 (en) 2017-11-07
JP2012531202A (en) 2012-12-10
KR20140146180A (en) 2014-12-24
EP2446052B1 (en) 2018-08-08
RU2539032C2 (en) 2015-01-10
US20180073015A1 (en) 2018-03-15
US20180312832A1 (en) 2018-11-01
RU2014144463A (en) 2015-06-20
CN102459643A (en) 2012-05-16
CN102459643B (en) 2016-06-01
WO2010151416A1 (en) 2010-12-29
US20140221220A1 (en) 2014-08-07
SG10201403451QA (en) 2014-09-26
US20140206548A1 (en) 2014-07-24
EP3409792A1 (en) 2018-12-05
US20140213463A1 (en) 2014-07-31
SG176691A1 (en) 2012-01-30
JP6125578B2 (en) 2017-05-10
EP3409792B1 (en) 2023-09-20
US20140194295A1 (en) 2014-07-10
IL217200A0 (en) 2012-02-29
EP2446052A1 (en) 2012-05-02
AU2010263172A1 (en) 2012-01-19
IL217200A (en) 2016-02-29
KR20120044941A (en) 2012-05-08
US20160251721A1 (en) 2016-09-01
US20140256567A1 (en) 2014-09-11
JP2016005469A (en) 2016-01-14
CA2765949C (en) 2016-03-29
RU2012101828A (en) 2013-07-27
CA2765949A1 (en) 2010-12-29
US11214793B2 (en) 2022-01-04

Similar Documents

Publication Publication Date Title
US11905511B2 (en) Method of measuring adaptive immunity
US20170335386A1 (en) Method of measuring adaptive immunity
EP3212790B1 (en) Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples
US10246701B2 (en) Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
AU2012347460A1 (en) Diagnosis of lymphoid malignancies and minimal residual disease detection
US20150167084A1 (en) Quantitative Assessment of Human T-Cell Repertoire Recovery After Allogeneic Hematopoietic Stem Cell Transplantation
US20220073983A1 (en) Compositions and methods for immune repertoire sequencing
US20230416810A1 (en) Compositions and methods for immune repertoire monitoring
JP2022544578A (en) Targeted hybrid capture method for determining T cell repertoire
US20230340602A1 (en) Compositions and methods for immune repertoire monitoring

Legal Events

Date Code Title Description
AS Assignment

Owner name: FRED HUTCHINSON CANCER RESEARCH CENTER, WASHINGTON

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROBINS, HARLAN S;WARREN, EDUS H, III;CARLSON, CHRISTOPHER SCOTT;SIGNING DATES FROM 20101112 TO 20110316;REEL/FRAME:026118/0148

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR, MA

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:FRED HUTCHINSON CANCER RESEARCH CENTER;REEL/FRAME:042470/0535

Effective date: 20170522

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:FRED HUTCHINSON CANCER RESEARCH CENTER;REEL/FRAME:042589/0244

Effective date: 20170522